
National Bowel Cancer Audit 2009



This Annual Report contains data from both the 2006/07 and 2007/08 reporting periods, which cover patients with a diagnosis date from 1 April 2006 to the 31 July 2007 and 1 August 2007 to 31 July 2008. Data from Wales covers the periods April 2006 to March 2007 and April 2007 to March 2008.

This report was prepared by:

Association of Coloproctology of Great Britain and Ireland Paul Finan Jason Smith

The Northern and Yorkshire Cancer Registry and Information Service Eva Morris

The NHS Information Centre for health and social care Kimberley Greenaway

The National Bowel Cancer Audit Annual Report 2009 is available to download from (http://www.ic.NHS.uk/ canceraudits, www.nbocap.org.uk and www.acpgbi.org.uk)

Prepared in partnership with:



The Healthcare Quality Improvement Partnership (HQIP) promotes quality in healthcare. HQIP holds commissioning and funding responsibility for the National Bowel Cancer Audit and other national clinical audits.



The NHS Information Centre for Health and Social Care (The NHS IC) is England's central, authoritative source of essential data and statistical information for frontline decision makers in health and social care. The NHS IC managed the publication of the 2009 annual report.

Northern and Yorkshire Cancer Registry and Information Service The Northern and Yorkshire Cancer Registry & Information Service (NYCRIS) is a member of the United Kingdom Association of Cancer Registries (UKACR) which has a long term role in monitoring trends in the patterns of cancer in the population. NYCRIS carried out the analysis of the data for the 2009 Annual Report.



The Association of Coloproctology of Great Britain and Ireland (ACPGBI) is the professional body that represents UK colorectal surgeons. ACPGBI provided a clinical interpretation of the data analysed in the 2009 Annual Report.

National Bowel Cancer Audit 2009

Contents

Acknowledgements	4
Foreword by President of ACPGBI	5
Foreward by National Clinical Director for Cancer	6
Commentary on the National Bowel Cancer Audit	7
Executive Summary	8
Main findings	8
Recommendations	9
The National Bowel Cancer Audit	10
Development of the Audit	10
Progress of the Audit	10
Recommendation	10
Participating Trusts, case ascertainment and data completeness	11
Audit population	11
Trust participation	11
Case ascertainment and data completeness	13
Main Findings	19
Discussion of patients at a multi-disciplinary team meeting (MDT)	20
Patients seeing a clinical nurse specialist (CNS)	21
Reporting of clinico-pathological Dukes' stage	22
Use of CT scanning in patients with colorectal cancer	24
Use of pre-operative MR scanning in rectal cancer patients	25
Use of pre-operative radiotherapy in patients with rectal cancer	26
ASA (American Society of Anaesthesiologists) grade in patients undergoing surgical intervention	28
Cases undergoing urgent or emergency surgery	29
Surgical procedures for colorectal cancer	31
Use of laparoscopic procedures in colorectal cancer surgery	33
Rates of abdominoperineal excision of the rectum and anus (APER)	35
Permanent stoma rates for rectal cancer	37
Post-operative mortality	39
Reporting of status of circumferential resection margins in rectal cancer.	43
Reporting of extramural vascular invasion	44
Median number of nodes obtained and identified following major excision	45
Post-operative length of stay (LOS)	48
Summary	49
Local Action Plans	50
Appendices	51
Appendix 1: Summary of 2006/7 data	52
Appendix 2: Summary of 2007/8 data	62
Appendix 3: Colorectal cancer outcomes audit in Leicester	72
Appendix 4: Examples of collection of high quality complete data	73
Appendix 5: Local Action Plan (LAP) based on the recommendations of 2009 Annual Report	75

Acknowledgements

The National Bowel Cancer Audit, commissioned by the Healthcare Quality Improvement Partnership (HQIP), has been developed by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and is managed by The NHS Information Centre for Health and Social Care (The IC).

The data for Wales has been supplied from the Cancer Network Information System Cymru (CANISC) team. Jeff Stamatakis reviewed and advised on the content of the annual report.

The analyses for this report were undertaken by The Northern and Yorkshire Cancer Registry and Information Service (NYCRIS) who are designated the lead registry for colorectal cancer. The analysis team consisted of Eva Morris, James Thomas and Faye Taylor from NYCRIS and Jason Smith and Paris Tekkis from the ACPGBI.

Connecting for Health provided the development team and the Helpdesk for submission of data via the Open Exeter system.

The National Bowel Cancer Audit Project Team consists of:

- Paul Finan (ACPGBI)
- Jason Smith (ACPGBI)
- Paris Tekkis (ACPGBI)
- Eva Morris (NYCRIS)
- Kimberley Greenaway (The IC)
- Steve Dean (The IC)

The National Bowel Cancer Audit Project Board consists of:

- Nigel Scott (ACPGBI)
- Martin Old (The IC)
- Steve Dean (The IC)
- Helen Laing (HQIP)

The Bowel Cancer Audit is the result of an immense amount of work by many people and the Project Team and Board would like to acknowledge this.

Foreword by President of ACPGBI

It is in keeping with the tradition of the Association that we are auditing all results. The history of audit has emanated from the steeped history of our craft and one of the first people who comes to mind in auditing his results is Professor Goligher who led his magnificent department for decades. His spirit has been instilled into his students and distant disciples with its inevitable transmission to the subsequent generations that are forming the membership of our Association. It is only befitting that the current Chairman of the National Audit is from the very same Goligher Unit. Mr Finan and his team have done a magnificent job.

A few points have not escaped me and, I am sure, the readership. These include the significant increase in the number of respondent trusts. Every Trust in England and Wales is now registered with the National Bower Cancer Audit. This on its own is a major triumph to the craft in general and to those notables, like Jeff Stamatakis and Mike Thompson to name but two, who initiated regional programmes that transformed bowel cancer audit within a few short years into a nationwide exercise. The recruitment of some of the most active brains in colorectal surgery like Paris Tekkis and Jason Smith added another dimension to the exercise from which we are all benefiting as well as enjoying.

As a histopathologist, I can see even more the value of the MDTs in advancing the science and discipline of coloproctology through audits and applying accepted practice to our professional approaches. I regard MDTs and minimum data sets as the true data 'incubators' that form the bases of audits. The 'job is not finished yet' as we have some areas to work on and refine. I do encourage Trusts and colorectal surgeons to read this report and use it as a benchmark of how the Nation is doing. I am of course looking forward to further improvement like an increase in the MR imaging of rectal cancers, improved recording of the Dukes' stage and a few other points that need to be addressed by each MDT. I also welcome very much the cross national collaboration with other bodies serving similar purposes, like NYCRIS and the National Cancer Intelligence Network. This cooperation is vital to solidify the collected data and make it even more useful as a tool for measuring our ability and capacity to undertake procedures. Indeed I already look forward to the next even more mature edition.

Many thanks Paul and the rest of the valuable team for their wonderful work. Without auditing our results, we will not maintain high standards or progress further.

The National Audit Programme has become the envy of the world and, indeed, very many important points have been made in various worldwide publications which refer to our Audit. Long may it last.



Najib Haboubi FRCPath, FRCS (Eng), President ACPGBI

p. h.l.

Foreword by National Clinical Director for Cancer

There is no doubt that progress is being made in relation to the early diagnosis and treatment of patients with bowel cancer in this country. The rollout of bowel cancer screening for men and women aged 60-69 years is going well and should cover the whole country by the end of this year. The quality of endoscopy services has improved very considerably. Waiting times for symptomatic patients have been reduced. Multidisciplinary team working is firmly established. The training programme related to total mesorectal excision has been completed and the programme for laparoscopic surgery is now well underway. More patients are benefiting from adjuvant chemotherapy. Most importantly, survival rates are improving.

However, there is also no doubt that more can and must be done. The Cancer Reform Strategy sets out the goal that cancer outcomes in this country should match the best in the world, but we know that survival rates in this country still lag behind the best in Europe. National audits provide a major opportunity both to measure service quality and to drive quality improvement. I am pleased to see that participation in the National Bowel Cancer Audit has risen, reaching 68 per cent of incident cases in 2007/8. However, we can and must go further both with participation rates and data completeness. Multidisciplinary teams need to record all relevant information on their patients if they are to provide optimal care. They should then ensure that this information is transmitted to cancer registries and relevant national audits.

This audit shows ongoing improvements, for example in relation to 30 day post-operative mortality. It also reveals wide variations between cancer networks. For example, the proportion of patients undergoing major resection appears to vary from around 20 per cent to around 80 per cent. Laparoscopic surgery rates vary from around 5 per cent to around 45 per cent and abdominoperineal excision rates from around 5 per cent to around 40 per cent. It is vital that cancer networks and individual multidisciplinary teams should reflect on their own results, improve reporting where necessary and ensure that they are providing the best possible care for their patients.



Prof Mike Richards National Clinical Director for Cancer

ha Ru

Commentary on the National Bowel Cancer Audit

I feel that all those involved with the National Bowel Cancer Audit can be proud of the achievements outlined in this year's report. With over 20,000 cases submitted in each 12-month period and all Trusts in England and Wales registered with the audit, we are clearly participating in a "National Audit". It is to be hoped that the targets achieved will secure the necessary funding for this project to continue for the foreseeable future.

Whilst noting the successes it is clear major challenges remain. Data completeness continues to be an issue and unless this can be improved, the future of the audit is threatened. It goes without saying that 30-day post-operative mortality rates need a date of surgery as well as a date of death. Similarly "APER rates" are difficult to determine without a well defined denominator.

The relevance of audit to every day practice is clear and it seems appropriate that the focus for audit should be with the multi-disciplinary teams. These teams are firmly established throughout the country and a sense of ownership of good quality data, submitted for audit purposes, makes feedback and local action planning a positive aspect of our service. The comprehensive comparative analyses presented this year should provide the incentive to improve in those areas where data collection is poor. My own interpretation of the data from Leeds for example is that we need to ensure that what we do is faithfully recorded in a form which is readily submitted to the audit from our bespoke cancer management system. The National Bowel Cancer Audit collects clinical data which is not readily available within other sources at a national level. However it will be clear to many that other systems do exist eg HES data and Cancer Registry data. The linkage of such systems to give a more comprehensive picture of the care afforded to patients with bowel cancer is an exciting prospect which is being explored within the framework of the National Cancer Intelligence Network. This linked dataset should be capable of informing us of the reasons for differences in outcome observed at both national and international levels.

I would conclude with thanks again to the many people involved with the audit. The success is due entirely to the perseverance shown over many years and one can only hope that those efforts will now be reflected in an established audit which will contribute to the care of patients with colorectal cancer.



Mr Paul Finan Chairman of Audit Project Team & Clinical Lead



Executive Summary

This Annual Report of the National Bowel Cancer Audit contains data from both the 2006/7 and 2007/8 reporting periods, and includes patients with a diagnosis date between 1 April 2006 and 31 July 2008.

There has been a substantial increase in Trust participation, case ascertainment and data completeness allowing more detailed comparisons between Trusts. 95 per cent of Trusts submitted data for this annual report and 20,262 cases were submitted for the 2007/8 reporting period, representing 68 per cent of the expected incident cases.

Measures of processes and outcome of care are shown to be improving. However, the results show a wide variation across Trusts and Cancer Networks, though this could, in part, be due to poor data completeness amongst some Trusts rather than an actual indicator of variation in care.

The audit measures aspects of process and outcome against a number of key standards or guidelines from NICE and the ACPGBI and the findings are contained in this report along with recommended actions for MDTs, Trusts, Networks and Commissioners.

Main findings

- all Trusts in England and Wales are now registered with the National Audit
- Trust participation increased to 95 per cent
- case ascertainment overall increased to 69 per cent (reporting period 2007/8) with 68.5 per cent of Trusts achieving the expected case ascertainment target of >80 per cent
- data completeness remains an issue, with only 50 per cent of units collecting >80 per cent of the data items needed for calculating risk-adjusted mortality
- 82 per cent of cases of bowel cancer were discussed at an MDT meeting. However, the reported audit data shows that the number of patients discussed at an MDT meeting varied substantially between Cancer Networks, ranging from 36 per cent to 99 per cent
- the reported involvement of a clinical nurse specialist increased from 41 per cent to 51 per cent between the two reporting periods. However, the reported audit data shows that the number of patients seeing a clinical nurse specialist varied substantially between Cancer Networks, ranging from 12 per cent to 97 per cent
- a Dukes' stage was submitted in less than 55 per cent of cases although a "derived" Dukes' stage brought this figure up to over 76 per cent
- there are disappointing figures reported for the use of CT and MR imaging (61 per cent and 51 per cent respectively in the 2007/8 reporting period). The reported audit data shows that the reported use of CT and MR imaging varied

substantially between Cancer Networks, ranging from 14 per cent to 92 per cent for CT scanning and from 7 per cent to 84 per cent for MR imaging

- 32.1 per cent of cases of rectal cancer had pre-operative radiotherapy, either long course chemo-radiotherapy or short course (5x5) radiotherapy. Considerable variation was reported in the use of pre-operative radiotherapy across Cancer Networks ranging from 0 per cent to 74 per cent
- ASA grade was recorded in almost 70 per cent of cases where a surgical intervention was recorded
- 69 per cent of patients with colorectal cancer were managed in the elective/scheduled setting, with 18 per cent undergoing urgent/emergency surgery and the remainder unknown
- major resections were undertaken in 60 per cent of cases in both time periods. There was either no procedure recorded or no procedure undertaken in 30 per cent of cases
- the proportion of major resections of colorectal cancer completed laparoscopically in the 2006/7 reporting period was 8.3 per cent and this increased to 17.2 per cent in the 2007/8 data collection period. However, the reported audit data shows that the proportion of major resections completed laparoscopically varied substantially between Cancer Networks, ranging from 3 per cent to 40 per cent
- the APER rate was 17 per cent for the 2007/8 reporting period. There was considerable variation in the use of this procedure across Cancer Networks ranging from 0 per cent to 33 per cent
- permanent stomas were performed in at least 34 per cent of cases of rectal cancer in the 2007/8 reporting period, again with a wide variation between Networks ranging from 3 per cent to 51 per cent
- the 30-day post-operative mortality continued to fall (rate of 4.5 per cent overall)
- the status of the circumferential margin in cases of rectal cancer was noted in almost 59 per cent of cases in 2007/8
- extramural vascular invasion on resected specimens was seen in 26 per cent of cases where this feature was reported. The presence or absence was not reported in almost one third of specimens in the latter of the two reporting periods
- a median of 15 lymph nodes was reported per resected specimen
- the median post-operative length of stay following resection of a colorectal tumour was 9 days.

Recommendations

- Trusts should establish mechanisms for reviewing their audit data and ensure maximum data completeness of the essential dataset prior to submission for the 2010 Annual Report
- colorectal MDTs should ensure that all patients with bowel cancer are discussed and the results of pre-operative imaging (CT and MR), in elective cases, reviewed prior to the decision to treat
- all bowel cancer patients should be seen by a clinical nurse specialist and reasons for falling below the national standard investigated by individual colorectal MDTs
- all Trusts should accurately record a clinico-pathological Dukes' staging for all patients with colorectal cancer and this should be agreed at the MDT
- pathologists should complete the relevant Royal College of Pathologists minimum dataset for all cases of resected bowel cancer. MDTs should ensure that these data items are reviewed at their meetings
- Networks should continue to refine their protocols for the use of pre-operative radiotherapy in patients with rectal cancer in order to ensure its use in appropriate cases
- efforts should be made to manage patients with colorectal cancer in the elective setting whenever possible, regardless of the mode of admission. MDTs should note the reasons for emergency surgery
- the five variables: age, Dukes' stage, urgency of operation (CEPOD category), cancer excision and ASA grade, used for risk adjustment, should be recorded in all cases
- Trusts should ensure adherence to the ACPGBI guideline and NICE recommendations for the use of laparoscopic surgery and preceptorship training
- Trusts and Networks should review local APER rates together with permanent stoma rates for rectal cancer and compare these with the Cancer Network and national rates
- Trusts and Networks should review their 30-day postoperative mortality rates, noting and exploring significant variance from observed Network and national figures
- Trusts should ensure adherence to the NICE guidance of removing and examining a median of 12 lymph nodes from their resected surgical specimens
- Trusts and MDTs should review the provision of those aspects of service which help to reduce the length of stay following resection of colorectal cancers

- Trust Service Improvement or Clinical Governance teams should utilise the draft National Bowel Cancer Audit local action plan in support of their service improvement, clinical governance, and cancer peer review activity
- Networks and Cancer Service Commissioners should use the findings of this report and its recommendations to support monitoring, review and contracting activity in relation to bowel cancer services. In addition they should ensure that all Trusts providing such a service contribute to the National Bowel Cancer Audit.

The National Bowel Cancer Audit

Development of the Audit

The audit was established to investigate whether the care received by bowel cancer patients was consistent with recommended practice and to identify areas where improvements could be made. The original audit was developed by the Association of Coloproctology of Great Britain & Ireland (ACPGBI) and then commissioned by the Healthcare Commission and subsequently by the Healthcare Quality Improvement Partnership. The audit is managed by the NHS Information Centre for health and social care (IC). This audit is one of five national cancer audits being undertaken in England and Wales but offers Trusts from Scotland and Ireland the opportunity to submit data for comparative purposes.

The overall aim of the audit is to measure the quality of care received by patients with bowel cancer, to ensure that "best practice" can be identified and encouraged, and to identify deficiencies within the service at a Trust, Network or national level. The audit answers questions relating to the process of care, identifies variations in treatment and this year reports risk-adjusted clinical outcome measures. Reporting of results by submitting unit enables comparisons to be made and offers the opportunity to improve the quality of data submitted by focussing on the prime role of the multidisciplinary team in the audit process.

The audit is a collaboration between:

- The Association of Coloproctology of Great Britain and Ireland
- The NHS Information Centre for health and social care

The analysis for this annual report was provided by The Northern and Yorkshire Cancer Registry and Information Service and other members of the analytical team. The infrastructure and Helpdesk for the audit is provided by Connecting for Health.

All patients in England and Wales with a diagnosis of bowel cancer are eligible for inclusion, however, the audit accepts data from Scotland, Northern Ireland and Republic of Ireland.

Each year the audit publishes an annual report describing its findings. This annual report contains data from both the 2006/7 reporting period; patients with a diagnosis date from 1 April 2006 to 31 July 2007, and the 2007/8 reporting period; patients with a diagnosis date from 1 August 2007 to 31 July 2008. The 2010 annual report will contain data from patients with a diagnosis date from 1 August 2008 to 31 July 2009.

Progress of the Audit

Since initial data collection in 2000/01 the National Bowel Cancer Audit has substantially increased Trust participation and case ascertainment. Originally submission of data was from a small group of enthusiasts. In 2006 the National Bowel Cancer Audit became one of the National Clinical Audit Support Programme (NCASP) cancer audits. A webbased data collection system allowing either direct data entry or upload via a csv file has facilitated a substantial increase in Trust participation and case ascertainment. However there still needs to be an improvement in data completeness.

Recommendation

Trusts should establish mechanisms for reviewing their audit data prior to submission to the audit and ensure maximum data completeness of the essential dataset prior to submission for the 2010 Annual Report.

Participating Trusts, case ascertainment and data completeness

Audit population

21,170 cases were submitted for the period covering 1 April 2006 to 31 July 2007 and 20,262 were submitted for the period of 1 August 2007 to 31 July 2008, this is approximately 68 per cent of the annual incidence.

Table 1 shows the characteristics of the audit's patient population. Around 73 per cent of the participants were identified as receiving some form of surgical intervention whilst approximately 60 per cent were recorded as receiving a major surgical resection.

Trust participation

Audit Finding

95 per cent of eligible NHS Trusts in England and 100 per cent of Welsh Trusts have participated in the audit

Results

146 of 153 NHS Trusts (95 per cent) in England have participated in the audit by submitting their data to the National Bowel Cancer Audit data collection system. 7 NHS Trusts (5 per cent) have registered to submit their data to the audit but have not submitted any records.

Characteristic		2006/7	2006/7		2007/8		Total	
		n	%	n	%	n	%	
Total number of	cases	21,170		20,262		41,432		
Total number surgically treated cases		15,670		14,780		30,450		
Total number ma	ajor resections	12,612		12,216		24,828		
Sex	Male	11,785	55.7	11,453	56.5	23,238	56.1	
	Female	9,351	44.2	8,746	43.2	18,097	43.7	
	Not Reported	34	0.2	63	0.3	97	0.2	
Age	<60	4,020	19.0	3,728	18.4	7,748	18.7	
	61-70	5,535	26.1	5,554	27.4	11,089	26.8	
	71-80	7,121	33.6	6,707	33.1	13,828	33.4	
	>80	4,492	21.2	4,273	21.1	8,765	21.2	
	Unknown	2	0.0	0	0.0	2	0.0	
Cancer site	Colon	12,478	58.9	12,322	60.8	24,800	59.9	
	Rectosigmoid	1,786	8.4	1,749	8.6	3,535	8.5	
	Rectum	6,698	31.6	6,184	30.5	12,882	31.1	
	Unknown	208	1.0	7	0.0	215	0.5	

Table 2

Table 1

Number of Trusts submitting data to the National Bowel Cancer Audit 2006/8

Region	Trusts su		
	2006	7 2007/8	
England	13	5 138	
Wales	1	2 12	
Northern Ireland		1 1	
Republic of Ireland		2 1	
Other		1 0	
Total	15	1 152	

All 12 Welsh Trusts have participated in the audit (table 2). The Welsh data submission covers the periods 1 April 2006 to 31 July 2007 and 1 August 2007 to 31 March 2008. Data have also been submitted from a number of Trusts in Republic of Ireland, Northern Ireland and one private hospital.


Discussion

The figures are indicative of a successful audit both in terms of coverage and case ascertainment.

The 7 Trusts that have still to submit data to the audit are urged to consider the local reasons for non-participation (table 3). The multi-disciplinary team (MDT) should be the focus for the national bowel cancer audit, taking responsibility for submission of high quality data and being in a position to receive feedback and to implement local action plans (LAP).

Recommendation

Colorectal MDTs should ensure that all cases of bowel cancer are submitted to the National Bowel Cancer Audit.



Case ascertainment and data completeness

Audit Finding

The proportion of Trusts with good case ascertainment (>80 per cent) has improved between the two periods from 50 per cent to 69 per cent. In the 2007/8 reporting period only 13 per cent of submitting Trusts had poor case ascertainment

Methods

Case ascertainment from English NHS Trusts has been estimated by comparison with the National Cancer Data Repository (a combination of cancer registry data and Hospital Episode Statistics (HES) data). Case ascertainment from Welsh NHS Trusts has been calculated by comparison with the number of registrations by the Wales Cancer Intelligence and Surveillance Unit, the cancer registry for Wales. No similar data are available for Northern Ireland or the Republic of Ireland and so case ascertainment figures cannot be provided for organisations from these areas. Data completeness was assessed by calculating the average completeness of the five variables needed for the ACPGBI mortality model: age, Dukes' stage, urgency of operation, cancer excision and ASA grade.

Results

The following table lists all those Trusts in England and Wales that are eligible to submit data to the audit (and those from Ireland who have also submitted) and indicates their case ascertainment and data completeness based on the five mortality model variables listed in previous reports. The figures for both case ascertainment and data completeness can be found in Appendices 1 and 2. Case ascertainment may exceed 100 per cent as it is based on an estimate of annual incidence within each Trust. The Trusts are ordered by Cancer Network.

Grade Case Ascertainment (CA)		Case Ascertainment (CA)	Data Completeness (DC)
Good		>80 % completeness	<20 % missing
Fair		50-80 % completeness	20-50 % missing
Poor		<50 % completeness	>50 % missing

Table 3

Traffic lighting for case ascertainment and data completeness by Unit and Network over the two reporting time periods of 2006/7 and 2007/8.

Organisation	2006/7		2007/8	
	% CA	% DC	% CA	% DC
Lancashire & South Cumbria Cancer Network				
University Hospitals of Morecambe Bay NHS Trust	56.6	58.3 📕	>100 ●	45.7
Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	80.0 ●	38.3 🔺	>100 ●	88.3
Lancashire Teaching Hospitals NHS Foundation Trust	No data submitted		>100 ●	67.6
East Lancashire Hospitals NHS Trust	60.0	47.1 🔺	41.1 🔺	69.3
Greater Manchester & Cheshire Cancer Network				
The Mid Cheshire Hospitals NHS Trust	0.8 🔺	80.0 ●	43.7 🔺	88.0
Christie Hospital NHS Foundation Trust	>100 ●	81.2 🌑	>100 ●	93.2
East Cheshire NHS Trust	1.0 🔺	100.0 🔵	1.3 🔺	100.0
University Hospitals of South Manchester NHS Foundation Trust	>100 ●	88.6 🔵	87.9 🌑	90.9
Salford Royal NHS Foundation Trust	64.7	74.6	56.1	80.3
Trafford Healthcare NHS Trust	No data submitted		58.5	95.0
Bolton Hospitals NHS Trust	>100 ●	92.4 🌑	>100 ●	80.4
Tameside and Glossop Acute Services NHS Trust	>100 ●	70.2	>100 ●	82.3
Wrightington, Wigan and Leigh NHS Trust	1.2 🔺	100.0 🌑	62.6	90.1
Central Manchester University Hospitals NHS Foundation Trust	43.8 🔺	73.1 📕	1.5 🔺	40.0
Pennine Acute Hospitals NHS Trust	20.7 🔺	94.4 🌑	37.1 🔺	95.6
Stockport NHS Foundation Trust	3.9 🔺	75.0 📕	66.2 📕	72.5
Merseyside & Cheshire Cancer Network				
Wirral University Teaching Hospital NHS Foundation Trust	85.8 ●	76.4	>100 ●	77.4
St Helens and Knowsley Hospitals NHS Trust	>100 ●	90.9 🌑	>100 ●	87.7
Aintree University Hospitals NHS Foundation Trust	1.4	80.0 ●	97.0 ●	74.9

Table 3 (continued) Traffic lighting for case ascertainment and data completeness by Unit and Network over the two reporting time periods of 2006/7 and 2007/8.

Organisation	2006/7		2007/8	
	% CA	% DC	% CA	% DC
Clatterbridge Centre For Oncology NHS Foundation Trust	N/A	20.7 🔺	N/A	20.0
Countess of Chester Hospital NHS Foundation Trust	>100 ●	88.5 🔵	>100 ●	83.0
Royal Liverpool and Broadgreen University Hospitals NHS Trust	>100 ●	78.7 📕	58.5	64.7
Southport and Ormskirk Hospital NHS Trust	>100 ●	92.3 🌑	No data submitted	
Warrington and Halton Hospitals NHS Foundation Trust	94.8 ●	72.7 📕	>100 ●	63.7
Yorkshire Cancer Network				
Bradford Teaching Hospitals NHS Foundation Trust	57.1	81.6 🌑	>100 ●	82.0
York Hospitals NHS Foundation Trust	>100 ●	64.0	>100 ●	77.1
Harrogate and District NHS Foundation Trust	77.8	95.7 🌑	>100 ●	92.1
Airedale NHS Trust	63.3	93.7 🌑	>100 ●	84.9
Leeds Teaching Hospitals NHS Trust	>100 ●	60.5	>100 ●	82.6
Calderdale and Huddersfield NHS Foundation Trust	77.4	92.1 🌑	56.2	92.0
Mid Yorkshire Hospitals NHS Trust	63.0	86.8 ●	>100 ●	78.2
Humber & Yorkshire Coast Cancer Network				
Scarborough & North East Yorkshire Health Care NHS Trust	No data submitted		No data submitted	
Northern Lincolnshire and Goole Hospitals NHS Foundation Trust	0.4	80.0 ●	37.7 🔺	77.8
Hull and East Yorkshire Hospitals NHS Trust	77.6	94.9 ●	91.5 ●	92.0
North Trent Cancer Network				
Barnsley Hospital NHS Foundation Trust	27.5	63.6	>100 ●	79.3
The Rotherham NHS Foundation Trust	15.0	83.2	91.6	91.9
Chesterfield Royal Hospital NHS Foundation Trust	No data submitted	05.2	No data submitted	51.5
Sheffield Teaching Hospitals NHS Foundation Trust	44.1	66.6	>100 ●	76.5
Doncaster and Bassetlaw Hospitals NHS Foundation Trust	12.8	82.9	22.9	86.7
Pan Birmingham Cancer Network	20.4.4	70.0	F0.6	
Walsall Hospitals NHS Trust	39.4	79.9	59.6	80.0
Heart of England NHS Foundation Trust	77.4	79.0	>100	79.7
University Hospital Birmingham NHS Foundation Trust	65.3 6 5.3 8 1.8 •	73.1 6 9.5	63.9	93.9
Sandwell and West Birmingham Hospitals NHS Trust	01.0	09.0	70.7	01.0
Arden Cancer Network				
South Warwickshire General Hospitals NHS Trust	>100 ●	77.9 📕	96.8 ●	84.1
University Hospitals Coventry and Warwickshire NHS Trust	>100 ●	76.4 📕	>100 ●	73.0
George Eliot Hospital NHS Trust	64.3	78.8	>100 ●	79.1
Worcestershire Acute Hospitals NHS Trust	7.6 🔺	73.8	>100 ●	77.1
Mid Trent Cancer Network				
Sherwood Forest Hospitals NHS Foundation Trust	59.5	81.5 🌑	>100 ●	81.7 (
United Lincolnshire Hospitals NHS Trust	0.4 🔺	90.0 ●	No data submitted	
Nottingham University Hospitals NHS Trust	>100 ●	89.5 🌑	>100 ●	61.9
Derby & Burton Cancer Network				
Burton Hospitals NHS Trust	22.0	58.4	7.1 🔺	87.5
Derby Hospitals NHS Foundation Trust	>100 ●	86.7 ●	>100 ●	77.2
Leicestershire, Northamptonshire & Rutland Cancer Network				
Kettering General Hospital NHS Trust	64.1	38.2 🔺	No data submitted	
Northampton General Hospital NHS Trust	48.1	88.2	70.2	74.2
University Hospitals of Leicester NHS Trust	>100	92.2	>100	92.6
Mount Vernon Cancer Network		<u> </u>	400 -	
Luton and Dunstable Hospital NHS Foundation Trust	66.4	60.0	>100	58.5
West Hertfordshire Hospitals NHS Trust	78.0	66.2	No data submitted	
East and North Hertfordshire NHS Trust	>100 ●	95.2 🌑	>100 ●	94.4

Table 3 (continued)

% CA >100 ● 7.3 ▲ >100 ● >100 ● 2.2 ▲ No data submitted >100 ● x → x → x → x → x → x → x → x → x → x →	% DC	% CA >100 ● 75.2 ■ >100 ● >100 ● 28.2 ▲ >100 ●	% DC 67.9 78.1 89.3 82.5 63.6
7.3 ▲ >100 ● >100 ● 2.2 ▲ No data submitted >100 ●	90.0 • 85.5 • 86.7 •	75.2 ■ >100 ● >100 ● 28.2 ▲	78.1 89.3 82.5
7.3 ▲ >100 ● >100 ● 2.2 ▲ No data submitted >100 ●	90.0 • 85.5 • 86.7 •	75.2 ■ >100 ● >100 ● 28.2 ▲	78.1 89.3 82.5
>100 • >100 • 2.2 ▲ No data submitted	85.5 • 86.7 •	>100 • >100 • 28.2 ▲	89.3 82.5
>100 • 2.2 ▲ No data submitted	86.7 ●	>100 • 28.2 ▲	82.5
2.2 ▲ No data submitted		28.2	
No data submitted	73.0		63.6
>100 ●		>100 ●	
			84.8
No data submitted	82.9 🌑	98.6 ●	61.3
		No data submitted	
9.3 🔺	80.0 ●	>100 ●	79.9
No data submitted		No data submitted	
>100 ●	87.6 ●	No data submitted	
>100 ●	86.4 🔵	87.1 ●	88.3
82.6 ●	74.2	62.6	78.6
93.3 🌒	71.3 📕	>100 ●	84.2
8.0 🔺	85.0 🌑	>100 ●	84.0
35.8 🔺	63.6	60.4	91.1 (
>100 ●	73.2 📕	>100 ●	77.9
>100 ●	74.3	>100 ●	71.2
6.6 🔺	35.0 🔺	3.3 🔺	33.3
23.3 🔺	27.6 🔺	38.5 🔺	53.1
No data submitted		86.2 ●	27.1
>100 ●	89.4 🌑	>100 ●	77.8
>100 ●	80.2 ●	>100 ●	80.2
No data submitted		No data submitted	
18.1 🔺	69.2	84.8 ●	81.5
15.2	81.8 ●	22.7 🔺	58.2
6.0 🔺	40.0 🔺	88.0 ●	61.3
31.1 🔺	51.2	79.4	50.1
72 5	82.0	68.9	82.2
			87.6
			83.8
			88.3
>100	45.6	>100 ●	79.8
>100	90 1 🗭	>100	76.6
			76.8
>100 •	96.9	>100 •	89.6
00.0	FA A		
			76.5
			90.7
			74.5
			61.3
>100 ●	63.7		76.8
	>100 ● >100 ● >100 ● >100 ● 82.6 ● 93.3 ● 93.3 ● 35.8 ▲ >100 ● >10 ● >10 ● >10 ● >	>100 87.6 >100 86.4 >100 86.4 82.6 74.2 93.3 71.3 80.0 85.0 35.8 63.6 >100 73.2 >100 73.2 >100 74.3 >100 74.3 >100 74.3 >100 74.3 >100 74.3 >100 74.3 35.8 23.3 27.6 No data submitted 1 >100 80.2 No data submitted 1 15.2 81.8 15.2 81.8 15.2 81.8 15.2 82.0 31.1 51.2 36.9 82.5 >100 45.0 98.8 88.1 >100 90.1 >100 90.1 >100 90.1 >100 90.1 >100 90.1 90.0 52.6	>100 87.6 No data submitted >100 86.4 87.1 82.6 74.2 62.6 93.3 71.3 >100 82.6 74.2 62.6 93.3 71.3 >100 93.3 71.3 >100 82.6 63.6 60.4 >100 74.3 >100 >100 74.3 >100 >100 74.3 >100 >100 74.3 >100 85.0 3.3 85.0 33.3

Organisation	2006/7		2007/8	
5	% CA	% DC	% CA	% DC
Three Counties Cancer Network				
Hereford Hospitals NHS Trust	>100 ●	95.6 ●	>100 ●	93.9
Gloucestershire Hospitals NHS Foundation Trust	0.7 🔺	100.0 ●	25.4 🔺	87.3
Thames Valley Cancer Network				
Heatherwood and Wexham Park Hospitals NHS Foundation Trust	>100 ●	24.6 🔺	>100 ●	40.0
Milton Keynes General Hospital NHS Foundation Trust	39.7 🔺	80.8 ●	56.9	63.2
Royal Berkshire NHS Foundation Trust	No data submitted		No data submitted	
Great Western Hospitals NHS Foundation Trust	>100 ●	85.5 🌑	86.5 🔵	88.2
Oxford Radcliffe Hospitals NHS Trust	34.6 🔺	87.9 🌑	71.7	80.9
Buckinghamshire Hospitals NHS Trust	24.6 🔺	96.2 ●	33.3 🔺	97.4
Central South Coast Cancer Network				
sle of Wight Healthcare NHS Trust	>100 ●	81.6 ●	94.3 ●	73.3
Southampton University Hospitals NHS Trust	0.7 🔺	40.0 🔺	>100 ●	95.2
Portsmouth Hospitals NHS Trust	>100 ●	83.8 ●	>100 ●	79.3
Winchester and Eastleigh Healthcare NHS Trust	>100 ●	75.3 📕	>100 ●	77.6
Basingstoke & North Hampshire NHS Foundation Trust	No data submitted		>100 ●	68.7
Salisbury NHS Foundation Trust	>100 ●	90.2 ●	>100 ●	88.6
Royal West Sussex NHS Trust	99.3 ●	92.4 🌑	>100 ●	85.4
Surrey, West Sussex & Hampshire Cancer Network				
Royal Surrey County Hospital NHS Trust	74.6	78.2	69.2	63.3
Frimley Park Hospital NHS Foundation Trust	No data submitted		67.5	86.2
Ashford and St Peter's Hospitals NHS Trust	No data submitted		16.2 🔺	20.0
Sussex Cancer Network Worthing and Southlands Hospitals NHS Trust	0.5	80.0 ●	>100 ●	67.2
East Sussex Hospitals NHS Trust	1.1	83.3 •	>100 •	76.7
Brighton and Sussex University Hospitals NHS Trust	5.7	64.7	56.1	66.4
Kent & Medway Cancer Network				
Dartford And Gravesham NHS Trust	15.0	95.7 ●	>100 ●	97.5
Medway NHS Trust	36.4	79.2	15.4	93.7
East Kent Hospitals NHS Trust	2.8	20.0 🔺	72.6	20.0
Maidstone And Tunbridge Wells NHS Trust	1.7 🔺	80.0 ●	48.3	81.6
Greater Midlands Cancer Network				
Mid Staffordshire General Hospitals NHS Trust	40.9	20.0 🔺	58.2	20.0
University Hospital of North Staffordshire NHS Trust	No data submitted		No data submitted	
The Royal Wolverhampton Hospitals NHS Trust	28.0	69.4	>100 ●	69.1
Dudley Group of Hospitals NHS Trust	67.1	91.7 ●	67.9	87.1
Shrewsbury and Telford Hospital NHS Trust	>100 ●	80.5 ●	>100 ●	83.4
North of England Cancer Network				
South Tyneside NHS Foundation Trust	>100 ●	89.4 ●	99.5 ●	81.7
City Hospitals Sunderland NHS Foundation Trust	85.7	91.1 •	78.7	90.6
North Cumbria Acute Hospitals NHS Trust	59.2	75.3	>100	82.5
Gateshead Health NHS Foundation Trust	66.4	87.9	82.9	87.5
The Newcastle Upon Tyne Hospitals NHS Foundation Trust	74.7	72.1	86.5	83.1
Northumbria Health Care NHS Foundation Trust	61.2	82.4	98.3	83.6
South Tees Hospitals NHS Trust	90.0	81.0	>100	85.5
North Tees and Hartlepool NHS Trust	89.1	81.1	>100 ●	77.8
torar rees and naracpoortins must	0.1	01.1	~100 -	11.0

Organisation	2006/7		2007/8	
	% CA	% DC	% CA	% DC
Anglia Cancer Network				
Bedford Hospital NHS Trust	0.8 🔺	40.0 🔺	>100 ●	54.3
The Queen Elizabeth Hospital King's Lynn NHS Trust	>100 ●	88.7 ●	44.8 🔺	62.2
Peterborough and Stamford Hospitals NHS Foundation Trust	95.6 ●	81.8 ●	64.4	24.9 🔺
James Paget Healthcare NHS Foundation Trust	>100 ●	80.9 🌑	>100 ●	86.1 ●
Ipswich Hospital NHS Trust	No data submitted		No data submitted	
West Suffolk Hospitals NHS Trust	54.4	81.3 ●	>100 ●	37.7 🔺
Cambridge University Hospitals NHS Foundation Trust	5.9 🔺	78.7 📕	>100 ●	78.6
Norfolk and Norwich University Hospital NHS Trust	32.3 🔺	74.3	>100 ●	82.3
Hinchingbrooke Health Care NHS Trust	No data submitted		65.3	88.4
Essex Cancer Network				
Southend University Hospital NHS Foundation Trust	90.4 ●	92.3 ●	No data submitted	
Basildon and Thurrock University Hospitals NHS Foundation Trust	No data submitted		85.8 ●	64.8
Essex Rivers Healthcare NHS Trust	0.4	100.0 ●	No data submitted	
Mid Essex Hospital Services NHS Trust	0.7 🔺	20.0 🔺	6.4 🔺	76.0
North Wales Cancer Network				
North West Wales NHS Trust	>100 ●	77.9	>100	89.9
Conwy and Denbighshire NHS Trust	>100	89.0 ●	99.0	98.6
North East Wales NHS Trust	81.8 ●	62.3	98.9 ●	94.1
South East Wales Cancer Network				
North Glamorgan NHS Trust	96.8 ●	84.1 ●	>100 ●	87.6
Pontypridd & Rhondda NHS Trust	>100	75.3	>100	90.3
Gwent Healthcare NHS Trust	>100 ●	79.9	94.6 ●	77.0
Cardiff & Vale NHS Trust	82.8 ●	75.8	>100 ●	71.3
South West Wales Cancer Network				
Ceredigion & Mid Wales NHS Trust	96.4 ●	89.8 ●	>100 ●	93.2
Pembrokeshire & Derwen NHS Trust	>100 ●	93.6 ●	96.2 ●	95.9
Carmarthenshire NHS Trust	>100 ●	92.4 ●	96.6 ●	91.2
Swansea NHS Trust	>100 ●	92.5 ●	96.5 🌑	91.8
Bro Morgannwg	92.0 ●	79.1 📕	97.4 ●	89.2
Republic of Ireland				
St James Hospital, Ireland	N/A	91.5 ●	No data submitted	
Southern Health and Social Care Trust, Ireland	N/A	91.2 ●	No data submitted	
Beaumont Hospital, Dublin	No data submitted		N/A	80.3
Northern Ireland				
Belfast	N/A	79.1 📕	N/A	79.4
Other				
Princess Grace Hospital	N/A	100.0 ●	No data submitted	

Figures 2 and 3 summarise the data for both case ascertainment and data completeness for the two data collection periods.

Discussion

There has been an improvement in Trust participation, case ascertainment and data completeness, which is greatly encouraging. However, data completeness remains an issue. For meaningful analysis, especially risk adjusted outcomes and comparative audit, the data should be as complete as possible. Data completeness ensures that the audit can truly reflect the national picture and individual Trust results as well as facilitate risk adjustment.

Trusts should concentrate on improving their data completeness. Submitting high quality data will allow Trusts to monitor their results against previous performance, which together with the development of local action plans will ensure a continuous improvement in the quality of the care they provide.

Recommendation

Trusts should establish mechanisms for reviewing their audit data prior to submission to the audit and ensure maximum data completeness of the essential dataset prior to submission for the 2010 Annual Report.





Figure 3



Main Findings

Discussion of patients at a multi-disciplinary team meeting (MDT)

Audit finding

84 per cent of cases were reported to have been discussed at an MDT meeting in 2007/8.

Standard

NICE guidance and Peer Review recommendations are that 95 per cent to 100 per cent of patients should be discussed at an MDT meeting.

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: All patients with colorectal cancer should have the benefit of a suitably informed surgical opinion and their management should be discussed by the MDT.

Background

The management of colorectal cancer has become increasingly complex, both in terms of staging the disease and in the options for treatment. Local procedures, with curative intent, are likely to increase with the advent of bowel screening programmes. Decisions on the use of preoperative chemotherapy, radiotherapy or a combination of both, post-operative adjuvant and palliative chemotherapy, and referral for surgical treatment of metastatic disease, are becoming commonplace. There are also efforts at increasing recruitment of eligible patients into clinical trials.

Although MR and CT imaging have made clinical decisions more precise and pathological examination of specimens has helped in identification of "high-risk groups", there remain many uncertainties, which can only be resolved by full discussion between radiologists, pathologists, oncologists and surgeons.

The way to ensure patients receive the maximum benefit from these new modalities and treatment schedules is by discussion at a multidisciplinary team (MDT) meeting. Patients need the reassurance that a team rather than a single clinician has discussed all options and that the MDT has selected the best treatment for them.

Methods

The contents of the field MDT_DISCUSSION_INDICATOR in the dataset indicate whether a patient has been discussed at an MDT meeting. The data entered into this field were, therefore, compared over the two reporting periods. The denominators for these analyses are the total number of individuals submitted to the audit.

Results

The number of patients recorded as being discussed at an MDT meeting increased from 80.3 per cent in 2006/7 to 83.7 per cent in 2007/8 (table 4). The level of data completeness also increased over the two reporting periods but, overall, no data were supplied about MDT discussion in 13.4 per cent of cases.

Discussion

Over 80 per cent of cases of colorectal cancer were discussed at an MDT meeting. Although it may never be possible to discuss all patients before treatment the aim should be to be as close to 100 per cent as possible and to improve performance each year. The reported audit data shows that the number of patients discussed at an MDT meeting varied substantially between Cancer Networks, ranging from 36 per cent to 99 per cent.

Recommendation

Trusts should ensure that all bowel cancer patients are discussed at an MDT meeting.

Table 4 Number of cases discussed at an MDT meeting							
MDT Discussion	2006/7		2007/8		Total		
	n	%	n	%	n	%	
No	873	4.1	1,033	5.1	1,906	4.6	
Yes	17,001	80.3	16,966	83.7	33,967	82.0	
Not reported	3,296	15.6	2,263	11.2	5,559	13.4	

Patients seeing a clinical nurse specialist (CNS)

Audit finding

51 per cent of patients were reported as being seen by a clinical nurse specialist in 2007/8.

Standard

NICE guidance is that 100 per cent of patients should be seen by a specialist nurse.

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: Patients with colorectal cancer should have access to a colorectal nurse specialist for advice and support from the time they receive the diagnosis. The patient who may require a stoma should be seen by a stoma nurse prior to surgery and the referral should be made at the earliest opportunity to allow adequate time for preparation.

Methods

The contents of the field NURSE_SEEN in the dataset indicate whether a patient has had contact with a CNS. The data entered into this field were, therefore, compared over the two reporting periods. The denominator for this analysis was the total number of individuals submitted to the audit.

Results

The number of patients seeing a CNS increased from 40.9 per cent in 2006/7 to 51.2 per cent in 2007/8, showing a 10 per cent increase in this standard of care. The level of data completeness for this data item was poor and in nearly 40 per cent of cases no information was supplied to indicate whether a CNS had been involved in patient care.

Discussion

The 10 per cent increase in patients seeing a clinical nurse specialist is encouraging; however, guidance is that 100 per cent of patients with bowel cancer should have access to a clinical nurse specialist. The data indicates that only 51 per cent of cases entered into the audit are receiving this care. This low figure could be due to poor data completeness rather than a true reflection of the care provided. It is hoped that the value of these data may be more to encourage Trusts to collect it accurately so that individual Trusts can monitor their own achievements and to aim for the national guideline of all patients with bowel cancer having access to a clinical nurse specialist. The reported audit data shows that the number of patients seeing a clinical nurse specialist varied substantially between Cancer Networks, ranging from 12 per cent to 97 per cent.

Recommendation

All bowel cancer patients should be seen by a clinical nurse specialist.

Table 5 Proportion of patients seen by a clinical nurse specialist							
Patient seen by CNS	2006/7		2007/8		Total		
	n	%	n	%	n	%	
No	3,605	17.0	2,514	12.4	6,119	14.8	
Yes	8,657	40.9	10,373	51.2	19,030	45.9	
Unknown	8,908	42.1	7,375	36.4	16,283	39.3	

Reporting of clinico-pathological Dukes' stage

Audit finding

Dukes' staging was reported in less than 55 per cent of cases. By analysis of other data submitted a derived Dukes' stage was determined in 76 per cent of cases.

Background

Accurate staging of colorectal cancer is of the utmost importance. Staging determines outcome as presented in a recent publication from the National Cancer Intelligence Network revealing five-year survival rates of 93 per cent for Dukes' stage A disease to 6 per cent for stage D. Those patients with more advanced disease will be recommended adjuvant therapy and patients with metastatic disease may require further surgery or palliative measures. As well as allowing decisions to be made on further treatment, the stage of the disease is one of the five variables in the riskadjusted modelling of post-operative mortality.

Methods

Two Dukes' stages have been reported. The first is that supplied directly to the audit in the field MODIFIED_DUKES. A number of other fields exist in the dataset, however, that indicate the extent of disease within particular patients. In many cases it was apparent that the MODIFIED_DUKES field had not been completed but staging information was available from other fields. As a consequence, a second Dukes' stage was derived from these other staging variables to increase the proportion of cases that could be staged. The following rules were applied to derive this stage:

- If the T stage was stated as T1 or T2 and the patient was node negative then the patient was allocated to Dukes' A
- If the T stage was stated as T3 or T4 and the patient was node negative then the patient was allocated to Dukes' B

- If positive nodes were recorded then the patient was deemed a Dukes' C
- If any of the fields (including pre-operative staging fields) indicated that a patient had distant metastases then stage defaulted to Dukes' D
- If data in any of the relevant fields conflicted then the most advanced stage reported was adopted.

Results

The MODIFIED_DUKES field was completed in only 54.6 per cent of the cases submitted (tables 6 & 7). Using all the staging information supplied, however, it was possible to derive a Dukes stage' for 76.1 per cent of patients.

Discussion

Dukes' stage is poorly recorded in the data submitted to the audit. The stage of the disease is of great importance in risk adjustment. MDTs should make every effort to arrive at a clinico-pathological stage for every patient with bowel cancer and then record this information. Pathological stage needs to be combined with the results of all other findings (radiological and operative) and an "integrated" clinicopathological stage obtained.

It is imperative that the staging of disease approaches 100 per cent and should be one of the main aims for the data submitted for the 2010 annual report.

Recommendation

All Trusts should accurately record a clinico-pathological Dukes' stage and this should be agreed at the MDT for all patients with colorectal cancer.

Dukes' stage		2006/7		2007/8		Total	
		n	%	n	%	n	9
Supplied	А	1,520	7.2	1,328	6.6	2,848	6.
	В	3,990	18.8	3,291	16.2	7,281	17.
	С	3,417	16.1	2,930	14.5	6,347	15.
	D	2,857	13.5	3,271	16.1	6,128	14.3
	Unknown	9,386	44.3	9,442	46.6	18,828	45.4
Derived	А	1,839	8.7	1,879	9.3	3,718	9.0
	В	4,932	23.3	4,786	23.6	9,718	23.
	С	5,290	25.0	5,154	25.4	10,444	25.
	D	3,982	18.8	3,683	18.2	7,665	18.
	Unknown	5,127	24.2	4,760	23.5	9,887	23.

Dukes' stage		2006/7		2007/8		Total		
		n	%	n	%	n	%	
Supplied	А	1,251	9.9	1,071	8.8	2,322	9.4	
	В	3,469	27.5	2,773	22.7	6,242	25.1	
	С	2,906	23.0	2,435	19.9	5,341	21.5	
	D	1,104	8.8	1,232	10.1	2,336	9.4	
	Unknown	3,882	30.8	4,705	38.5	8,587	34.6	
Derived	А	1,543	12.2	1,594	13.0	3,137	12.6	
	В	4,272	33.9	4,147	33.9	8,419	33.9	
	С	4,174	33.1	4,152	34.0	8,326	33.5	
	D	1,776	14.1	1,462	12.0	3,238	13.0	
	Unknown	847	6.7	861	7.0	1,708	6.9	

Use of CT scanning in patients with colorectal cancer

Audit finding

61 per cent of patients were reported to have had a CT scan during their care in the 2007/8 reporting period.

Standard

NICE guidance is that 100 per cent of patients should be given a CT scan. ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: All patients with colon or rectal cancer should have pre-operative staging by CT scan to determine the local extent of the disease and the presence of lung or liver metastases. In patients presenting with obstruction, CT scanning should be carried out to exclude pseudo-obstruction before operation.

Background

No

Yes

Good pre-operative staging identifies patients with early disease that may be cured by endoscopic or minimal surgery and, in contrast, also identifies those with extensive disease and minimal symptoms who are best managed without major surgery. It is, therefore, an important part of a patient's pre-operative management that a CT scan is performed in all who subsequently have an elective operation. It is more difficult to do this in an emergency situation although this is increasingly required to identify which patients with large bowel obstruction have disseminated disease and are best treated with an internal colonic stent without surgery.

Methods

No field exists in the dataset to simply indicate whether a patient underwent a CT scan but rather this variable is inferred from the field that reports whether liver metastases were identified by CT scan (PAT_PROC_RESULT_CT_SCAN). If this field has been completed (whether positive or negative for metastases) then it was taken that a patient underwent a CT scan. If the field is blank then it was assumed no CT scan was performed. The denominators used for the analysis were all patients and all those undergoing a surgical procedure.

Results

Overall, the number of patients having a CT scan increased from 54.9 per cent in 2006/7 to 60.9 per cent in 2007/8 (tables 8 & 9). In nearly 43 per cent of cases no data was recorded. The proportion of surgically treated cases that underwent a CT scan increased from 58.2 per cent in 2006/7 to 66.0 per cent in 2007/8.

Discussion

These data indicate that many Trusts are failing the 100 per cent standard contained within the NICE Guidelines. However, these poor results may be due to incomplete data submission rather than a lack of resources for CT imaging. But, if 'failing' MDTs do suffer from an inadequate CT resource then they should use this information to persuade their Trusts to provide them with appropriate resources for this important aspect of a bowel cancer patient's care. The reported audit data shows that the number of patients having a CT scan varied substantially between Cancer Networks, ranging from 14 per cent to 92 per cent.

Recommendation

41.8

58.2

5,116

9.920

34.0

66.0

11,754

19,163

38.0

62.0

CT scanning should be performed on all patients with colorectal cancer.

Table 8 Proportion of patients with colorectal cancer undergoing CT imaging						
CT reported	2006/7		2007/8		Total	
	n	%	n	%	n	%
No	9,544	45.1	7,931	39.1	17,475	42.2
Yes	11,626	54.9	12,331	60.9	23,957	57.8
Table 9 Proportion of surgically treated patients undergoing CT imaging						
CT reported	2006/7		2007/8		Total	
	n	%	n	%	n	%

6.638

9.243

Use of pre-operative MR scanning in rectal cancer patients

Audit finding

For patients with rectal cancer MR imaging was used to stage the disease in 51 per cent of cases overall and 58 per cent in those treated surgically in the 2007/8 reporting period

Standard

NICE guidance is that patients with invasive rectal cancers for whom surgery is being considered should have magnetic resonance imaging (MRI) scans before treatment begins.

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommend that: All patients with rectal cancer should have MR scans of the pelvis to stage the tumour and asses involvement of adjacent organs.

Background

Evidence shows that pre-operative radiotherapy reduces local recurrence, one of the most unpleasant complications of rectal cancer surgery; therefore Trusts should identify patients with threatened margins pre-operatively so they may receive the potential benefit of this treatment. MR imaging is currently the best modality for identifying these high-risk patients and, hence, optimising treatment plans.

Methods

Yes

There is, again, no single field in the dataset that indicates whether an MR scan was undertaken. Rather there are a number of fields that indicate the pre-operative stage determined by an MR scan. If any of these fields (PAT_ PROC_RESULT_T_MRI_SCAN_1, PAT_PROC_RESULT_N_MRI_ SCAN_1, MARGIN_THREATENED) were completed then a patient was defined as having undergone an MR scan. If the fields were empty then a patient was defined as not having received this pre-operative staging intervention. All patients and all surgically treated rectal cancer patients are included in this analysis. Please note that malignant rectal polyps are included in the total number of rectal cancer patients that require staging. These patients will have T1 lesions by default but they should still have the same workup as non-polyp cancers.

Results

Overall, the number of rectal cancer patients receiving a preoperative MR scan increased from 41.3 per cent in 2006/7 to 51.1 per cent in 2007/8 (tables 10 & 11). 54.0 per cent were identified as not receiving a pre-operative MR scan. Amongst surgically treated patients the rates of MR scanning use were higher with, 52.3 per cent of patients undergoing this investigation.

Discussion

The high proportion of patients recorded as not receiving this investigation may be a consequence of poor data completion. For Trusts achieving below average rates of MR use these results should encourage them to either improve their data collection or reflect on the care they are providing. They should aim to improve next year and encourage their Chief Executive and Management to provide the resources for this activity. The reported audit data shows that the number of patients having a MR scan varied substantially between Cancer Networks, ranging from 7 per cent to 84 per cent.

Recommendation

47.0

2,474

Patients with rectal cancer who are to be treated for their primary disease should be staged with an MR scan.

Table 10 Proportion of patients with rectal cancer having an MR scan pre-opera	tively					
MR reported	2006/7		2007/8		Total	
	n	%	n	%	n	%
No	3,935	58.7	3,024	48.9	6,959	54.0
Yes	2,763	41.3	3,160	51.1	5,923	46.0
Table 11 Proportion of surgically treated rectal cancer patients having an MR sc		ely	2007/8		Tedal	
MR reported	2006/7		2007/8		Total	
	n	%	n	%	n	%
No	2,448	53.0	1,762	41.6	4,210	47.4

2.171

58.4

4,645

52.3

Use of pre-operative radiotherapy in patients with rectal cancer

Audit finding

Overall 32 per cent of cases of rectal cancer were reported to have pre-operative radiotherapy, either long course chemo-radiotherapy or short course (5x5) radiotherapy. Considerable variation was observed across Cancer Networks in the use of pre-operative radiotherapy.

Standard

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: Patients with resectable rectal cancer should be considered for pre-operative shortterm radiotherapy with surgery performed within 1 week of completion of radiation.

Background

Whether or not a patient receives pre-operative radiotherapy will depend on many factors including case-mix and local protocols. The use of radiotherapy should also be determined by audited outcome measures of local recurrence and margin status. The use of this treatment is, therefore, an important parameter to measure, both in terms of determining the need for radiotherapy services and, in future, to determine the degree to which it reduces local recurrence at a national level rather than just in the context of randomised controlled trials.

Methods

Information in the field TELETHERAPY_TYPE_GIVEN was used to determine whether a patient had received pre-operative radiotherapy. If the data provided indicated a patient had had short course or long course pre-operative radiotherapy then they were deemed as receiving this intervention. As pre-operative radiotherapy is only used to treat patients with rectal tumours then the denominator used was all patients with rectal cancer who underwent any surgical intervention.

Results

Overall, 32.1 per cent of surgically treated rectal cancer patients underwent some form of pre-operative radiotherapy (table 12). There was no significant change over the two reporting periods in the proportion of patients receiving this intervention. Significant variation was observed in the use of this treatment across Cancer Networks (Figure 4).

Discussion

Radiotherapy has a major role in the management of rectal cancer. Despite the results of randomised controlled trials its use varies throughout the country. The importance for the future is to determine accurately the proportion of patients receiving radiotherapy, and to have the ability to follow up these patients in the longer term. The reported audit data shows that the number of patients having pre-operative radiotherapy varied substantially between Cancer Networks, ranging from 0 per cent to 74 per cent.

Recommendation

Networks should continue to refine their protocols for the use of pre-operative radiotherapy in patients with rectal cancer in order to ensure it is used in all appropriate cases.

Table 12 Use of pre-operative radiotherapy in patients with rectal cancer												
Pre-operative radiotherapy	2006/7		2007/8		Total							
	n	%	n	%	n	%						
None or unknown	2,253	68.6	2088	67.1	4,341	67.9						
Short course	425	12.9	416	13.4	841	13.1						
Long course	608	18.5	606	19.5	1,214	19.0						

006/7	2007/8									
	ou =									
	Other									
	Northern Ireland									
	Republic of Ireland				_					
	South West Wales Cancer Network									
	South East Wales Cancer Network									
	North Wales Cancer Network					1	-			
	Essex Cancer Network									
	Anglia Cancer Network									
	North of England Cancer Network			1						
	Greater Midlands Cancer Network									
	Kent & Medway Cancer Network									
	Surrey, West Sussex & Hampshire Cancer Network									
	Central South Coast Cancer Network									
	Thames Valley Cancer Network Three Counties Cancer Network									
	Avon, Somerset & Wiltshire Cancer Network Dorset Cancer Network									
	Peninsula Cancer Network									
	South West London Cancer Network									
	South West London Cancer Network									
	North East Cancer Network									
	North London Cancer Network			1	-					
	West London Cancer Network									
	Mount Vernon Cancer Network									
	Leicestershire, Northamptonshire & Rutland Cancer Network			1	-	-				
	Derby & Burton Cancer Network									
	Mid Trent Cancer Network									
	Arden Cancer Network									
	Pan Birmingham Cancer Network		1	1						
	North Trent Cancer Network									
	Humber & Yorkshire Coast Cancer Network									
	Yorkshire Cancer Network									
	Merseyside & Cheshire Cancer Network					-	1			
	Greater Manchester & Cheshire Cancer Network									
	Lancashire & South Cumbria Cancer Network									
								-		
tage of patient		0	10	20	30	40	50	60	70	80
pre-operative erapy										

ASA (American Society of Anaesthesiologists) grade in patients undergoing surgical intervention

Audit finding

Overall, ASA grade was reported in 69 per cent of cases where a surgical intervention was recorded.

Background

55 per cent of patients presenting with colorectal cancer are over 70 years old and may have co-existent morbidity. Without ASA grade, or another validated score for comorbidity, post-operative mortality cannot be risk-adjusted.

Methods

The contents of the field ASA_GRADE within the audit dataset were used to determine each patient's ASA grade. This data item may not be recorded for those individuals who do not undergo a surgical intervention. In consequence, the denominator for these analyses was the number of individuals who underwent any surgical intervention. This included those who underwent major resections, local excision and palliative procedures.

Results

ASA grade was recorded in 69.3 per cent of cases (table 13).

Discussion

The ASA grade is very often recorded at surgery by the anaesthetist and is a simple grade to note for audit purposes. Although it was reported in 69.3 per cent of cases every effort should be made to record this grade on all patients with bowel cancer undergoing surgical intervention as this is the factor with the greatest variance in the operative mortality model.

Recommendation

ASA grade should be recorded for all patients with bowel cancer undergoing surgical intervention.

Table 13 ASA grade as recorded for all patients undergoing any surgical intervention												
ASA grade	2006/7		2007/8		Total							
	n	%	n	%	n	%						
Fit	1,627	10.2	1,598	10.6	3,225	10.4						
Relevant disease	5,864	36.9	5,351	35.6	11,215	36.3						
Restrictive disease	2,956	18.6	3,128	20.8	6,084	19.7						
Life-threatening disease	49	0.3	5	0.0	54	0.2						
Moribund	419	2.6	430	2.9	849	2.7						
Unknown	4,966	31.3	4,524	30.1	9,490	30.7						

Cases undergoing urgent or emergency surgery

Audit finding

Overall 69 per cent of patients having surgery for colorectal cancer were managed in the elective/ scheduled setting, with 18 per cent undergoing urgent/ emergency procedures.

Standard

NICE guidance is that facilities and services should be established to provide stenting for patients with intestinal obstruction, particularly those with serious comorbidity, so that high-risk emergency surgery may be avoided. Cancer Networks should assemble teams with appropriate expertise and sufficient capacity to stent about 15 people per million population per annum. Decision-making generally on the use of stents should be the responsibility of colorectal cancer MDTs. Stents should be inserted within 48 hours of admission, by appropriately trained individuals (usually interventional radiologists, ideally working with endoscopists).

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: In patients with large bowel obstruction, the insertion of an expanding stent is an acceptable treatment option where adequate local expertise exists. Stenting may be used either for palliation or as a bridge to surgery.

Background

Patients having emergency surgery are at a much higher risk of dying in the post-operative period. Although it is commonly assumed that emergency surgery is the result of delayed diagnosis, these patients tend to have a shorter history before surgery and they may represent a sub-set of cancers that are biologically more aggressive. It is important to identify these cases as they will significantly affect the risk-adjustment of a unit's overall post-operative mortality. With a five-fold increase in the post-operative mortality of patients treated urgently or as an emergency it is important to attempt to convert emergency cases to elective if at all possible. This is possible with some cases of large bowel obstruction.

Methods

The mode of operation was determined from the field within the dataset called SURGICAL_URGENCY_MODE_OF_OP. The denominator used for the analysis was all patients who underwent any form of surgical intervention including local excisions, major resections and palliative procedures.

Results

The CEPOD category, which is one of the five variables in the risk-adjusted modelling of post-operative mortality, was reported in all but 12 per cent of cases (table 14). The relationship of CEPOD category to post-operative mortality is shown in Figure 5.

Discussion


Whilst nearly 70 per cent of patients having surgery for colorectal cancer were managed in the elective/scheduled setting, a fair proportion (20 per cent) still underwent urgent/emergency procedures. This occurred despite recent advances in care, such as the use of stenting.

Wherever possible it is important to attempt to convert emergency cases to elective. This can be achieved in some cases of large bowel obstruction but these data suggest there will always be cases that require skilled surgical management in the emergency/urgent setting.

Recommendation

Efforts should be made to manage patients with colorectal cancer in the elective setting whenever possible, regardless of the mode of admission. CEPOD category should be recorded in all cases.

Table 14 CEPOD category of surgical procedure in patients with colorectal cancer												
CEPOD category	2006/7		2007/8		Total							
	n	%	n	%	n	%						
Elective	8,645	54.4	8,240	54.8	16,885	54.6						
Scheduled	2,157	13.6	2,370	15.8	4,527	14.6						
Urgent	1,463	9.2	1,458	9.7	2,921	9.4						
Emergency	1,492	9.4	1,279	8.5	2,771	9.0						
Unknown	2,124	13.4	1,689	11.2	3,813	12.3						



Surgical procedures for colorectal cancer

Audit finding

Major resections were undertaken in 60 per cent of cases in both time periods. More minor procedures were undertaken in 10 per cent of cases and no procedure recorded or no record of surgery in the remainder.

Background

The mainstay of treatment for colorectal cancer is surgical resection. There may, however, be some changes to the proportion undergoing this intervention in the future. The newly introduced screening programmes for colorectal cancer may increase the incidence of Dukes' stage A tumours and evidence suggests many of these tumours can be removed endoscopically without major surgical intervention. In addition, locally advanced rectal tumours may be treated with pre-operative chemo-radiotherapy and in up to 20 per cent of cases there is a complete pathological response when the tumour-bearing area is subsequently removed. In consequence, some Trusts are considering adopting a "wait and see" policy for these tumours, particularly if surgery would entail an APER. A strength of the Audit will be to observe changes in surgical and non-surgical techniques over time.

Methods

Table 15

Information in the field PRIMARY_PROCEDURE_NAME was used to determine the type of procedure undertaken. In some cases this field had not been completed but it was still possible to determine that these individuals had undergone surgery as other relevant fields had been completed (for example MAJOR_POSTOP_COMPLICATION OR ANASTOMOSIS_DONE). In these cases patients were defined as receiving a surgical intervention in the other/not known category.

Results

Some form of surgical intervention was reported in 74.7 per cent of patients. Around 60 per cent of patients underwent a major surgical resection whilst local excisions and polypectomies were used in around 2 per cent of cases (Table 15). Figures 6 and 7 show there was significant variation in the types of surgical procedure undertaken by network over the two reporting periods.

Discussion

There are major differences in operation rates between Networks. These should be explored further but may represent poor data completeness, particularly as the non-reporting rate significantly affected the differences observed. The low incidence of laparotomy or laparoscopy alone indicates better pre-operative staging of potentially curative cases.

Recommendation

Cancer Networks should refer to these findings and ensure that their Trusts capture complete data on surgical procedures.

Surgery type	2006/7		2007/8		Total		
	n	%	n	%	n	%	
Major resection	12,612	59.6	12,216	60.3	24,828	59.9	
Local excision	192	0.9	179	0.9	371	0.9	
Polypectomy	275	1.3	257	1.3	532	1.3	
Stoma	1,073	5.1	1,070	5.3	2,143	5.2	
Stent	211	1.0	256	1.3	467	1.1	
Laparotomy only	132	0.6	106	0.5	238	0.6	
Laparoscopy only	28	0.1	33	0.2	61	0.1	
Examination Under Anaesthetic	28	0.1	29	0.1	57	0.1	
Other/Not known	1,358	6.4	919	4.5	2,277	5.5	
Not reported/No surgery	5,261	24.9	5,197	25.6	10,458	25.2	

Major resection		Local	excis	ion			1	Von	rese	ectio	onal	pro	cedu	ure			Oth	ner/l	Jnk	now	'n			No	sur	rgei	ry	
ercentage of Il cases	100%																											
	80%																											
	60%							ł										-										
	40%								-									-										
	20%								-													-					-	
	0%	Lar Gr	Me	논	No Par	- Ar	<u>s</u> ;	De lei	M	×,	N	N SO	Sol	Per		걸	Th	Ce		Ke	٩	N	A 2	No	Sol	Sol	Re	North
		Greater Manchester & Cheshire Cancer Network Lancashire & South Cumbria Cancer Network	Merseyside & Cheshire Cancer Network	Humber & Yorkshire Coast Cancer Network	Pan Birmingham Cancer Network North Trent Cancer Network	Arden Cancer Network	Mid Trent Cancer Network	Leicestershire, Northamptonshire	Mount Vernon Cancer Network	West London Cancer Network	North London Cancer Network	South East London Cancer Network	South West London Cancer Network	Peninsula Cancer Network	Avon, Somerset & Wiltshire Cancer Network	Three Counties Cancer Network	Thames Valley Cancer Network	Central South Coast Cancer Network	Surrey We		Greater Midlands Cancer Network	North of England Cancer Network	Essex Cancer Network	North Wales Cancer Network	South East Wales Cancer Network	South West Wales Cancer Network	Republic of Ireland	Other Northern Ireland
		anchest & Sout	& Che	Yorkshi	gham (t Cance	cer Net	Cancer	ire, Noi	non Ca	on Can	on Car	Londor	: Londc	ancer I	erset &	nties Ca	lley Car	ith Coa	West Sussex & F	dway C	dlands	ngland	er Netw	es Canc	Wales (: Wales	fireland	eland
		er & C h Cum	shire C	re Coa	r Netw	work	Netwo	thamp	ncer N	cer Net	ner Ne	1 Cance	n Can	Vetwo	Wiltsh	ncer N	ncer Ne	st Can	x & Ha	ancer	Cancer	Cancer	/ork	er Netv	Cancer	Cance	0	
		heshire bria Ca	ancer l	ist Can	Netwo vork		rk	otonsh	etwor	twork	etwork	er Netv	cer Net	¥	iire Cai	etwor	etwork	cer Ne	impshi	Netwo	r Netw	r Netw		work	Netwo	r Netw		
		e Canci ancer N	Netwo	cer Ne	ork	-	7	τÞ				work	twork		ncer N	~		twork	re Can	řk	ork	ork			ork	/ork		
		er Netv Jetwor	ŗ	twork				utlanc							etwork	_			cer Ne									
		k vork						Cance							~				twork									
								& Rutland Cancer Network																				

operations used by Car	ncer Network – 2007/8 repo	rting period		
Major resection	Local excision	Non resectional procedure	Other/Unknown	No surgery
Percentage of all cases	100%			
	80%			
	60%			
	40%			
	20%			
	North Trent Cancer Network Humber & Yorkshire Coast Cancer Network Yorkshire Cancer Network Merseyside & Cheshire Cancer Network Greater Manchester & Cheshire Cancer Network Lancashire & South Cumbria Cancer Network %	Peninsula Cancer Network South West London Cancer Network South East London Cancer Network North East Cancer Network North London Cancer Network West London Cancer Network Mount Vernon Cancer Network Leicestershire, Northamptonshire & Rutland Cancer Network Derby & Burton Cancer Network Mid Trent Cancer Network Arden Cancer Network Pan Birmingham Cancer Network	Greater Midlands Cancer Network Kent & Medway Cancer Network Sussex Cancer Network Surrey, West Sussex & Hampshire Cancer Network Central South Coast Cancer Network Thames Valley Cancer Network Three Counties Cancer Network Avon, Somerset & Wiltshire Cancer Network	Other Northern Ireland Republic of Ireland South West Wales Cancer Network South East Wales Cancer Network North Wales Cancer Network Essex Cancer Network Anglia Cancer Network North of England Cancer Network

Figure 7

Use of laparoscopic procedures in colorectal cancer surgery

Audit finding

The proportion of major resections of colorectal cancer completed laparoscopically in the 2006/7 reporting period was 8.3 per cent and, in the 2007/8 data collection period, 17.2 per cent. The reported conversion rate remains constant at 23 per cent.

Standard

NICE guidance states that laparoscopic surgery (including laparoscopically assisted surgery) is recommended as an alternative to open surgery for people with colorectal cancer if:

• both laparoscopic and open surgery are suitable for the person and their condition

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: All laparoscopic colorectal operations should be performed by surgeons properly trained in colorectal surgery who have also undergone preceptorship laparoscopic training, particularly in rectal procedures. Their results should be carefully monitored.

Background

Laparoscopic techniques for resection of colorectal cancer were slow to be adopted within the UK. The initial concerns, over the adequacy of resection and the frequency of local recurrence, have proved unfounded and the use of laparoscopy has now been sanctioned by NICE. Major efforts have been directed at training in laparoscopic techniques but there is general acceptance of the need for further training in this area.

Methods

The field in the dataset entitled SURGICAL_ACCESS was used to distinguish between patients treated via laparoscopic or open surgery. Patients were allocated into three groups; laparoscopic completed, laparoscopic converted and open surgery. Those patients for whom this field was not completed were assumed to have undergone an open procedure. The denominator for this analysis was all patients who underwent a major resection.

Results

There was a significant increase in the proportion of patients receiving some form of laparoscopic surgery over the two reporting periods with the proportion increasing from 10.8 per cent in 2006/7 to 22.5 per cent in 2007/8 (table 16).

The proportion of procedures that were laparoscopic at the outset but were subsequently converted to open procedures remained constant over the two reporting periods at around 23 per cent.

Figure 8 shows there was considerable variation in the number of laparoscopic procedures by Cancer Network.

Discussion

The number of cases of colorectal cancer treated laparoscopically is increasing. In the future, completion of the pathological variables within the audit should allow detailed comparisons to be made with open surgery. Some concerns have been raised over laparoscopic rectal surgery and these too could be addressed. The technical difficulties encountered within the pelvis, often related to the instrumentation, may reveal an increase in complications.

It is hoped that the National Audit can address some of these issues in 2010 or 2011. The reported audit data shows that the number of resections completed laparoscopically varied substantially between Cancer Networks, ranging from 3 per cent to 40 per cent.

Recommendation

Trusts should ensure adherence to the ACPGBI guideline and NICE recommendations for the use of laparoscopic surgery and preceptorship training.

Table 16 Proportion of major resections performed laparoscopically												
Approach to surgery	2006/7		2007/8		Total							
	n	%	n	%	n	%						
Open/Unknown	11,254	89.2	9,469	77.5	20,723	83.5						
Laparoscopic completed	1,047	8.3	2,098	17.2	3,145	12.7						
Laparoscopic converted	311	2.5	649	5.3	960	3.9						

006/7 2007/8									
	_								
Other Northern Ireland									
		_							
Republic of Ireland South West Wales Cancer Network									
South Vest Wales Cancer Network South East Wales Cancer Network									
North Wales Cancer Network									
Essex Cancer Network									
Anglia Cancer Network									
North of England Cancer Network									
Greater Midlands Cancer Network									
Kent & Medway Cancer Network									
Sussex Cancer Network									
Surrey, West Sussex & Hampshire Cancer Network									
Central South Coast Cancer Network									
Thames Valley Cancer Network									
Three Counties Cancer Network									
Avon, Somerset & Wiltshire Cancer Network									
Dorset Cancer Network									
Peninsula Cancer Network									
South West London Cancer Network									
South East London Cancer Network									
North East Cancer Network		1							
North London Cancer Network									
West London Cancer Network									
Mount Vernon Cancer Network									
Leicestershire, Northamptonshire & Rutland Cancer Network									
Derby & Burton Cancer Network		÷.							
Mid Trent Cancer Network									
Arden Cancer Network									
Pan Birmingham Cancer Network									
North Trent Cancer Network			-						
Humber & Yorkshire Coast Cancer Network			_						
Yorkshire Cancer Network									
Merseyside & Cheshire Cancer Network									
Greater Manchester & Cheshire Cancer Network									
Lancashire & South Cumbria Cancer Network									
centage of patients	0	10	20	30	40	50	60	70	80
lergoing resection									
an attempted									

Rates of abdominoperineal excision of the rectum and anus (APER)

Audit finding

The APER rate was 16.6 per cent for the 2007/8 reporting period. There was considerable variation in the use of this procedure across Cancer Networks.

Standard

NICE guidance states that APER rates should be kept to a minimum. The permanent stoma rate is therefore used as measure of quality of surgical care.

The ACPGBI guidance recommended that: The overall proportion of rectal cancers treated by APER should be less than 30 per cent.

Background

APER is a valid operation for tumours of the low rectum and in patients where it is felt that the functional results obtained with a low restorative resection would significantly affect quality of life. The Audit's findings are in keeping with recent publications which have shown a wide variation in the use of APER by unit and Network.

Methods

Patients undergoing APER operations were identified from the field in the dataset entitled PRIMARY_PROCEDURE_ NAME. In this analysis the denominator was all patients coded as possessing a rectal tumour who underwent a major resection.

It is of note, however, that a number of patients with tumours at other sites within the bowel were also coded as receiving APERs (Table 17).

As this operation is only used for tumours within the rectum this suggests there are errors in the coding of either tumour site or the operative procedure undertaken. In addition, when comparisons of the types of rectal cancer operations used across Networks were undertaken (Figures 9 and 10 overleaf) some networks appeared to have a very low proportion undergoing anterior resection, Hartmann's procedure and APERs on their rectal cancer patients. As these operations form the mainstay of rectal cancer surgery it seems that there may, again, be a problem with the coding of procedures.

Results

The reported rate of APER would appear to have fallen from 23.8 per cent to 16.6 per cent across the two reporting periods (table 18). This figure, lower than expected, will be reported again in the 2010 report. Analysis by Cancer Network has shown a wide variation of APER rates from over 40 per cent to 6 per cent.

Discussion

Although APER rates by Trust and Network are receiving increasing interest and are the subject of much debate these audit findings demonstrate the difficulty of gaining accurate figures for this procedure. Analysis of the numbers of reported cases by Cancer Network reveal both gross incomplete and under-reporting of surgical procedures for rectal cancer. It is imperative that future audits capture complete and accurate date on surgical procedures for rectal cancer, particularly where it involves a permanent stoma. The reported audit data shows that the APER rates varied substantially between Cancer Networks, ranging from 0 per cent to 33 per cent.

Recommendation

Trusts and Networks should review local APER rates in relation to the NICE standard and the findings of this report.

Table 17 Numbers of cases undergoing APER							
Tumour site	Other	APER	Total				
Colon	24,755	45	24,800				
Rectosigmoid	3,502	33	3,535				
Rectum	11,585	1,297	12,882				
Unknown	206	9	215				
Total	40,048	1,384	41,432				

Table 18

Use of APER amongst those patients coded as having rectal cancer and listed as undergoing a major surgical resection

Surgery type	2006/7		2007/8		Total		
	n	%	n	%	n	%	
Other	2,504	76.2	2,595	83.4	5099	79.7	
APER	782	23.8	515	16.6	1297	20.3	
Total	3,286	100	3,110	100	6,396	100	

APER	Anterior resection	Hartmann's	Other
ercentage of Il cases	100%		
	80%		
	60%		
	40%		
	20%		
	Humber & Yorkshire Coast Cancer Network Yorkshire Cancer Network Merseyside & Cheshire Cancer Network Greater Manchester & Cheshire Cancer Network Lancashire & South Cumbria Cancer Network	North London Cancer Network West London Cancer Network Mount Vernon Cancer Network Leicestershire, Northamptonshire & Rutland Cancer Network Derby & Burton Cancer Network Mid Trent Cancer Network Arden Cancer Network Pan Birmingham Cancer Network North Trent Cancer Network	Other Northern Ireland Republic of Ireland South West Wales Cancer Network South East Wales Cancer Network Anglia Cancer Network Essex Cancer Network Cancer Network Surrey, West Sussex & Hampshire Cancer Network Surrey, West Sussex & Hampshire Cancer Network Thames Valley Cancer Network Thames Valley Cancer Network Three Counties Cancer Network Conset Cancer Network South Susset & Wiltshire Cancer Network South West London Cancer Network South West London Cancer Network North East Cancer Network

APER	Anteric	or resection			Hart	tmann	's		0	Othe	r															
Percentage of all cases	100%																									
	80%																			ł						
	60%										·						ľ			ł						
	40%											-														
	20%		ľ									-					ľ		-							
	0%	ଳ ବ ବ ବ	승 표 결	Pa	₽≤	<u>ک</u> و	Ξ	\leq	z z	S	So Le		Þ	<u> </u>	ት	S S	S K	ត ត្	Z]	, rs	י Z	So	S		z g	
		Greater Manchester & Cheshire Cancer Network Greater Manchester & Cheshire Cancer Network Lancashire & South Cumbria Cancer Network	Humber & Yorkshire Coast Cancer Network	Pan Birmingham Cancer Network	Mid Trent Cancer Network	Leicestershire, Northamptonshire Derby & Burton Cancer Network	Mount Vernon Cancer Network	West London Cancer Network	North East Cancer Network	South East London Cancer Network	South West London Cancer Network	Dorset Cancer Network	Avon, Somerset & Wiltshire Cancer Network	Three Counties Cancer Network	Central South Coast Cancer Network	Surrey, West Sussex & Hampshire Cancer Network	Kent & Medway Cancer Sussex Cancer Network	Greater Midlands Cancer Network	North of England Cancer Network	Anglia Cancer Network	North Wales Cancer Network	South East Wales Cancer Network	South West Wales Cancer Network	Northern Ireland	Other	
		ide & Mand Ire & S		hingha	nt Can ancer	rshire, Burto	/ernor	ndon	ast Car	ast Lor	a can lest Lo	ancer	omerse	valley ountie	South	Vest S	Medway Cancer Network	Midla	f Engla	ncer N	ales C	ast Wa	lest W	n Ireia	2 2 2 2	
		Cheshi nester	kshire	am Cai	cer Ne Netwo	n Can	1 Canc	Cance	N upor	ndon (ndon	Netw	et & M	s Cance	Coast	ussex	ay car Netwi	nds Ca	and Ca	letwo	ancer	les Ca	ales C	rid	5 -	
		ire Ca & Ch Cumb	Coas	ncer N	etworł ork	iampt cer Ne	er Ne	r Netv	etwor	Cancei	Cance	ork	/iltshi	er Net	Cance	& Han	ncer N ork	ancer	ancer	R R	Netw	ncer l	ancer			
		ر eshire ria Ca	t Can	letwo	~	etwor	twork	vork	k k	r Netv	er Net		re Car	twork	er Net	npshir	etwo	Netwo	Netwo		ork	Vetwo	Netw			
		Vetwo Canc ncer l	cer Ne	řk		()				vork	work		ncer N		work	e Car	R	- rk	ork			ork	ork			
		ork er Ne Vetwo	twor			lutlar							etwo			ncer N										
		twork ork	~			id Car							¥			letwo										
		~				ncer N										ŗ										
						& Rutland Cancer Network																				

Permanent stoma rates for rectal cancer

Audit finding

Permanent stomas were performed in 34 per cent of cases of rectal cancer in the 2007/8 reporting period.

Standard

NICE guidance states that a reduced rate of stoma formation is likely to improve quality of life for individual patients and reduce long-term costs to the NHS.

Background

As well as APER, other procedures will leave a patient with rectal cancer with a permanent stoma. Included in this group would be Hartmann's procedures and low anterior resections with a loop stoma which is never closed or fashioned postoperatively because of a poor functional result. Some would suggest that for low rectal tumours an ultra-low Hartmann's procedure could be performed which obviates the need for a perineal wound, particularly following pre-operative radiotherapy. It therefore seems sensible to try and estimate the rate of permanent stoma within this group of patients.

Methods

Table 10

In these analyses the proportion of rectal cancer patients who received either a Hartmann's procedure, an APER or who were coded as receiving a permanent stoma in the field STOMA_ PROCEDURE were determined. The denominator was all rectal cancer patients who underwent a major resection.

Results

The percentage of rectal cancer patients who received a permanent stoma dropped over the two study periods from 37.6 per cent, in the 2006/7 reporting period, to 33.8 per cent in the 2008/9 reporting period, with an overall rate of 35.7 per cent (Table 19). There was a significant variation in the permanent stoma rate between Cancer Network (Figure 11).

Discussion

The incidence of permanent stoma in patients with rectal cancer remains high but is probably realistic when one considers the factors such as pre-operative treatment, level of tumour, age of patient and deficient sphincter function. As it stands the audit is unable to ascertain the true incidence of "permanent" stomas due to incomplete data entry. There will be temporary stomas that are not closed and variance in the denominator between Trusts. It will be for future audits to try and explain the reasons for any variation seen either over time or between Networks. The reported audit data shows that the permanent stoma rates varied substantially between Cancer Networks, ranging from 3 per cent to 51 per cent.

Recommendation

Trusts and Networks need to review their stoma rates in conjunction with the findings of the report and take steps to ensure that procedures resulting in permanent stoma are used appropriately.

Permanent stoma rates within patients with rectal cancer						
Permanent stoma	2006/7		2007/8		Total	
	n	%	n	%	n	%
No/Unknown	2,052	62.4	2,058	66.2	4,110	64.3
Stoma	1,234	37.6	1,052	33.8	2,286	35.7
Total	3,286	100	3,110	100	6,396	100

	_							
Other								
Northern Ireland								
Republic of Ireland					1			
South West Wales Cancer Network								
South East Wales Cancer Network								
North Wales Cancer Network								
Essex Cancer Network								
Anglia Cancer Network								
North of England Cancer Network								
Greater Midlands Cancer Network								
Kent & Medway Cancer Network								
Sussex Cancer Network								
Surrey, West Sussex & Hampshire Cancer Network				_	1	1		
Central South Coast Cancer Network								
Thames Valley Cancer Network Three Counties Cancer Network								
Avon, Somerset & Wiltshire Cancer Network Dorset Cancer Network								
Peninsula Cancer Network								
South West London Cancer Network				-				
South West London Cancer Network								
North East Cancer Network								
North London Cancer Network								
West London Cancer Network								
Mount Vernon Cancer Network								
Leicestershire, Northamptonshire & Rutland Cancer Network								
Derby & Burton Cancer Network								
Mid Trent Cancer Network								
Arden Cancer Network								
Pan Birmingham Cancer Network					;			
North Trent Cancer Network								
Humber & Yorkshire Coast Cancer Network								
Yorkshire Cancer Network								
Merseyside & Cheshire Cancer Network								
Greater Manchester & Cheshire Cancer Network								
Lancashire & South Cumbria Cancer Network			1.1					
ge of rectal cancer	0	10	20	30	40	50	60	70
undergoing a section known to	Ŭ	10	20	50	10	50	00	

Post-operative mortality

Audit finding

The post-operative 30-day mortality was 4.3 per cent in the 2007/8 period.

Standard

ACPGBI Guidelines for the Management of Colorectal Cancer 2007 recommended that: Surgeons should expect to achieve an operative mortality of less than 20 per cent for emergency surgery and less than 7 per cent for elective surgery for colorectal cancer.

Background

The Audit has focussed on post-operative mortality as an important measure of quality of care. It is relatively easy to record and measure but it is unsafe to use for comparative audit without adjustment for case mix. It is the principal outcome measurement most susceptible to misuse and misreporting.

It is also important to emphasise that a single year's postoperative mortality is not always an accurate measure of the quality of care provided. There are natural year on year variations and four to five years of high quality data may be required before one can reliably quantify the significance of observed differences between Trusts. Performance should, therefore, be assessed on the basis of several years of good quality data, which will insure against the risk of falsely identifying a unit as providing sub-optimal care.

Methods

Death within 30-days of surgery was used to define postoperative mortality. Patients for whom no date of surgery was available or where an incorrect date of surgery had been supplied (eg, date of surgery was after the date of death) were excluded. The denominator for the analyses was all patients who underwent any form of surgical intervention.

Cases submitted to Open Exeter are automatically populated with dates of death. This should ensure that mortality information is complete for the entire patient cohort within the audit. A small number of Trusts did not submit their data into the Open Exeter system and for these organisations the date of death data has not been validated.

To identify whether any Trusts had outlying rates of 30-day mortality, funnel plots were constructed. All Trusts were included in the analysis irrespective of their level of case ascertainment or data completeness. Multiple imputation was undertaken (using a two level model of patients clustered within Trusts) to take account of missing values. Models were constructed both without any adjustment for case mix and with adjustment for the five case mix variables previously shown to be related to operative mortality (age, urgency of procedure, Dukes' stage, ASA grade and excision.)

Results

Overall post-operative mortality rates continue to decrease (from 7.04 per cent in 2001 to 4.3 per cent in 2008). This may be due to a number of factors including better selection of patients who will tolerate and obtain benefit from major surgery, improvements in service infrastructure to provide optimal post-operative care and better surgical technique.

Variation in post-operative mortality by cancer network is shown in Figure 13. All-cause 30-day mortality for the period 1 April 2006 to 31 July 2008 was calculated at 4.5 per cent (Table 20). The all-cause 30-day mortality rate for elective/ scheduled procedures was 3.0 per cent and for urgent/ emergency procedures was 10.8 per cent.

Figure 14 shows the unadjusted 30-day mortality rates. One Trust in the risk-adjusted analysis was identified as having operative mortality rates outside the 99 per cent confidence limits (Figure 15). This outlying Trust is known to have poor data quality with an exceptionally low number of patients with advanced stage disease, emergency surgery and poor ASA reporting. A review of the accuracy of the data supplied by this Trust is underway.

Discussion

It may be stating the obvious but accurately auditing 30-day post-operative mortality requires both a date for surgery and an accurate, validated date of death. This information was frequently missing from the data submitted. Accepting these problems, the observed all-cause mortality rates continue to fall when compared with previous annual reports. The observation of a four-fold increase in mortality for cases operated in the emergency/urgent setting only serves to emphasise the importance of risk-adjustment of these figures. Previous work from the audit has identified five variables that allow risk-adjusted mortality and particular attention needs to be paid to accurate recording of these factors.

Recommendation

Trusts and networks should review local mortality rates against the ACPGBI guidance in conjunction with the findings of the audit.






Table 20

Table 20 Status at 30-days post-surgical intervention						
Status at 30-days post-surgical	2006/7		2007/8		Total	
intervention	n	%	n	%	n	%
Alive	13,037	95.2	12,834	95.7	25,871	95.5
Dead	659	4.8	574	4.3	1,233	4.5
Total	13,696	100.0	13,408	100.0	27,104	100.0

2006/7	2007/8											
				0.1	_							
			N	Other								
				rn Ireland								
			•	of Ireland								
			Nest Wales Cance									
			East Wales Cance									
		N	orth Wales Cance									
			Essex Cance									
		N	Anglia Cance									
			of England Cance									
			r Midlands Cance									
		Kent	& Medway Cance									
			Sussex Cance									
	Su	rrey, West Sussex &	•									
			outh Coast Cance									
			mes Valley Cance									
			e Counties Cance									
		Avon, Somerset	& Wiltshire Cance									
			Dorset Cance									
			Peninsula Cance									
			est London Cance									
			ast London Cance									
			North East Cance									
			rth London Cance									
			est London Cance									
			unt Vernon Cance									
	Leicestershire	, Northamptonshire										
		Derb	y & Burton Cance									
			Mid Trent Cance									
			Arden Cance									
			irmingham Cance									
			North Trent Cance									
		Humber & York	shire Coast Cance									
			Yorkshire Cance									
			& Cheshire Cance									
	(Greater Manchester										
		Lancashire & Sout	th Cumbria Cance	r Network								
centage of patie					0	2	4	6	8	10	12	14
ng within 30 day urgery	5											

NB. Sussex Cancer Network only submitted 16 cases for the audit period 2006/7 and operative mortality could only be calculated amongst 8 patients. One patient died within 30-days of surgery, hence, their seemingly high operative mortality.





Reporting of status of circumferential resection margins in rectal cancer

Audit finding

The circumferential margin status was reported in 58 per cent of cases in 2007/8.

Background

The proportions of cases having an involved circumferential resection margin (CRM), after surgery is a surrogate marker of the quality of care rectal cancer patients receive. The CRM positive rate will reflect how accurately patients have been selected for pre-operative chemo-radiotherapy and the quality of surgery. It has also been shown to be an indicator of the risk of local recurrence, a much more difficult parameter to measure.

Methods

The field CIRCUMFERENTIAL_MARGINS was used to determine the number of patients for whom this data item was reported. The denominator for the analyses was all rectal cancer patients who underwent a major resection (including urgent/emergency procedures).

Results

The status of the circumferential margins was reported for 56.9 per cent of rectal cancer patients who underwent a major resection for their disease. This proportion increased from 55.7 per cent in the 2006/7 reporting period to 58.2 per cent in the 2007/8 reporting period. This data item was poorly completed with no mention of CRM status in over 40 per cent of cases. Amongst those cases where data were provided the CRM positivity rate was 10.3 per cent (Table 21).

Discussion

This variable has been poorly recorded by Trusts. The status of the margin is the responsibility of the pathologist but the feedback that this gives to other members of the MDT is of great importance in maintaining the quality of pre-operative imaging, surgical endeavours and the integrated working of the MDT.

Recommendation

Pathologists should record the status of the circumferential rectal resection margin in all cases of rectal cancer.

Table 21 Status of circumferential margin on pathology report of major resectio						
CRM status	2006/7		2007/8		Total	
	n	%	n	%	n	%
Negative	1,630	49.6	1,635	52.6	3,265	51.0
Positive	201	6.1	174	5.6	375	5.9
Not reported	1,455	44.3	1,301	41.8	2,756	43.1

Reporting of extramural vascular invasion

Audit finding

Extramural vascular invasion on resected specimens was seen in 26 per cent of cases where this feature was reported. The presence or absence was not reported in almost one third of specimens in the latter of the two reporting periods.

Background

It is estimated that extramural vascular invasion should be seen in at least 20 per cent of resected bowel cancer specimens. This data item, along with others such as margin involvement and nodal count, has been identified by the Royal College of Pathologists as being important when reporting on resected specimens of colorectal cancer.

Methods

The field EXTRAMURAL_VASCULAR_INVASION was used to determine the proportion of cases in which this pathological feature was found. As extramural vascular invasion can only be found during pathological examination of resected tumours, the denominator for these analyses was those individuals who underwent a major resection for their disease.

Results

Of those cases where a comment was made on extramural vascular invasion, it was found to be present 26.0 per cent of the time. Non-reporting rates were high at 25.2 per cent overall (Table 22).

Discussion

The full significance of extramural vascular invasion for clinical practice and adjuvant therapy has still to be determined.

Recommendation

The presence or absence of extramural vascular invasion should be reported on all resected specimens.

Table 22 Proportion of cases with a comment on extramural vascular invasion a	nd whether pre	sent or absent.				
Extramural Vascular Invasion	2006/7		2007/8		Total	
	n	%	n	%	n	%
Negative	7,600	60.3	6,135	50.2	13,735	55.3
Positive	2,426	19.2	2,401	19.7	4,827	19.4
Not reported	2,586	20.5	3,680	30.1	6,266	25.2

Median number of nodes obtained and identified following major excision

Audit finding

Nodal harvest was at an acceptable level with a median of 15.1 nodes and a mean of 14 nodes retrieved over the two reporting periods.

Standard

NICE guidance states that the histopathologist should search for as many lymph nodes as possible in the excised specimen and the number found should be audited. 12 or more nodes should normally be examined and if the median number is consistently below 12 the surgeon and histopathologist should discuss their techniques.

Background

Nodal harvest will be affected by the mode and nature of the surgery and whether or not the patient had pre-operative radiotherapy (see www.riskprediction.org.uk). It is well recognised, however, that seeking the highest nodal count possible will ensure optimal staging and allow for the most accurate estimation of clinical outcome.

Methods

The number of lymph nodes retrieved from each patient is recorded in the field NO_OF_LYMPH_NODES_FOUND.

Results


The mean number of lymph nodes retrieved has increased throughout the audit (Figure 16). The percentage of Trusts achieving the required median of 12 nodes per resected specimen was 78.6 per cent. Although there was some variation across Cancer Networks the majority were achieving the required standard (Figure 17). The median number of nodes per procedure is shown in Figure 18 and the effect of mean nodal account in those receiving radiotherapy is shown in Figure 19.

Discussion

Nodal harvest is well reported in the audit and good nodal counts are being observed. Particular difficulties may well be encountered as more cases have pre-operative neoadjuvant therapy. This should be evaluated in future audits.

Recommendation


Trusts should ensure adherence to the NICE guidance of removing and examining a median of 12 lymph nodes from their resected surgical specimens.




7 2007/8						
		_				
	Oth		1		<u> </u>	
	Northern Irela					
	Republic of Irela					
	South West Wales Cancer Netwo					
	South East Wales Cancer Netwo					
	North Wales Cancer Netwo			_		
	Essex Cancer Netwo					
	Anglia Cancer Netwo					
	North of England Cancer Netwo					
	Greater Midlands Cancer Netwo					
	Kent & Medway Cancer Netwo					
	Sussex Cancer Netwo					
	Surrey, West Sussex & Hampshire Cancer Netwo					
	Central South Coast Cancer Netwo					
	Thames Valley Cancer Netwo					
	Three Counties Cancer Netwo	'k				
	Avon, Somerset & Wiltshire Cancer Netwo	'k				
	Dorset Cancer Netwo	'k				
	Peninsula Cancer Netwo	'k		_		
	South West London Cancer Netwo	'k				
	South East London Cancer Netwo	'k 📃				
	North East Cancer Netwo	'k				
	North London Cancer Netwo	'k 📃	÷			
	West London Cancer Netwo	'k 📃				
	Mount Vernon Cancer Netwo	'k				
Leices	tershire, Northamptonshire & Rutland Cancer Netwo	'k				
	Derby & Burton Cancer Netwo	'k				
	Mid Trent Cancer Netwo	'k				
	Arden Cancer Netwo	'k				
	Pan Birmingham Cancer Netwo	'k				
	North Trent Cancer Netwo	'k				
	Humber & Yorkshire Coast Cancer Netwo	·k 📃				
	Yorkshire Cancer Netwo	'k				
	Merseyside & Cheshire Cancer Netwo	'k				
	Greater Manchester & Cheshire Cancer Netwo	·k 📃				
	Lancashire & South Cumbria Cancer Netwo	'k				

nodes retrieved

Figure 18 Median number of nodes obtained by operative procedure (2006/8)





Post-operative length of stay (LOS)

Audit finding

The median unadjusted post operative length of stay following resection of a colorectal tumour was 9 days

Background

LOS is probably a valid surrogate marker of the quality of care. Shorter stays will depend on better selection of patients for major surgery, by good pre-operative staging, colonic stenting in patients with disseminated disease presenting with large bowel obstruction, the introduction of laparoscopic surgery and enhanced recovery programmes.

Methods

LOS was defined as the number of days between the surgical intervention and the date of discharge from hospital (or death if the patient died in hospital). Patients were excluded from the analysis if their LOS exceeded one year or if the date of discharge/death was reported as being prior to the date of surgery or diagnosis.

Results

Median LOS overall for the period 1 April 2006 to 31 July 2008 was 9 days with a range of 7 to 11 days across the Cancer Networks (Figure 20). The figures reported are not adjusted for casemix.

Discussion

There are several initiatives contributing to the reduction in length of stay and equally considerable variations across Cancer Networks. The Audit should seek to document in the next few years the adoption of well-proven patterns of care that will serve to reduce length of stay.

Recommendation

Trusts and MDTs should review the provision of those aspects of service which help to reduce the length of stay following resection of colorectal cancers.

6/7 2007/8									
Other	-	4	4	4	4	4	4	4	4
Northern Ireland									
Republic of Ireland				- 1					
South West Wales Cancer Network									
South West Wales Cancer Network									
North Wales Cancer Network									
Essex Cancer Network									
Anglia Cancer Network	_			_					
North of England Cancer Network									
Greater Midlands Cancer Network									
Kent & Medway Cancer Network									
Sussex Cancer Network									
Surrey, West Sussex & Hampshire Cancer Network					-				
Central South Coast Cancer Network									
Thames Valley Cancer Network					-				
Three Counties Cancer Network									
Avon, Somerset & Wiltshire Cancer Network					1				
Dorset Cancer Network									
Peninsula Cancer Network									
South West London Cancer Network									
South East London Cancer Network					- 1				
North East Cancer Network									
North London Cancer Network									
West London Cancer Network									
Mount Vernon Cancer Network									
Leicestershire, Northamptonshire & Rutland Cancer Network									
Derby & Burton Cancer Network									
Mid Trent Cancer Network									
Arden Cancer Network									
Pan Birmingham Cancer Network									
North Trent Cancer Network									
Humber & Yorkshire Coast Cancer Network									
Yorkshire Cancer Network									
Merseyside & Cheshire Cancer Network									
Greater Manchester & Cheshire Cancer Network						-			
Lancashire & South Cumbria Cancer Network									

Summary

Throughout this audit report there has been an emphasis on the difficulty of interpretation of the results of the analyses because of incomplete data submission. This is in spite of the very real improvements in participation, and case ascertainment. With the introduction of colorectal MDTs throughout the country it seems appropriate that these are the correct fora for ensuring accurate and complete data submission and, on receipt of the report, discussing the local results in light of the national findings. Contained within Appendices 3 and 4 are examples of how the results are discussed locally (Leicester) and how data is captured (Portsmouth and Swansea). Whilst not being the only way that complete data can be obtained or local action plans discussed, they serve as a guide for further improvements within the National Bowel Cancer Audit.

Local Action Plans

As an integral part of participation in the audit, Trusts should discuss the national audit results with their local teams and develop local action plans to improve the quality of care. As part of the National Bowel Cancer Audit, the National Cancer Audit Support Programme (NCASP) has been tasked by the Healthcare Quality Improvement Partnership (HQIP) to produce an action planning toolkit to help support Cancer Networks in converting national audit data into changes in clinical practice and outcomes.

Local action plans can be used to identify areas for data collection and clinical practice that may fall below national standards and need improvement. Local action plans have the potential to convert local audit data into important changes in practice and thereby close the audit loop.

NCASP intend to provide local action plans purely as a toolkit to facilitate service improvement. The implementation of this is the remit of the hospitals, Trusts and Networks concerned. Local action plans will be linked to both peer review and the annual health check in the near future. There is also potential for using the results in conjunction with the Clinical Negligence Scheme for Trusts (CNST).

The National Bowel Cancer Audit has developed local action plans based on the recommendations of the 2009 Annual Report (Appendix 5).

An example of how the colorectal team in Leicester has already started to discuss the national audit data locally and disseminate best practice is detailed in the Appendix.

Appendices

Appendix 1: Summary of 2006/7 data

Key: MR – Number of patients estimated/reported as undergoing a major resection OM – Number of patients reported as receiving any surgical treatment LOS – Number of patients eligible to be included in length of stay calculations

Organisation	ex	imated pected umber -						N	umber su	
						4	All cases		Rectal t	umours
	Total	MR	Total	ST	MR	ОМ	LOS	Total	ST	MR
Lancashire & South Cumbria Cancer Network										
University Hospitals of Morecambe Bay NHS Trust	233	187	132	90	53	67	40	50	27	12
Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	235	188	188	135	33	125	5	70	38	7
Lancashire Teaching Hospitals NHS Foundation Trust	220	176								
East Lancashire Hospitals NHS Trust	253	203	152	115	67	100	39	82	55	25
Greater Manchester & Cheshire Cancer Network										
	125	100	1	1	0	1	1	1	1	0
The Mid Cheshire Hospitals NHS Trust		100								
Christie Hospital NHS Foundation Trust	25	20	50	28	15	26	26	20	10	5
East Cheshire NHS Trust	105	84	1	1	1	0	1	0	0	0
University Hospitals of South Manchester NHS Foundation Trust	135	108	162	119	101	117	117	44	29	25
Salford Royal NHS Foundation Trust	128	103	83	69	59	63	65	18	15	12
Trafford Healthcare NHS Trust	87	69								
Bolton Hospitals NHS Trust	158	127	194	121	110	119	108	56	31	29
Tameside and Glossop Acute Services NHS Trust	127	101	166	71	61	57	70	48	22	16
Wrightington, Wigan and Leigh NHS Trust	168	135	2	2	2	2	2	0	0	0
Central Manchester University Hospitals NHS Foundation Trust	87	69	38	33	26	11	26	13	13	8
Pennine Acute Hospitals NHS Trust	463	371	96	82	77	79	77	28	22	18
Stockport NHS Foundation Trust	203	163	8	6	6	6	6	2	2	2
Merseyside & Cheshire Cancer Network										
Wirral University Teaching Hospital NHS Foundation Trust	225	180	193	147	126	138	131	42	30	21
it Helens and Knowsley Hospitals NHS Trust	182	145	200	154	127	83	114	68	42	27
Aintree University Hospitals NHS Foundation Trust	220	176	3	1	1	1	1	1	0	0
Clatterbridge Centre For Oncology NHS Foundation Trust			213	0	0	0	0	113	0	0
Countess of Chester Hospital NHS Foundation Trust	113	91	139	102	78	98	99	24	16	12
Royal Liverpool and Broadgreen University Hospitals NHS Trust	205	164	229	184	128	177	4	68	48	26
Southport and Ormskirk Hospital NHS Trust	158	127	161	133	113	113	125	0	0	0
Warrington and Halton Hospitals NHS Foundation Trust	207	165	196	98	78	85	82	72	45	30
Yorkshire Cancer Network										
	205	164	117	93	79	90	91	41	32	24
Bradford Teaching Hospitals NHS Foundation Trust										
York Hospitals NHS Foundation Trust	232	185	282	211	87	130	187	77	50	17
Harrogate and District NHS Foundation Trust	123	99	96	89	81	84	78	32	29	26
Airedale NHS Trust	122	97	77	70	68	67	66	17	15	15
Leeds Teaching Hospitals NHS Trust	400	320	407	295	235	244	32	145	100	65
Calderdale and Huddersfield NHS Foundation Trust	202	161	156	114	97	113	106	55	39	36
Mid Yorkshire Hospitals NHS Trust	333	267	210	109	91	103	88	69	27	22
Humber & Yorkshire Coast Cancer Network										
Northern Lincolnshire and Goole Hospitals NHS Foundation Trust	233	187	1	1	1	1	0	0	0	0
Hull and East Yorkshire Hospitals NHS Trust	323	259	251	249	237	184	198	77	76	66
icarborough & North East Yorkshire Health Care NHS Trust	142	113	231	243	231	104	150		70	00
North Trent Cancer Network										
Barnsley Hospital NHS Foundation Trust	142	113	39	1	1	1	0	15	1	1
Chesterfield Royal Hospital NHS Foundation Trust	178	143								
The Rotherham NHS Foundation Trust	127	101	19	19	19	19	19	8	8	8
heffield Teaching Hospitals NHS Foundation Trust	322	257	142	129	96	0	0	48	43	23
Doncaster and Bassetlaw Hospitals NHS Foundation Trust	297	237	38	33	28	33	15	11	11	11
Pan Birmingham Cancer Network										
-	470	100	67	62	EO	60	FC	24	21	72
Walsall Hospitals NHS Trust	170	136	67	63	58	60	56	34	31	27
Heart of England NHS Foundation Trust	443	355	343	265	222	251	239	109	81	59
Jniversity Hospital Birmingham NHS Foundation Trust	455	364	297	182	148	164	170	92	55	44
Sandwell and West Birmingham Hospitals NHS Trust	202	161	165	119	93	103	63	53	42	24

comes %	Oute													teness %	ata comple	C			
Media LO (days	CRM	Median no. of nodes	EMVI	Stoma	APER	Urgent or Emergency	Preop RT	MRI ST	MRI All	CT ST	CT All	Nurse	MDT	Derived Dukes	Supplied Dukes	ASA	Urgent	Excision	Age
	58.3	8	30.2	66.7	25.0	25.6	3.7	70.4	52.0	45.6	37.1	4.5	78.0	43.2	11.4	47.8	70.0	62.2	100
1	0.0	10	0.0	42.9	25.0	10.4	0.0	70.4	10.0	45.6	1.1	4.5 0.0	54.3	43.2 20.2	11.4	2.2	43.0	27.4	100
	0.0	10	0.0	12.5	20.0	10.1	0.0	7.5	10.0	0.7		0.0	51.5	20.2	15.1	2.2	15.0	27.1	100
1	12.0	18	1.5	20.0	16.0	32.2	0.0	43.6	35.4	13.0	13.2	25.7	58.6	21.7	21.7	9.6	43.5	60.9	100
2	0.0	0	0.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	0.0	100
1	80.0	15	13.3	20.0	0.0	3.6	45.5	100.0	90.0	89.3	92.0	52.0	78.0	88.0	56.0	96.4	100.0	53.6	100
1	0.0	11	0.0	0.0	0.0	100.0	0.0	0.0	0.0	100.0	100.0	0.0	100.0	100.0	100.0	100.0	100.0	100.0	100
1	92.0	16	20.8	72.0	56.0	13.4	69.0	72.4	56.8	84.0	80.9	2.5	2.5	77.2	74.7	82.4	100.0	85.7	100
1	0.0	11	18.6	66.7	41.7	21.7	0.0	93.3	94.4	58.0	59.0	50.6	95.2	86.7	39.8	46.4	95.7	91.3	100
1	82.8	12	0.0	41.4	34.5	24.0	0.0	0.0	0.0	0.0	0.5	0.0	1.5	84.0	76.3	95.9	99.2	90.9	100
1	0.0	10	0.0	37.5	6.3	8.5	45.5	50.0	29.2	90.1	44.0	37.3	89.2	36.7	11.4	54.9	94.4	90.1	100
	0.0	13	50.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	0.0	100.0	100.0	100.0	100.0	100.0	100
1	0.0	15	30.8	0.0	0.0	0.0	0.0	0.0	0.0	69.7	73.7	28.9	10.5	89.5	86.8	93.9	3.0	81.8	100
1	88.9	10	16.9	27.8	16.7	30.5	8.7	54.5	46.4	65.9	66.7	69.8	70.8	90.6	78.1	97.6	100.0	96.3	100
	0.0	13	0.0	50.0	50.0	16.7	0.0	50.0	50.0	83.3	75.0	87.5	87.5	75.0	25.0	83.3	66.7	100.0	100
	52.4	13	14.3	28.6	9.5	15.0	26.7	60.0	52.4	22.4	22.3	55.4	92.7	73.6	24.9	77.6	89.8	89.8	100
	48.1	11	17.3	22.2	11.1	36.4	11.1	0.0	0.0	0.0	0.0	63.5	98.5	77.5	77.0	88.3	98.7	90.3	100
1	0.0	21	0.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	66.7	33.3	100.0	66.7	0.0	100.0	100.0	100.0	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	3.3	3.3	0.0	0.0	0.0	100
	100.0	15	0.0	16.7	16.7	23.5	35.3	0.0	0.0	2.0	1.4	0.0	98.6	68.3	66.2	97.1	99.0	80.4	100
1	65.4	16	18.0	3.8	0.0	26.1	32.0	2.1	1.5	0.5	0.4	53.3	88.2	51.1	42.4	84.8	87.5	78.8	100
1	0.0 26.7	13 10	16.8 17.9	0.0 50.0	0.0 20.0	9.0 18.4	0.0 6.7	0.0 0.0	0.0 0.0	100.0 36.7	100.0 44.9	82.0 3.6	100.0 99.0	91.3 51.5	76.4 24.5	91.7 55.1	100.0 96.9	93.2 86.7	100 100
	20.7	10	17.5	50.0	20.0	10.4	0.7	0.0	0.0	50.7	44.5	5.0	55.0	51.5	24.5	55.1	50.5	00.7	100
	66.7	17	26.7	20.0	0.2	F 4	27.5	07.5	07.0	70 5	00.2	05.5	41.0		22.4	07.0	00.0	00.2	100
	66.7 17.6	17 11	36.7 28.7	20.8 29.4	8.3 29.4	5.4 24.2	37.5 0.0	87.5 84.0	87.8 79.2	78.5 64.5	80.3 64.2	85.5 62.8	41.0 94.7	83.8 67.4	23.1 3.9	97.8 87.2	98.9 87.2	88.2 41.7	100 100
	88.5	14	37.0	23.4	15.4	11.2	75.9	86.2	81.3	93.3	92.7	99.0	99.0	93.8	85.4	97.8	100.0	95.5	100
	93.3	20	48.5	80.0	60.0	5.7	26.7	100.0	100.0	87.1	88.3	90.9	98.7	97.4	74.0	97.1	100.0	97.1	100
1	7.7	18	8.5	36.9	33.8	4.1	0.0	4.0	2.8	11.9	8.6	25.8	40.5	62.9	48.9	12.5	58.0	83.1	100
	86.1	14	18.6	50.0	30.6	11.4	27.5	76.9	76.4	89.5	90.4	22.4	25.0	89.1	76.3	99.1	100.0	85.1	100
	90.9	12	28.6	36.4	22.7	17.4	35.7	77.8	46.4	76.1	55.2	41.9	77.6	69.0	56.2	95.4	98.2	84.4	100
	0.0	18	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	0.0	100.0	100.0	100
1	90.9	11	22.8	45.5	28.8	14.9	68.4	86.8	87.0	59.8	59.8	85.3	83.3	98.8	94.8	80.3	99.6	99.6	100
	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	100.0	10.3	20.5	89.7	20.5	17.9	0.0	100.0	100.0	100
	0.0	8	15.8	50.0	37.5	15.8	62.5	25.0	25.0	73.7	73.7	84.2	100.0	100.0	15.8	100.0	100.0	100.0	100
	0.0	0	0.0	30.4	13.0	10.9	0.0	0.0	2.1	0.0	0.7	0.7	2.1	73.9	66.9	0.0	86.0	79.8	100
	18.2	18	10.7	54.5	45.5	3.0	27.3	63.6	63.6	63.6	60.5	0.0	13.2	57.9	44.7	84.8	100.0	84.8	100
	59.3	15	22.4	33.3	25.9	12.7	32.3	6.5	5.9	9.5	9.0	89.6	91.0	82.1	7.5	98.4	100.0	93.7	100
	30.5	20	44.1	33.9	20.3	21.9	43.5	56.8	47.7	63.4	64.1	39.9	62.1	81.6	34.4	73.6	95.5	91.7	100
1	75.0	17	48.6	31.8	18.2	15.4	23.6	1.8	2.2	7.7	6.7	63.3	90.2	60.3	8.8	88.5	85.2	83.0	100
1	16.7	14	9.7	33.3	25.0	10.1	13.6	28.6	26.4	57.1	51.5	90.9	95.8	76.4	57.0	47.1	56.3	87.4	100

Organisation	ex	mated pected umber -						N	lumber su	
						1	All cases		Rectal t	umours
	Total	MR	Total	ST	MR	OM	LOS	Total	ST	MR
Arden Cancer Network										
South Warwickshire General Hospitals NHS Trust	158	127	170	125	114	123	124	52	35	27
University Hospitals Coventry and Warwickshire NHS Trust	272	217	305	177	149	168	172	118	72	52
George Eliot Hospital NHS Trust	115	92	74	59	51	48	50	18	15	12
Worcestershire Acute Hospitals NHS Trust	368	295	28	22	20	21	20	10	9	8
Mid Trent Cancer Network										
Sherwood Forest Hospitals NHS Foundation Trust	190	152	113	100	96	64	88	39	31	30
United Lincolnshire Hospitals NHS Trust	445	356	2	2	2	2	1	1	1	1
Nottingham University Hospitals NHS Trust	397	317	474	370	340	327	341	174	113	97
Derby & Burton Cancer Network										
Burton Hospitals NHS Trust	150	120	33	23	22	23	23	31	23	22
	260	208	301	23	197	23	23	108	85	56
Derby Hospitals NHS Foundation Trust	200	208	301	242	197	230	233	108	Cõ	סכ
Leicestershire, Northamptonshire & Rutland Cancer Network										
Kettering General Hospital NHS Trust	172	137	110	79	22	56	58	32	21	9
Northampton General Hospital NHS Trust	177	141	85	84	77	82	72	26	26	24
University Hospitals of Leicester NHS Trust	455	364	541	406	355	341	352	162	118	91
Mount Vernon Cancer Network										
Luton and Dunstable Hospital NHS Foundation Trust	125	100	83	62	49	60	0	33	26	23
Nest Hertfordshire Hospitals NHS Trust	212	169	165	156	126	0	0	63	59	47
ast and North Hertfordshire NHS Trust	245	196	270	222	205	215	216	85	70	61
West London Cancer Network										
The Hillingdon Hospital NHS Trust	95	76	110	93	85	89	8	32	25	22
Ealing Hospital NHS Trust	55	44	4	4	4	4	4	1	1	1
West Middlesex University Hospital NHS Trust	62	49	120	120	89	78	52	27	27	. 19
Chelsea and Westminster Hospital NHS Foundation Trust	62	49	88	60	53	45	47	17	9	8
North West London Hospitals NHS Trust	227	181	5	4	4	4	4	1	1	1
Imperial College Healthcare NHS Trust	182	145								
North London Cancer Network										
Royal Free Hampstead NHS Trust	93	75	103	89	83	73	83	20	18	16
The Whittington Hospital NHS Trust	75	60	7	7	7	7	7	1	1	1
Jniversity College London Hospitals NHS Foundation Trust	67	53	133	108	90	26	61	32	25	18
Barnet and Chase Farm Hospitals NHS Trust	187	149	282	225	203	154	172	79	58	51
The Princess Alexandra Hospital NHS Trust	127	101								
North Middlesex University Hospital NHS Trust	68	55								
North East London Cancer Network										
Barking, Havering and Redbridge Hospitals NHS Trust	337	269	278	161	136	157	109	82	32	24
Whipps Cross University Hospital NHS Trust	105	84	98	81	68	81	16	30	25	19
Newham University Hospital NHS Trust	50	40	4	1	1	0	0	1	0	0
Barts and The London NHS Trust	95	76	34	29	25	8	6	8	8	8
Homerton University Hospital NHS Foundation Trust	40	32	95	73	52	68	60	31	22	13
South East London Cancer Network										
Queen Elizabeth Hospital NHS Trust	103	83	115	79	63	35	0	30	17	7
Bromley Hospitals NHS Trust	122	97	8	0	0	0	0	4	0	0
Queen Mary's Sidcup NHS Trust	90	72	21	0	0	0	0	7	0	0
Guy's and St Thomas' NHS Foundation Trust	65	52			-	-	-		-	-
The Lewisham Hospital NHS Trust	63	51	95	58	48	36	42	37	21	18
King's College Hospital NHS Foundation Trust	68	55	83	47	38	45	42	12	7	5

n n n nu nu <th>come</th> <th>Out</th> <th></th> <th>eteness %</th> <th>Data comple</th> <th>[</th> <th></th> <th></th> <th></th>	come	Out													eteness %	Data comple	[
000 870 910 932 108 603 885 97 361 322 76 83 39 124 173 365 224 11 808 907 903	Mea (d	CRM	no. of	EMVI	Stoma	APER							Nurse	MDT			ASA	Urgent	Excision	Age
000 870 910 932 108 603 885 97 361 322 76 83 39 124 173 365 224 11 808 907 903																				
100 888 940 780 311 774 811 554 622 610 890 900 800 800 900 800 800 900 800 800 900 800 800 900 800 900 800 800 900 800 800 100 <td></td> <td>100.0</td> <td>12</td> <td>27.2</td> <td>51.9</td> <td>40.7</td> <td>18.4</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.8</td> <td>0.6</td> <td>0.0</td> <td>99.4</td> <td>85.3</td> <td>0.6</td> <td>97.6</td> <td>99.2</td> <td>92.0</td> <td>100</td>		100.0	12	27.2	51.9	40.7	18.4	0.0	0.0	0.0	0.8	0.6	0.0	99.4	85.3	0.6	97.6	99.2	92.0	100
000 90.9 1000 91.8 46.4 92.9 92.6 83.9 90.0 88.9 0.0 18.2 12.5 97.5 25.0 17 0.0 100 96.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 11.1 11.1 11.2									8.3							10.8				100
000 90.9 1000 91.8 46.4 92.9 92.6 83.9 90.0 88.9 0.0 18.2 12.5 97.5 25.0 17 0.0 100 96.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 11.1 11.1 11.2																				100
100 1000 500 1000 1																				100
100 1000 500 1000 1																				
100 95. 71.4 81.4 87.3 99.8 97.9 81.0 81.4 73.6 70.0 13.3 13.1 23.7 49.4 15.5 31.1 100 957. 17.4 0.0 78.8 78.8 84.8 0.0 84.8 77.8 78.8 44.7 13.6 71.4 32.1 94.4 15.6 60.4 100 957. 17.4 0.0 78.8 95.6 70.8 95.7 78.8 44.7 13.6 71.4 11.1 11.2 11.2 77.8 6 92.9 98.8 91.8 83.5 58.8 15.3 14.3 80.8 80.4 42.2 13.1 12.2 41.7 11.1 11.2 11.1 12.2 13.7 80.8 80.8 80.4 22.4 12.1 13.8 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7 80.7		100.0	14	47.9	46.7	20.0	14.0	51.6	87.1	71.8	86.0	80.5	98.2	99.1	86.7	11.5	100.0	100.0	96.0	100
100 957 17.4 0.0 78.8 78.8 84.8 60.0 84.8 67.0 90.3 91.3 95.7 0.0 26.4 45.5 18.2 9 66.4 100 90.9 81.8 80.2 80.7 82.4 96.0 70.8 89.4 88.4 77.8 78.8 44.7 13.6 21.4 32.1 23.4 116 80.4 100 91.7 97.6 92.9 55.8 91.8 83.5 58.8 15.3 14.3 80.8 80.0 46.2 13.1 29.2 41.7 11.7 11 12.5 13.6 14.7 13.6 13.6 13.6 13.6		0.0	13	50.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	100.0	50.0	100.0	100.0	100.0	50.0	100.0	100.0	100
100 90.9 81.8 60.2 80.7 82.4 90.0 70.8 89.4 77.8 78.8 44.7 13.6 21.4 32.1 29.4 16 60.0 100 91.7 97.6 92.9 55.8 90.9 55.8 90.9 55.8 10.0 0.0 0.0 0.0 0.0 11.4 11.1 11.1 11.7 11.1 13.1 26.8 10.0 10.0 12.9 43.5 60.9 0.0 11.3 10.0<		3.1	15	49.4	23.7	11.3	18.9	50.0	79.6	73.6	81.4	81.0	97.9	99.8	87.3	81.4	71.4	99.5	95.4	100
100 90.9 81.8 60.2 80.7 82.4 90.0 70.8 89.4 77.8 78.8 44.7 13.6 21.4 32.1 29.4 16 60.0 100 91.7 97.6 92.9 55.8 90.9 55.8 90.9 55.8 10.0 0.0 0.0 0.0 0.0 11.4 11.1 11.1 11.7 11.1 13.1 26.8 10.0 10.0 12.9 43.5 60.9 0.0 11.3 10.0<																				
100 29.1 39.2 22.8 0.0 45.5 80.9 21.8 0.0 0.0 0.0 0.0 11.1<		86.4	9	18.2	45.5	36.4	0.0	95.7	91.3	90.3	87.0	84.8	0.0	84.8	78.8	78.8	0.0	17.4	95.7	100
100 917 976 929 588 918 835 588 153 14.3 808 46.2 131 292 41.7 11.7 11 12.5 100 97.1 75.8 81 289 63.2 83.0 90.0 51.0 81.1 74.7 75.3 42.0 22.4 23.1 43.5 60.0 10.0 12.9 43.5 60.0 10.0 </td <td></td> <td>80.4</td> <td>16</td> <td>29.4</td> <td>32.1</td> <td>21.4</td> <td>13.6</td> <td>44.7</td> <td>78.8</td> <td>77.8</td> <td>88.4</td> <td>89.4</td> <td>70.8</td> <td>96.0</td> <td>82.4</td> <td>80.7</td> <td>80.2</td> <td>81.8</td> <td>90.9</td> <td>100</td>		80.4	16	29.4	32.1	21.4	13.6	44.7	78.8	77.8	88.4	89.4	70.8	96.0	82.4	80.7	80.2	81.8	90.9	100
100 917 976 929 588 918 835 588 153 14.3 808 46.2 131 292 41.7 11.7 11 12.5 100 97.1 75.8 81 289 63.2 83.0 90.0 51.0 81.1 74.7 75.3 42.0 22.4 23.1 43.5 60.0 10.0 12.9 43.5 60.0 10.0 </td <td></td>																				
100 92.1 96.6 89.2 83.2 85.0 100.0 51.0 82.1 81.0 74.7 76.3 42.0 22.4 23.1 45.1 34.6 13 86.8 100 87.1 75.8 8.1 28.9 33.7 91.6 27.7 43.4 43.5 6.1 7.7 0.0 12.9 43.5 60.9 0.0 13 0.0 100 80.8 0.0 75.3 73.9 81.8 97.0 52.1 93.9 93.6 0.0 0.0 10.0 16.4 16.7 7.0 0.0 14.0 16.4 37.7 15.1 11 75.4 100 94.6 100.0 32.7 91.0 6.4 6.4 7.5 0.0 0.0 4.0 24.7 18.2 31.8 1.2 7.7 0.0 10.0 </td <td></td> <td>77.8</td> <td>13</td> <td>18.2</td> <td>11.1</td> <td>11.1</td> <td>11.4</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>21.8</td> <td>80.9</td> <td>45.5</td> <td>0.0</td> <td>22.8</td> <td>39.2</td> <td>29.1</td> <td>100</td>		77.8	13	18.2	11.1	11.1	11.4	0.0	0.0	0.0	0.0	0.0	21.8	80.9	45.5	0.0	22.8	39.2	29.1	100
100 97.0 75.8 8.1 28.9 33.7 91.6 27.7 43.4 43.5 61 77 0.0 12.9 43.5 60.9 0.0 13.0 0 100 80.8 0.0 76.3 73.9 81.8 97.0 52.1 93.9 93.6 0.0 0.0 20.3 0.0 25.5 31.9 32.5 10 78.7 100 92.3 99.5 92.8 91.1 94.4 100.0 95.2 66.7 65.8 0.0 0.0 14.0 16.4 37.7 15.1 111 75.4 100 94.6 100.0 32.2 79.1 82.7 90.0 64.4 64.7 75.0 0.0		12.5	11	11.7	41.7	29.2	13.1	46.2	80.8	80.8	14.3	15.3	58.8	83.5	91.8	58.8	92.9	97.6	91.7	100
100 80.8 0.0 76.3 73.9 81.8 97.0 52.1 93.9 92.6 0.0 0.0 0.0 1.00 1.00 1.01 77.7 1.51 1.11 77.4 100 92.3 99.5 92.8 91.1 94.4 1000 52.6 65.8 0.0 0.0 1.00 1.64 37.7 15.1 1.11 75.4 100 94.6 1000 5.2 71.7 41.0 10.0 100.0		86.8	13	34.6	45.1	23.1	22.4	42.0	76.3	74.7	81.0	82.1	51.0	100.0	85.0	83.2	89.2	96.6	92.1	100
100 80.8 0.0 76.3 73.9 81.8 97.0 52.1 93.9 92.6 0.0 0.0 0.0 1.00 1.00 1.01 77.7 1.51 1.11 77.4 100 92.3 99.5 92.8 91.1 94.4 1000 52.6 65.8 0.0 0.0 1.00 1.64 37.7 15.1 1.11 75.4 100 94.6 1000 5.2 71.7 41.0 10.0 100.0																				
100 92.3 99.5 92.8 91.1 94.4 100.0 95.2 66.7 65.8 0.0 0.0 14.0 16.4 37.7 15.1 111 75.4 100 94.6 100.0 32 79.1 18.2.7 90.0 64.4 64.4 7.5 0.0 100.0		0.0	13	0.0	60.9	43.5	12.9	0.0	7.7	6.1	43.5	43.4	27.7	91.6	33.7	28.9	8.1	75.8	87.1	100
10 94 100 32 79.1 82.7 90.0 6.4 7.5 0.0 0.0 4.0 24.7 182 31.8 12 7 0.0 100 100.0 75.0 75.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0		78.7	10	32.5	31.9	25.5	0.0	20.3	0.0	0.0	93.6	93.9	52.1	97.0	81.8	73.9	76.3	0.0	80.8	100
100 1750 750 1000 <		75.4	11	15.1	37.7	16.4	14.0	0.0	0.0	0.0	65.8	66.7	95.2	100.0	94.4	91.1	92.8	99.5	92.3	100
100 1750 750 1000 <																				
88.3 77.5 78.3 85.0 88.3 92.5 100 94.0 97.0 17.5 26.3 44.1 34.8 16 89.5 25.0 34.0 27.2 22.0 12.5 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.2 25.0 34.0 27.0 25.0 34.0 27.0 25.0 34.0 27.0 25.0 34.0 27.0 25.0 34.0 27.0 25.0 34.0 27.0 25.0 34.0 27.0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td>-</td><td></td><td></td><td></td><td>100</td></t<>													-			-				100
100 90.0 98.3 95.0 50.0 84.1 98.9 93.2 90.0 64.7 66.7 22.2 20.0 12.5 25.0 34.0 27.0 25.0 100 75.0 50.0 40.0 100.0 80.0 75.0 100.0 100.0 0.0 0.0 0.0 25.0 1.2 0.0 100 75.0 50.0 40.0 100.0 80.0 75.0 100.0 10.0 0.0 0.0 0.0 0.0 0.0 25.0 1.1 0.0 100 93.3 93.3 48.3 79.6 96.1 99.0 93.3 87.6 70.0 77.8 50.0 21.3 31.3 43.8 30.1 14.4 68.8 100 84.8 89.8 97.2 66.9 88.7 100.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0			12		0.0	0.0	0.0	0.0	100.0	100.0	100.0		100.0			100.0		75.0	100.0	100
1000 75.0 50.0 40.0 100.0 80.0 60.0 75.0 100.0 100.0 0.0 0.0 0.0 25.0 1.2 0.0 100 93.3 93.3 48.3 79.6 96.1 99.0 90.3 89.3 87.6 70.0 77.8 50.0 2.13 31.3 43.8 30.1 14 68.8 100.0 100.0 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 10.					42.1		17.5								92.5	88.3			77.5	98.3
Image: 1 mm		25.0			25.0	12.5	20.0	22.2	66.7	64.7	90.0	90.9			84.1	50.0	95.0	98.3	90.0	100
100 100. 85.7 100. 14.3 85.7 100. 100. 100. 100. 0.0		0.0	12	25.0	0.0	0.0	0.0	0.0	100.0	100.0	75.0	80.0	60.0	80.0	100.0	40.0	50.0	75.0	100.0	100
100 100. 85.7 100. 14.3 85.7 100. 100. 100. 100. 0.0																				
100 84.3 89.9 97.2 66.9 88.7 100.0 94.0 93.2 95.4 50.0 48.0 52.0 15.7 11.1 11.1 7.8 11.6 94.4 100 93.8 99.1 68.9 70.2 89.0 98.6 39.7 92.9 93.3 63.3 69.0 35.6 115.1 37.3 49.0 21.7 13.8 86.3 1 100 93.8 91.1 1.0 1.		68.8	14	30.1	43.8	31.3	21.3	50.0	77.8	70.0	87.6	89.3	90.3	99.0	96.1	79.6	48.3	93.3	93.3	100
100 93.8 99.1 68.9 70.2 89.0 98.6 39.7 92.9 93.3 63.3 69.0 35.6 15.1 37.3 49.0 21.7 13 86.3 6 1 <td></td> <td>100.0</td> <td>11</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>0.0</td> <td>100.0</td> <td>100.0</td> <td>100.0</td> <td>100.0</td> <td>85.7</td> <td>14.3</td> <td>100.0</td> <td>85.7</td> <td>100.0</td> <td>100</td>		100.0	11	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	100.0	85.7	14.3	100.0	85.7	100.0	100
Image: Normal Sector Image: No		94.4	16	7.8	11.1	11.1	15.7	52.0	48.0	50.0	95.4	93.2	94.0	100.0	88.7	66.9	97.2	89.8	84.3	100
100 86.4 98.8 65.4 6.1 71.4 100.0 1.0 86.7 87.7 13.3 12.0 0.0 16.0 26.3 26.3 0.0 12 63.2 100 100.0 100.0 100.0 20.0 25.0 25.0 25.0 100.0 25.0 100.0 0.0		86.3	13	21.7	49.0	37.3	15.1	35.6	69.0	63.3	93.3	92.9	39.7	98.6	89.0	70.2	68.9	99.1	93.8	100
100 86.4 98.8 65.4 6.1 71.4 100.0 1.0 86.7 87.7 13.3 12.0 0.0 16.0 26.3 26.3 0.0 12 63.2 100 100.0 100.0 100.0 20.0 25.0 25.0 25.0 100.0 25.0 100.0 0.0																				
100 86.4 98.8 65.4 6.1 71.4 100.0 1.0 86.7 87.7 13.3 12.0 0.0 16.0 26.3 26.3 0.0 12 63.2 100 100.0 100.0 100.0 20.0 25.0 25.0 25.0 100.0 25.0 100.0 0.0																				
		54.2	13	6.6	41.7	25.0	13.0	30.6	62.5	53.7	78.9	81.3	36.3	79.9	53.6	42.4	61.5	78.9	88.2	100
100 89.7 20.7 93.1 14.7 79.4 97.1 61.8 14.7 10.3 25.0 25.0 0.0 3.4 12.5 50.0 40.0 13 12.5 100 82.2 100.0 80.8 3.2 71.6 100.0 15.8 12.6 13.7 6.5 9.1 9.1 9.6 23.1 53.8 9.6 14 46.2 100 82.8 100.0 10.0 15.8 12.6 13.7 6.5 9.1 9.1 9.6 23.1 53.8 9.6 14 46.2 100 83.5 86.1 62.0 40.0 50.4 96.5 0.0 10.0 0.0 0.0 0.0 0.0 31.6 42.9 42.9 0.0 18 0.0 10.0 100 0.0		63.2	12	0.0	26.3	26.3	16.0	0.0	12.0	13.3	87.7	86.7	1.0	100.0	71.4	6.1	65.4	98.8	86.4	100
100 82.2 100.0 80.8 3.2 71.6 100.0 15.8 12.6 13.7 6.5 9.1 9.1 9.6 23.1 53.8 9.6 14 46.2 100 82.2 100.0 80.8 3.2 71.6 100.0 15.8 12.6 13.7 6.5 9.1 9.1 9.6 23.1 53.8 9.6 14 46.2 100 83.5 86.1 62.0 40.0 50.4 96.5 0.0 0.0 0.0 0.0 0.0 31.6 42.9 42.9 0.0 18 0.0 100 100 83.5 86.1 62.0 40.0 50.4 96.5 0.0 0.0 0.0 0.0 0.0 31.6 42.9 42.9 0.0 18 0.0 100 100 0.0 0.0 0.0 75.0 100.0 12.5 62.5 0.0 50.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0		0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	25.0	50.0	100.0	25.0	25.0	100.0	100.0	100.0	100
No. No. <td></td> <td>12.5</td> <td>13</td> <td>40.0</td> <td>50.0</td> <td>12.5</td> <td>3.4</td> <td>0.0</td> <td>25.0</td> <td>25.0</td> <td>10.3</td> <td>14.7</td> <td>61.8</td> <td>97.1</td> <td>79.4</td> <td>14.7</td> <td>93.1</td> <td>20.7</td> <td>89.7</td> <td>100</td>		12.5	13	40.0	50.0	12.5	3.4	0.0	25.0	25.0	10.3	14.7	61.8	97.1	79.4	14.7	93.1	20.7	89.7	100
100 0.0 0.0 75.0 100.0 12.5 62.5 0.0 50.0 0.0		46.2	14	9.6	53.8	23.1	9.6	9.1	9.1	6.5	13.7	12.6	15.8	100.0	71.6	3.2	80.8	100.0	82.2	100
100 0.0 0.0 75.0 100.0 12.5 62.5 0.0 50.0 0.0																				
100 0.0 0.0 38.1 52.4 100.0 4.8 4.8 0.0 14.3 0.0																		86.1		100
Image: Note of the state of the st											0.0	62.5			75.0		0.0			100
		0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	4.8	4.8	100.0	52.4	38.1	0.0	0.0	0.0	100
		100.0	15	77 Q	55.6	22.2	22.4	4.8	52.4	37.8	74 1	76.8	80.0	9/1 7	75.9	74.7	86.2	98.5	87.0	100
100 87.2 97.9 72.3 43.4 77.1 91.6 59.0 77.1 83.0 41.7 57.1 14.3 31.9 20.0 40.0 34.2 16 0.0																				100

Organisation	ex	mated pected umber						I	Number su	bmitted	
	n	umber -					All cases		Rectal 1	umours	
	Total	MR	Total	ST	MR	ОМ	LOS	Total	ST	MR	
South West London Cancer Network											
Mayday Healthcare NHS Trust	138	111	25	22	20	22	21	11	9	8	
Kingston Hospital NHS Trust	185	148									
St George's Healthcare NHS Trust	112	89	17	14	11	13	5	8	5	3	
The Royal Marsden NHS Foundation Trust	17	13	1	0	0	0	0	1	0	0	
Epsom and St Helier University Hospitals NHS Trust	235	188	73	63	56	57	0	23	22	18	
Peninsula Cancer Network											
South Devon Health Care NHS Foundation Trust	217	173	157	136	110	131	127	40	30	22	
Northern Devon Healthcare NHS Trust	152	121	56	45	23	41	42	14	10	1	
Royal Cornwall Hospitals NHS Trust	282	225	285	210	46	198	66	103	71	8	
Royal Devon and Exeter NHS Foundation Trust	340	272	336	258	220	250	254	94	72	57	
Plymouth Hospitals NHS Trust	283	227	317	271	62	214	163	89	68	15	
Dorset Cancer Network											
Dorset County Hospital NHS Foundation Trust	137	109	174	137	124	132	102	49	34	29	
Poole Hospital NHS Foundation Trust	182	145	207	166	144	155	141	50	37	27	
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust	215	172	278	213	192	204	187	75	52	42	
Aven Conserved 9 Miltahim Conserve Nativezela											
Avon, Somerset & Wiltshire Cancer Network	427	101	114	96	21	72	41	40	25	4	
Weston Area Health NHS Trust	127	101	114	86	31	73	41	40	25	4	
Yeovil District Hospital NHS Foundation Trust	115	92	77	59	29	53	55	51	39	12	
University Hospitals Bristol NHS Foundation Trust	128	103	179	137	65	124	122	47	31	10	
Taunton and Somerset NHS Foundation Trust	218	175	189	154	76	148	99	56	40	15	
Royal United Hospital Bath NHS Trust North Bristol NHS Trust	258 302	207 241	276 293	220 231	106 124	196 224	20 116	120 100	85 71	18 24	
	502	241	295	251	124	224	110	100	71	24	
Three Counties Cancer Network											
Hereford Hospitals NHS Trust	140	112	149	118	109	102	112	40	32	26	
Gloucestershire Hospitals NHS Foundation Trust	457	365	3	2	1	2	0	2	1	0	
Thames Valley Cancer Network											
Heatherwood and Wexham Park Hospitals NHS Foundation Trust	170	136	191	0	0	0	0	58	0	0	
Milton Keynes General Hospital NHS Foundation Trust	98	79	39	26	14	26	18	16	12	3	
Great Western Hospitals NHS Foundation Trust	163	131	180	133	87	119	128	41	33	15	
Oxford Radcliffe Hospitals NHS Trust	370	296	128	119	101	118	118	64	55	42	
Buckinghamshire Hospitals NHS Trust	240	192	59	57	50	39	45	22	21	18	
Royal Berkshire NHS Foundation Trust	220	176									
Central South Coast Cancer Network											
Isle of Wight Healthcare NHS Trust	112	89	130	106	95	82	97	39	29	23	
Southampton University Hospitals NHS Trust	302	241	2	0	0	0	0	2	0	0	
Portsmouth Hospitals NHS Trust	327	261	485	371	337	353	353	136	101	88	
Winchester and Eastleigh Healthcare NHS Trust	130	104	154	123	115	113	87	48	35	31	
Basingstoke & North Hampshire NHS Foundation Trust	128	103									
Salisbury NHS Foundation Trust	137	109	159	135	117	125	129	48	43	34	
Royal West Sussex NHS Trust	178	143	177	57	44	44	53	60	20	14	
Surrey, West Sussex & Hampshire Cancer Network											
Royal Surrey County Hospital NHS Trust	123	99	92	84	75	75	77	29	28	24	
Frimley Park Hospital NHS Foundation Trust	123	136	52		,,,	15		23	20	24	
Ashford and St Peter's Hospitals NHS Trust	1/0	130									
Surrey and Sussex Healthcare NHS Trust	150	120									

come							_							eteness %				_	
Me ((CRM	Median no. of nodes	EMVI	Stoma	APER	Urgent or Emergency	Preop RT	MRI ST	MRI All	CT ST	CT All	Nurse	MDT	Derived Dukes	Supplied Dukes	ASA	Urgent	Excision	Age
	37.5	13	30.0	25.0	12.5	0.0	0.0	77.8	72.7	54.5	60.0	36.0	88.0	84.0	28.0	31.8	95.5	90.9	100
	33.3	20	9.1	66.7	33.3	14.3	0.0	40.0	25.0	50.0	47.1	23.5	88.2	70.6	58.8	71.4	100.0	78.6	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	0.0	0.0	0.0	100
	0.0	0	0.0	33.3	33.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.1	67.1	0.0	0.0	88.9	100
	05.5	12	17.2	26.4	4 5	27.2	20.0	66.7	62.5	90.7	90.2	047	00.4	20.2		100.0	100.0	07 5	100
	95.5 0.0	12 12	17.3 0.0	36.4 0.0	4.5 0.0	27.2 95.6	20.0 0.0	66.7 80.0	62.5 71.4	89.7 82.2	89.2 80.4	84.7 80.4	99.4 100.0	89.8 92.9	22.3 66.1	100.0 95.6	100.0 100.0	87.5 51.1	100 100
	37.5	12	0.0	12.5	12.5	16.7	0.0	12.7	14.6	0.0	0.4	3.2	79.6	29.5	9.1	28.1	65.7	21.9	100
	82.5	11	19.5	49.1	21.1	19.0	19.2	73.6	69.1	24.8	21.7	84.5	97.6	100.0	92.9	58.5	98.1	91.1	100
	0.0	8	0.0	20.0	13.3	22.1	0.0	33.8	29.2	5.2	5.0	0.9	91.2	22.4	18.6	8.1	78.6	22.9	100
	41.4	15	18.5	27.6	24.1	11.7	5.9	32.4	30.6	79.6	80.5	43.7	53.4	79.3	75.9	86.9	94.9	92.7	100
	48.1	14	24.3	33.3	11.1	13.3	8.1	86.5	78.0	86.1	84.1	72.0	95.7	82.6	78.7	72.9	94.0	92.8	100
	64.3	14	0.0	26.2	19.0	13.6	14.8	78.8	73.3	84.5	84.2	0.0	2.9	98.2	97.5	92.0	100.0	94.8	100
	0.0	12	0.0	0.0	0.0	12.0	0.0	40.0	4 2 F	0.1	11.4	10 5	(2.2	67.5	20.6	46.5	20 5	20.4	100
	0.0 16.7	12 15	0.0	0.0 16.7	0.0 16.7	12.8 22.0	0.0 5.1	40.0 66.7	42.5 66.7	8.1 78.0	11.4 77.9	10.5 36.4	63.2 89.6	67.5 92.2	38.6 54.5	46.5 94.9	39.5 98.3	38.4 50.8	100 100
	10.7	12	0.0	40.0	30.0	32.1	0.0	74.2	70.2	37.2	40.2	15.6	91.6	44.7	25.1	32.1	56.9	50.8	100
	6.7	14	1.3	13.3	0.0	13.0	15.0	80.0	60.7	18.8	18.0	40.7	92.1	77.8	17.5	29.2	83.1	49.4	100
	5.6	14	0.0	0.0	0.0	81.4	11.5	50.6	50.8	19.1	19.9	0.0	100.0	96.4	73.2	0.0	95.5	50.0	100
	0.0	17	0.0	4.2	0.0	22.5	9.6	78.9	66.0	41.6	41.3	2.0	99.0	77.1	62.8	95.2	95.2	54.1	100
	100.0	10	20.2	42.3	23.1	28.0	28.1	87.5	77.5	84.7	85.2	77.2	94.0	94.6	89.9	93.2	99.2	95.8	100
	0.0	20	0.0	0.0	0.0	0.0	0.0	100.0	50.0	50.0	66.7	66.7	100.0	100.0	100.0	100.0	100.0	100.0	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	99.0	25.1	23.0	0.0	0.0	0.0	100
	0.0	0	0.0	66.7	66.7	3.8	0.0	33.3	37.5	0.0	0.0	35.9	41.0	74.4	69.2	80.8	100.0	53.8	100
	53.3	14	0.0	60.0	0.0	22.6	3.0	69.7	63.4	68.4	69.4	43.9	96.7	92.2	86.7	90.2	83.5	66.9	100
	57.1	17	23.8	28.6	23.8	13.4	5.5	81.8	76.6	70.6	71.1	43.8	75.8	81.3	53.9	99.2	99.2	87.4	100
	88.9	12	42.0	33.3	11.1	29.8	28.6	76.2	77.3	93.0	93.2	66.1	96.6	93.2	88.1	100.0	100.0	93.0	100
	56.5	11	20.0	43.5	26.1	58.5	20.7	82.8	74.4	76.4	76.2	76.2	98.5	81.5	32.3	84.0	96.2	95.3	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	50.0	0.0	50.0	50.0	100.0	100.0	100.0	0.0	0.0	0.0	100
	50.0	12	7.4	34.1	28.4	23.5	1.0	66.3	66.9	70.9	70.1	0.0	100.0	82.9	43.7	84.4	96.8	94.1	100
	74.2	13	28.7	45.2	35.5	9.8	14.3	48.6	45.8	88.6	87.0	2.6	5.8	78.6	12.3	69.9	100.0	94.3	100
	100.0	17	25.6	14.7	8.8	16.3	9.3	67.4	64.6	90.4	91.2	79.9	100.0	89.9	63.5	98.5	100.0	88.9	100
	71.4	8	11.4	21.4	21.4	33.3	14.3	40.0	40.0	84.2	83.6	0.0	23.7	95.5	89.8	93.0	98.2	80.7	100
	95.8	21	24.0	37.5	33.3	16.7	21.4	64.3	62.1	82.1	81.5	80.4	91.3	81.5	7.6	92.9	95.2	95.2	100
	55.0	21	2 7.0	57.5	55.5	10.7	- I.T	UT.J	02.1	02.1	01.5		51.5	01.5	7.0	52.5	33.2	55.2	100

Organisation	ex	imated pected						Ν	lumber su	bmitted	
	r	umber -					All cases		Rectal t	tumours	
	Total	MR	Total	ST	MR	ОМ	LOS	Total	ST	MR	
Sussex Cancer Network											
Worthing and Southlands Hospitals NHS Trust	190	152	1	1	1	1	0	0	0	0	
East Sussex Hospitals NHS Trust	285	228	3	2	2	2	2	0	0	0	
Brighton and Sussex University Hospitals NHS Trust	212	169	12	5	4	5	5	2	0	0	
Kent & Medway Cancer Network											
Dartford and Gravesham NHS Trust	93	75	14	14	14	13	13	1	1	1	
Medway NHS Trust	165	132	60	31	20	27	0	22	9	2	
East Kent Hospitals NHS Trust	360	288	10	0	0	0	0	5	0	0	
Maidstone and Tunbridge Wells NHS Trust	232	185	4	4	4	4	4	0	0	0	
Greater Midlands Cancer Network											
Mid Staffordshire General Hospitals NHS Trust	183	147	75	0	0	0	0	30	0	0	
University Hospital of North Staffordshire NHS Trust	302	241									
The Royal Wolverhampton Hospitals NHS Trust	203	163	57	51	50	41	43	17	14	13	
Dudley Group of Hospitals NHS Trust	253	203	170	23	21	23	21	44	7	5	
Shrewsbury and Telford Hospital NHS Trust	303	243	312	249	231	243	4	98	85	78	
North of England Cancer Network											
South Tyneside NHS Foundation Trust	130	104	131	109	100	99	97	46	38	35	
City Hospitals Sunderland NHS Foundation Trust	210	168	180	143	133	138	139	60	44	42	
North Cumbria Acute Hospitals NHS Trust	243	195	100	104	93	98	84	45	31	24	
Gateshead Health NHS Foundation Trust	140	112	93	63	56	56	22	20	12	8	
The Newcastle Upon Tyne Hospitals NHS Foundation Trust	285	228	213	174	145	161	115	68	58	43	
Northumbria Health Care NHS Foundation Trust	343	275	213	174	145	176	169	68	61	43 56	
South Tees Hospitals NHS Trust	283	275	255	130	169	163	105	93	57	52	
North Tees and Hartlepool NHS Trust	230	184	205	142	132	136	29	62	42	35	
County Durham and Darlington NHS Foundation Trust	357	285	397	277	254	241	165	131	84	73	
Anglia Cancer Network											
Bedford Hospital NHS Trust	127	101	1	0	0	0	0	1	0	0	
						97	94				
The Queen Elizabeth Hospital King's Lynn NHS Trust	152	121	169	103	94	-	-	66	36	33	
Peterborough and Stamford Hospitals NHS Foundation Trust	213	171	204	168	157	160	148	55	35	35	
James Paget Healthcare NHS Foundation Trust	180	144	219	169	146	160	159	63	37	27 5	
West Suffolk Hospitals NHS Trust	162	129	88	27	14	24	23	42	13		
Cambridge University Hospitals NHS Foundation Trust	253	203	15	15	14	15	15	12	12	11	
Norfolk and Norwich University Hospital NHS Trust	452	361	146	94	59	85	85	56	28	16	
Ipswich Hospital NHS Trust Hinchingbrooke Health Care NHS Trust	255 100	204 80									
Essex Cancer Network											
Southend University Hospital NHS Foundation Trust	233	187	211	184	158	137	175	53	40	23	
Basildon and Thurrock University Hospitals NHS Foundation Trust	160	128									
Essex Rivers Healthcare NHS Trust	242	193	1	1	1	1	1	0	0	0	
Mid Essex Hospital Services NHS Trust	147	117	1	0	0	0	0	1	0	0	
North Wales Cancer Network											
North West Wales NHS Trust	0	0	226	184	153	183	155	72	48	35	
Conwy and Denbighshire NHS Trust	0	0	213	135	126	119	63	62	34	31	
North East Wales NHS Trust	0	0	140	105	100	70	60	46	28	28	
South West Wales Cancer Network											
Carmarthenshire NHS Trust	0	0	179	145	118	135	143	55	39	33	
Swansea NHS Trust	0	0	278	246	199	234	243	77	65	46	
Bro Morgannwg	0	0	200	162	145	157	141	55	36	33	

			I	Data comple	eteness %													Out	comes %
Age	Excision	Urgent	ASA	Supplied Dukes	Derived Dukes	MDT	Nurse	CT All	CT ST	MRI All	MRI ST	Preop RT	Urgent or Emergency	APER	Stoma	EMVI	Median no. of nodes	CRM	Median LOS (days)
100	100.0	100.0	0.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9	0.0	0
100	100.0	100.0	50.0	66.7	100.0	100.0	33.3	100.0	100.0	0.0	0.0	0.0	50.0	0.0	0.0	0.0	25	0.0	16
100	80.0	60.0	0.0	83.3	83.3	100.0	75.0	0.0	0.0	0.0	0.0	0.0	60.0	0.0	0.0	0.0	5	0.0	13
100	100.0	92.9	92.9	92.9	92.9	92.9	7.1	14.3	14.3	100.0	100.0	0.0	0.0	0.0	0.0	7.1	18	0.0	6
100	67.7	96.8	58.1	73.3	78.3	98.3	46.7	81.7	90.3	90.9	77.8	0.0	35.5	0.0	0.0	45.0	12	50.0	0
100	0.0	0.0	0.0	0.0	0.0	90.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0.0	0
 100	100.0	75.0	100.0	25.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	25.0	11	0.0	7
100	0.0	0.0	0.0	0.0	0.0	66.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0.0	0
100	98.0	2.0	80.4	66.7	82.5	96.5	0.0	1.8	2.0	11.8	14.3	0.0	2.0	15.4	15.4	10.0	12	0.0	10
100	95.7	91.3	91.3	80.0	84.1	98.8	14.1	88.2	91.3	40.9	57.1	14.3	13.0	20.0	20.0	23.8	12	100.0	12
100	93.2	95.2	91.2	22.8	91.0	1.6	2.2	64.7	75.9	48.0	51.8	7.1	12.9	19.2	23.1	0.4	11	70.5	5
400	045		70.0	00.4	047	04.6	10.0	70.0	70.0	10.0	24.4	42.0		20.0	27.4	42.0		25.7	42
100	94.5	84.4	78.0	90.1	94.7	91.6	49.6	78.6	79.8	19.6	21.1	12.8	6.4	20.0	37.1	13.0	11	25.7	12
 100 100	93.0 90.4	89.5 66.3	81.8 49.0	91.1 70.8	92.2 88.2	83.9 90.3	54.4 30.6	89.4 61.8	90.2 65.4	36.7 8.9	43.2 9.7	66.7 12.9	23.1 6.7	33.3 12.5	42.9 20.8	30.1 5.4	13 14	90.5 8.3	11 7
100	90.4	93.7	49.0 68.3	87.1	97.8	81.7	4.3	46.2	60.3	6.9 5.0	8.3	12.9	19.0	12.5	20.8	17.9	14	87.5	13
100	90.2	50.0	40.2	80.3	99.1	91.5	13.6	82.2	82.8	36.8	36.2	44.8	8.6	32.6	37.2	4.8	12	14.0	11
100	97.5	81.8	68.2	64.8	97.1	82.9	27.1	72.4	73.2	7.4	8.2	52.5	11.6	25.0	39.3	8.3	10	26.8	9
 100	94.4	66.1	63.3	81.2	96.1	89.4	37.6	55.7	62.2	34.4	43.9	43.1	11.1	34.6	44.2	17.2	14	38.5	10
 100	95.8	70.4	57.7	81.5	88.3	91.7	32.7	39.0	44.4	12.9	14.3	27.9	10.6	14.3	14.3	17.4	9	34.3	7
100	95.7	67.9	48.0	56.9	84.6	86.6	33.5	71.8	78.3	33.6	33.3	43.0	14.1	16.4	23.3	11.0	10	32.9	10
100	0.0	0.0	0.0	100.0	100.0	100.0	100.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0.0	0
100	91.3	97.1	82.5	72.8	78.7	2.4	0.0	67.5	67.0	40.9	58.3	66.7	11.7	42.4	57.6	9.6	6	78.8	10
 100	94.0	100.0	91.7	23.0	74.0	100.0	0.0	74.0	78.6	69.1	80.0	0.0	9.5	31.4	60.0	0.0	13	65.7	9
 100 100	87.6 51.9	98.8 85.2	69.8 85.2	48.4 84.1	82.6 88.6	93.6 96.6	70.8 25.0	55.3 1.1	53.8 0.0	19.0 50.0	24.3 53.8	13.5 0.0	26.0 25.9	22.2 0.0	55.6 0.0	22.6 0.0	11 13	55.6 20.0	11 9
100	100.0	93.3	80.0	20.0	86.7	93.3	93.3	100.0	100.0	75.0	75.0	75.0	13.3	72.7	81.8	50.0	13	100.0	10
100	66.0	91.5	72.3	41.8	64.4	96.6	56.2	54.1	57.4	25.0	28.6	0.0	14.9	0.0	31.3	0.0	11	0.0	8
100	88.0	98.4	94.6	80.6	90.5	100.0	31.3	95.7	95.1	73.6	70.0	22.5	18.5	21.7	47.8	31.6	0	87.0	11
				100.0	100.0														
100	100.0	100.0		100.0	100.0		100.0	0.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	100.0	11	0.0	7
100	0.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0.0	0
100	90.8	94.6	32.6	71.7	73.0	94.2	58.4	77.0	81.0	45.8	50.0	22.9	20.1	22.9	37.1	12.4	12	48.6	9
100	94.1	95.6		62.9	69.0	79.3	67.1	67.1	81.5	48.4	70.6	41.2	17.8	32.3	45.2	4.8	11	74.2	9
100	99.0	40.0	36.2	36.4	44.3	36.4	35.0	31.4	34.3	13.0	14.3	57.1	5.7	35.7	39.3	21.0	16	21.4	10
100	85.5	97.2		86.0	86.6	97.8	73.2	74.9	73.1	52.7	56.4	2.6	9.7	24.2	60.6	29.7	8	81.8	12
100	81.3	100.0		86.3	86.7	92.1	40.3	79.5	78.5	39.0	38.5	9.1	35.4	26.1	43.5	36.7	14	93.5	12
100	95.7	79.0	45.7	75.0	77.5	89.5	45.0	67.0	67.9	61.8	75.0	21.1	18.5	51.5	78.8	21.4	12	27.3	9

Organisation	Est	timated							Number s	ubmitted	
3	e	kpected									
	1	number					All cases		Recta	tumours	
	Total	MR	Total	ST	MR	ОМ	LOS	Total	ST	MR	
Ceredigion & Mid Wales NHS Trust	0	0	53	45	39	44	41	17	14	12	
Pembrokeshire & Derwen NHS Trust	0	0	102	86	75	84	84	25	20	18	
South East Wales Cancer Network											
Pontypridd & Rhondda NHS Trust	0	0	142	122	106	121	115	47	36	26	
Gwent Healthcare NHS Trust	0	0	372	286	252	276	10	123	77	62	
Cardiff & Vale NHS Trust	0	0	210	171	146	168	107	72	63	50	
North Glamorgan NHS Trust	0	0	138	123	92	118	115	50	39	27	
Republic of Ireland											
St James Hospital, Ireland	0	0	207	170	148	161	153	56	44	35	
Southern Health and Social Care Trust, Ireland	0	0	182	138	133	135	137	50	36	35	
Northern Ireland											
Belfast	0	0	170	162	151	158	160	45	40	31	
Other											
Princess Grace Hospital	0	0	4	4	4	4	4	2	2	2	

			[Data comple	eteness %													Out	comes %
Age	Excision	Urgent	ASA	Supplied Dukes	Derived Dukes	MDT	Nurse	ct Ali	CT ST	MRI All	MRI ST	Preop RT	Urgent or Emergency	APER	Stoma	EMVI	Median no. of nodes	CRM	Median LOS (days)
100	91.1	95.6	75.6	86.8	86.8	90.6	22.6	66.0	77.8	5.9	7.1	0.0	17.8	41.7	41.7	20.5	11	16.7	13
100	88.4	100.0	89.5	90.2	90.2	74.5	81.4	87.3	86.0	80.0	95.0	30.0	34.9	66.7	72.2	13.3	12	88.9	9
100	88.5	96.7	8.2	83.1	85.2	83.8	22.5	55.6	54.1	59.6	69.4	19.4	9.0	26.9	61.5	29.2	10	23.1	9
100	89.2	98.3	36.7	75.5	79.8	47.6	47.0	55.9	53.1	27.6	28.6	12.5	29.0	22.6	40.3	15.5	11	37.1	4
100	87.7	87.1	39.2	64.8	71.9	83.8	41.0	51.4	51.5	36.1	39.7	36.5	15.2	26.0	32.0	26.7	13	88.0	8
100	74.8	89.4	99.2	57.2	81.2	97.8	82.6	69.6	73.2	10.0	12.8	10.3	13.0	22.2	29.6	14.1	12	14.8	8
100	88.2	96.5	85.9	87.0	93.2	100.0	86.5	92.8	95.3	83.9	90.9	43.2	14.1	34.3	40.0	33.1	15	97.1	11
100	97.1	100.0	89.9	69.2	82.4	100.0	0.0	69.2	71.0	2.0	2.8	43.2	23.9	8.6	57.1	26.3	16	82.9	8
100	95.7	100.0	100.0	0.0	43.5	100.0	80.6	5.3	5.6	48.9	50.0	41.5	23.5	45.2	61.3	26.5	15	90.3	9
100	100.0	100.0	100.0	100.0	100.0	100.0	75.0	75.0	75.0	100.0	100.0	0.0	25.0	0.0	0.0	50.0	17	100.0	11

Appendix 2: Summary of 2007/8 data

Key: MR – Number of patients estimated/reported as undergoing a major resection OM – Number of patients reported as receiving any surgical treatment LOS – Number of patients eligible to be included in length of stay calculations

Organisation	ex	imated pected umber						Ν	lumber su	Ibmitted	
						1	All cases		Rectal	tumours	
	Total	MR	Total	ST	MR	OM	LOS	Total	ST	MR	
Lancashire & South Cumbria Cancer Network											
University Hospitals of Morecambe Bay NHS Trust	175	140	213	163	25	105	4	73	46	3	
Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust	176	141	181	144	108	139	138	58	40	19	
Lancashire Teaching Hospitals NHS Foundation Trust	165	132	167	109	68	84	81	75	49	22	
East Lancashire Hospitals NHS Trust	190	152	78	38	27	26	17	41	12	7	
					,						
Greater Manchester & Cheshire Cancer Network											
The Mid Cheshire Hospitals NHS Trust	94	75	41	32	19	29	19	11	9	8	
Christie Hospital NHS Foundation Trust	19	15	23	19	16	19	19	12	9	8	
East Cheshire NHS Trust	79	63	1	1	1	1	1	0	0	0	
University Hospitals of South Manchester NHS Foundation Trust	101	81	89	75	62	74	74	24	18	17	
Salford Royal NHS Foundation Trust	96	77	54	38	24	32	33	29	18	8	
Trafford Healthcare NHS Trust	65	52	38	32	30	21	28	13	10	8	
Bolton Hospitals NHS Trust	119	95	160	101	91	100	96	53	33	32	
Tameside and Glossop Acute Services NHS Trust	95	76	125	111	91	81	105	27	20	13	
Wrightington, Wigan and Leigh NHS Trust	126	101	79	65	59	53	58	28	20	17	
Central Manchester University Hospitals NHS Foundation Trust	65	52	1	0	0	0	0	1	0	0	
Pennine Acute Hospitals NHS Trust	348	278	129	102	95	96	93	45	32	30	
Stockport NHS Foundation Trust	153	122	12.5	57	48	53	47	28	16	11	
	133	122	101	57	40	55	47	20	10		
Merseyside & Cheshire Cancer Network											
Wirral University Teaching Hospital NHS Foundation Trust	169	135	186	164	150	156	157	34	28	25	
St Helens and Knowsley Hospitals NHS Trust	136	109	169	111	78	82	94	58	37	20	
Aintree University Hospitals NHS Foundation Trust	165	132	160	124	105	116	116	29	23	17	
Clatterbridge Centre For Oncology NHS Foundation Trust	0	0	219	0	0	0	0	120	0	0	
Countess of Chester Hospital NHS Foundation Trust	85	68	121	118	80	96	94	42	41	26	
Royal Liverpool and Broadgreen University Hospitals NHS Trust	154	123	90	38	32	30	29	35	11	7	
Southport and Ormskirk Hospital NHS Trust	119	95	50	50	52	50	25	55		/	
Warrington and Halton Hospitals NHS Foundation Trust	115	124	157	151	126	132	140	62	59	46	
	135	124	157	151	120	152	140	02	55	40	
Yorkshire Cancer Network											
Bradford Teaching Hospitals NHS Foundation Trust	154	123	188	139	126	137	119	48	33	26	
York Hospitals NHS Foundation Trust	174	139	218	164	133	136	3	62	38	28	
Harrogate and District NHS Foundation Trust	93	74	95	82	77	75	79	37	31	28	
Airedale NHS Trust	91	73	108	91	85	89	85	29	23	19	
Leeds Teaching Hospitals NHS Trust	300	240	318	229	214	213	182	102	68	59	
Calderdale and Huddersfield NHS Foundation Trust	151	121	85	63	55	60	58	32	24	18	
Mid Yorkshire Hospitals NHS Trust	250	200	306	224	197	219	186	96	69	53	
	250	200	500	224	157	215	100	50	05	55	
Humber & Yorkshire Coast Cancer Network											
Northern Lincolnshire and Goole Hospitals NHS Foundation Trust	175	140	66	47	38	38	44	26	14	10	
Hull and East Yorkshire Hospitals NHS Trust	243	194	222	202	191	137	149	65	58	51	
Scarborough & North East Yorkshire Health Care NHS Trust	106	85									
North Trent Cancer Network											
Barnsley Hospital NHS Foundation Trust	106	85	107	57	52	45	1	42	24	19	
Chesterfield Royal Hospital NHS Foundation Trust	134	107									
The Rotherham NHS Foundation Trust	95	76	87	85	81	85	85	27	27	24	
Sheffield Teaching Hospitals NHS Foundation Trust	241	193	257	210	170	203	155	63	46	22	
Doncaster and Bassetlaw Hospitals NHS Foundation Trust	223	178	51	44	39	43	28	17	14	13	
Den Dimpingham Cancer Natural					1				1		
Pan Birmingham Cancer Network	400	402	76	70	60		C 7	24	24		
Walsall Hospitals NHS Trust	128	102	76	76	69	66	67	21	21	16	
Heart of England NHS Foundation Trust	333	266	416	328	272	316	311	111	87	62	
University Hospital Birmingham NHS Foundation Trust	341	273	218	175	158	166	172	76	61	53	
Sandwell and West Birmingham Hospitals NHS Trust	151	121	116	93	68	87	62	32	25	14	

comes	Out													teness %	oata comple	C			
Med L (da	CRM	Median no. of nodes	EMVI	Stoma	APER	Urgent or Emergency	Preop RT	MRI ST	MRI All	CT ST	CT All	Nurse	MDT	Derived Dukes	Supplied Dukes	ASA	Urgent	Excision	Age
	33.3	11	4.0	0.0	0.0	53.4	4.3	60.9	61.6	1.8	1.4	1.9	93.9	52.6	10.8	2.5	90.8	24.5	100
	52.6	12	19.4	36.8	15.8	20.1	15.0	87.5	77.6	41.0	39.8	66.9	93.9	77.9	62.4	95.8	100.0	83.3	100
	50.0	9	0.0	4.5	4.5	19.3	36.7	63.3	58.7	0.0	2.4	1.2	80.2	55.1	54.5	45.0	76.1	62.4	100
	0.0	14	0.0	14.3	14.3	31.6	0.0	41.7	29.3	18.4	12.8	47.4	66.7	39.7	38.5	36.8	97.4	73.7	100
	25.0	11	15.8	62.5	37.5	37.5	66.7	77.8	63.6	78.1	78.0	85.4	87.8	85.4	80.5	100.0	100.0	59.4	100
	100.0	12	31.3	100.0	75.0	5.3	77.8	100.0	100.0	94.7	91.3	60.9	60.9	100.0	87.0	94.7	100.0	84.2	100
	0.0	14	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100
	94.1	17	30.6	58.8	23.5	26.7	66.7	66.7	70.8	88.0	88.8	28.1	18.0	92.1	79.8	90.7	100.0	84.0	100
	12.5	14	20.8	62.5	50.0	5.3	33.3	83.3	82.8	5.3	3.7	90.7	96.3	66.7	64.8	63.2	100.0	73.7	100
	75.0	15	33.3	62.5	25.0	21.9	60.0	50.0	53.8	93.8	89.5	71.1	100.0	100.0	100.0	81.3	100.0	93.8	100
	87.5	13	0.0	31.3	25.0	11.9	0.0	0.0	0.0	0.0	0.0	26.3	45.0	70.0	60.6	96.0	54.5	91.1	100
	0.0	14	7.7	30.8	7.7	24.3	60.0	60.0	59.3	74.8	74.4	28.0	88.0	84.0	66.4	65.8	94.6	84.7	100
	88.2	12	13.6	35.3	29.4	9.2	85.7	61.9	46.4	92.3	92.4	96.2	1.3	81.0	64.6	96.9	98.5	90.8	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	0.0	100.0	100.0	100.0	0.0	0.0	0.0	100
	96.7	11	29.5	36.7	26.7	31.4	34.4	62.5	55.6	86.3	86.0	72.9	89.1	89.9	86.0	98.0	99.0	95.1	100
	36.4	12	35.4	54.5	36.4	7.0	6.3	43.8	28.6	84.2	78.2	53.5	59.4	76.2	34.7	77.2	64.9	86.0	100
	80.0	13	17.3	44.0	8.0	16.5	46.4	57.1	52.9	57.9	57.5	70.4	95.2	86.0	16.1	82.9	95.1	92.7	100
	15.0	13	2.6	0.0	0.0	36.0	48.6	51.4	43.1	19.8	17.8	72.8	94.7	91.1	81.7	87.4	96.4	73.0	100
	82.4	17	14.3	41.2	23.5	9.7	82.6	56.5	55.2	58.9	55.0	70.6	94.4	77.5	7.5	86.3	94.4	86.3	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	100
	100.0	11	0.0	3.8	3.8	16.9	58.5	0.0	0.0	83.1	81.8	0.0	99.2	72.7	72.7	82.2	91.5	68.6	100
	14.3	16	3.1	0.0	0.0	18.4	54.5	9.1	2.9	2.6	1.1	61.1	5.6	43.3	23.3	52.6	60.5	86.8	100
	60.9	11	19.8	45.7	19.6	26.5	47.5	44.1	45.2	43.7	42.7	35.0	68.2	83.4	22.9	11.3	98.0	86.1	100
	92.3	19	21.4	23.1	19.2	10.8	60.6	78.8	79.2	83.5	83.0	81.4	89.9	80.3	17.0	98.6	100.0	94.2	100
	92.5 89.3	19	21.4	14.3	19.2	22.6	15.8	78.8 81.6	79.2	65.5 76.2	78.0	1.4	98.2	82.1	17.0	98.0 97.6	94.5	94.2 81.7	100
	100.0	14	35.1	35.7	14.5	22.0	41.9	80.6	75.7	85.4	86.3	96.8	100.0	92.6	80.0	85.4	97.6	97.6	100
	100.0			57.9	31.6	8.8	65.2	87.0	79.3	90.1	88.0	68.5	99.1	92.6	40.7	92.3	97.6	97.6	100
	0.0	20 19	40.0 0.5	37.3	28.8	0.0 14.8	0.0	11.8	11.8	20.1	17.9	60.4	99.1	92.0 67.0	59.1	92.5 64.2	95.0	95.0	100
	94.4	13	30.9	50.0	38.9	7.9	33.3	79.2	78.1	96.8	88.2	80.0	77.6	97.6	72.9	93.7	98.4	95.2	100
	94.4 77.4	13	30.5	32.1	11.3	15.6	37.7	78.3	69.8	87.5	85.9	57.2	97.4	83.0	41.2	62.9	98.2	88.8	100
	90.0	14	42.1	50.0	10.0	25.5	78.6	71.4	65.4	68.1	68.2	75.8	93.9	75.8	42.4	66.0	100.0	80.9	100
	86.3	11	29.3	54.9	39.2	16.3	75.9	89.7	87.7	75.2	76.1	81.5	78.8	90.5	87.4	74.3	100.0	98.5	100
	5.3	10	13.5	42.1	15.8	5.3	0.0	87.5	52.4	87.7	51.4	57.9	87.9	58.9	26.2	80.7	98.2	91.2	100
	5.5	10	13.5	-12.1	15.0	5.5	0.0	07.5	52.7	07.7	51.4	57.5	07.5	50.5	20.2	00.7	50.2	51.2	100
	91.7	16	14.8	41.7	20.8	8.2	48.1	77.8	77.8	85.9	83.9	92.0	100.0	93.1	69.0	95.3	100.0	95.3	100
	81.8	28	27.6	40.9	27.3	28.1	32.6	50.0	57.1	82.4	84.0	68.5	84.0	81.3	38.5	61.4	95.2	87.1	100
	0.0	14	15.4	46.2	30.8	11.4	35.7	100.0	88.2	84.1	80.4	0.0	0.0	68.6	47.1	97.7	100.0	88.6	100
	87.5	17	36.2	25.0	18.8	22.4	4.8	19.0	19.0	42.1	42.1	97.4	96.1	84.2	9.2	94.7	100.0	96.1	100
	67.5 17.7	20	32.4	25.0	21.0	22.4	4.0 32.2	66.7	58.6	42.1 57.0	42.1 57.7	81.3	98.1	78.4	33.2	94.7 79.3	94.2	90.1	100
	75.5	20	37.3	67.9	39.6	13.1	63.9	85.2	85.5	89.1	88.5	76.6	97.7	92.2	89.0	90.9	94.2 96.0	92.1	100
	15.5	20	57.5	07.9	59.0	15.1	03.3	05.2	05.5	05.1	00.5	70.0	51.1	JZ.Z	0.00	50.5	50.0	55.7	100

Organisation	ex	imated pected umber						N	umber su	omitted
		aniber				A	All cases		Rectal t	umours
	Total	MR	Total	ST	MR	OM	LOS	Total	ST	MR
Arden Cancer Network										
South Warwickshire General Hospitals NHS Trust	119	95	115	86	75	80	80	31	24	21
University Hospitals Coventry And Warwickshire NHS Trust	204	163	214	131	113	121	124	79	52	40
George Eliot Hospital NHS Trust	86	69	96	74	62	63	59	14	12	8
Worcestershire Acute Hospitals NHS Trust	276	221	285	247	223	236	237	57	38	23
Mid Trent Cancer Network										
Sherwood Forest Hospitals NHS Foundation Trust	143	114	152	129	113	74	97	50	38	34
United Lincolnshire Hospitals NHS Trust	334	267	132	125	115	74	51	50	50	54
Nottingham University Hospitals NHS Trust	298	238	301	200	160	172	4	76	34	21
	250	250	501	200	100	172	4	70	74	21
Derby & Burton Cancer Network										
Burton Hospitals NHS Trust	113	90	8	1	1	1	1	6	0	0
Derby Hospitals NHS Foundation Trust	195	156	239	181	154	179	177	63	38	30
Leicestershire, Northamptonshire & Rutland Cancer Network										
Kettering General Hospital NHS Trust	129	103								
Northampton General Hospital NHS Trust	133	106	93	91	83	85	25	29	27	24
University Hospitals of Leicester NHS Trust	341	273	455	337	287	334	330	138	106	86
	341	215	-55	557	207	554	550	150	100	00
Mount Vernon Cancer Network										
Luton and Dunstable Hospital NHS Foundation Trust	94	75	140	73	63	67	0	40	23	19
West Hertfordshire Hospitals NHS Trust	159	127								
East and North Hertfordshire NHS Trust	184	147	220	169	160	167	154	67	50	46
West London Cancer Network										
The Hillingdon Hospital NHS Trust	71	57	91	88	81	86	85	18	18	15
Ealing Hospital NHS Trust	41	33	31	31	22	21	26	7	7	4
West Middlesex University Hospital NHS Trust	46	37	89	70	63	60	64	22	, 19	17
Chelsea and Westminster Hospital NHS Foundation Trust	46	37	87	65	55	52	49	26	14	12
North West London Hospitals NHS Trust	170	136	48	44	37	19	29	9	7	6
Imperial College Healthcare NHS Trust	136	109	139	108	93	95	98	44	33	27
North London Cancer Network										
Royal Free Hampstead NHS Trust	70	56	69	57	53	53	52	16	11	10
The Whittington Hospital NHS Trust	56	45	68	60	51	52	54	9	7	6
University College London Hospitals NHS Foundation Trust	50	40								
Barnet and Chase Farm Hospitals NHS Trust	140	112	122	95	86	71	83	29	20	14
The Princess Alexandra Hospital NHS Trust	95	76								
North Middlesex University Hospital NHS Trust	51	41								
North East London Cancer Network										
Barking, Havering and Redbridge Hospitals NHS Trust	253	202	158	114	94	109	110	48	29	24
Whipps Cross University Hospital NHS Trust	79	63	101	71	62	71	68	28	19	15
Newham University Hospital NHS Trust	38	30	55	38	28	36	32	17	14	5
Barts and The London NHS Trust	71	57	43	35	29	34	33	15	13	9
Homerton University Hospital NHS Foundation Trust	30	24	61	43	33	38	37	17	8	6
South East London Cancer Network										
Queen Elizabeth Hospital NHS Trust	78	62	113	29	26	17	0	19	0	0
Bromley Hospitals NHS Trust	91	73	3	0	0	0	0	2	0	0
Queen Mary's Sidcup NHS Trust	68	54	26	2	2	0	0	6	0	0
Guy's and St Thomas' NHS Foundation Trust	49	39	42	0	0	0	0	12	0	0
The Lewisham Hospital NHS Trust	48	38	56	30	14	15	15	17	6	2
King's College Hospital NHS Foundation Trust	51	41	124	2	2	1	1	42	1	1

comes 9	Out													teness %	Data comple	Ľ			
Media LC (day	CRM	Median no. of nodes	EMVI	Stoma	APER	Urgent or Emergency	Preop RT	MRI ST	MRI All	CT ST	CT All	Nurse	MDT	Derived Dukes	Supplied Dukes	ASA	Urgent	Excision	Age
1	23.8	12	34.7	28.6	19.0	14.0	54.2	95.8	96.8	93.0	93.0	60.0	94.8	87.0	39.1	95.3	96.5	89.5	100
	82.5	16	25.7	32.5	25.0	12.2	1.9	1.9	6.3	77.9	76.2	76.2	100.0	67.3	11.7	83.2	80.9	89.3	100
	62.5	17	27.4	25.0	12.5	24.3	50.0	75.0	64.3	68.9	64.6	63.5	92.7	74.0	29.2	81.1	97.3	87.8	100
1	26.1	15	29.6	43.5	4.3	42.5	26.3	86.8	70.2	80.2	77.5	25.3	93.0	89.8	38.9	62.3	93.9	90.3	100
	100.0		40.7		47.0	24.7	57.0	04.6	70.0	02.0	00.0	06.4	00.7		40.4	00.0	100.0	00.7	400
1	100.0	14	40.7	44.1	17.6	21.7	57.9	81.6	70.0	93.8	90.8	96.1	98.7	88.8	18.4	99.2	100.0	90.7	100
	9.5	14	35.0	19.0	4.8	0.5	5.9	44.1	52.6	73.0	76.4	96.3	97.0	73.4	68.8	1.0	55.0	84.5	100
		-																	
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	16.7	0.0	37.5	12.5	75.0	37.5	37.5	100.0		100.0	100
	60.0	18	33.8	43.3	10.0	13.8	55.3	78.9	79.4	76.8	76.6	63.6	94.6	79.1	19.2	84.5	91.2	91.2	100
1	75.0	10	4.8	66.7	29.2	22.0	0.0	77.8	79.3	63.7	62.4	41.9	88.2	67.7	14.0	65.9	100.0	91.2	100
1	83.7	14	31.4	48.8	17.4	21.4	70.8	79.2	77.5	78.3	80.0	55.6	99.1	83.5	81.5	90.8	100.0	90.5	100
	0.0	0	0.0	42.1	15.8	5.5	0.0	39.1	42.5	57.5	63.6	0.0	95.7	31.4	22.9	0.0	83.6	86.3	100
1	50.0	12	26.9	45.7	23.9	11.2	14.0	0.0	0.0	84.0	78.2	75.5	95.5	87.3	82.7	94.7	99.4	95.3	100
1	13.3	10	29.6	40.0	26.7	33.0	27.8	22.2	22.2	78.4	75.8	75.8	100.0	90.1	7.7	38.6	98.9	94.3	100
1	50.0	15	22.7	75.0	25.0	3.2	14.3	42.9	42.9	74.2	74.2	96.8	100.0	93.5	67.7	61.3	87.1	74.2	100
1	100.0	16	20.6	35.3	29.4	21.4	52.6	100.0	100.0	97.1	97.8	97.8	97.8	88.8	80.9	74.3	100.0	91.4	100
1	91.7	26	25.5	50.0	16.7	20.0	28.6	50.0	53.8	80.0	79.3	88.5	100.0	74.7	31.0	93.8	95.4	92.3	100
1	50.0	17	35.1	16.7	0.0	27.3	14.3	71.4	66.7	88.6	89.6	33.3	95.8	95.8	29.2	9.1	86.4	93.2	100
	92.6	25	31.2	22.2	14.8	15.7	45.5	81.8	77.3	71.3	74.8	92.8	95.7	95.7	32.4	99.1	99.1	93.5	100
1	100.0	16	28.3	30.0	20.0	7.0	45.5	100.0	75.0	89.5	89.9	85.5	100.0	89.9	69.6	0.0	43.9	93.0	100
	100.0	16	31.4	50.0	0.0	33.3	57.1	71.4	55.6	85.0	85.3	60.3	91.2	85.3	17.6	96.7	96.7	88.3	100
	100.0	16	36.0	42.9	42.9	9.5	15.0	85.0	82.8	96.8	95.1	38.5	96.7	86.1	76.2	74.7	100.0	90.5	100
	87.5	12	16.0	33.3	25.0	3.5	62.1	82.8	83.3	73.7	72.2	75.3	88.0	66.5	20.9	85.1	97.4	89.5	100
1	93.3	15	14.5	53.3	33.3	15.5	52.6	52.6	53.6	93.0	89.1	86.1	100.0	80.2	36.6	97.2	100.0	87.3	100
1	0.0	0	0.0	20.0	0.0	21.1	35.7	7.1	5.9	71.1	63.6	76.4	98.2	72.7	67.3	86.8	92.1	73.7	100
1	100.0	16	37.9	66.7	11.1	20.0	38.5	92.3	86.7	94.3	95.3	88.4	97.7	93.0	81.4	94.3	97.1	82.9	100
1	16.7	16	21.2	16.7	16.7	14.0	37.5	12.5	29.4	74.4	68.9	68.9	98.4	67.2	52.5	51.2	95.3	90.7	100
	0.0	18	0.0	0.0	0.0	24.1	0.0	0.0	0.0	0.0	0.0	0.0	97.3	33.6	31.9	34.5	100.0	89.7	100
	0.0	0	0.0	0.0	0.0	24.1	0.0	0.0	0.0	0.0	33.3	0.0	97.3	33.6 66.7	31.9 66.7	34.5 0.0	0.0	89.7 0.0	100
	0.0	23	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	96.2	73.1	65.4	0.0	0.0	100.0	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	75.0	0.0	81.0	0.0	100.0	35.7	35.7	0.0	0.0	0.0	100
	0.0	15	21.4	0.0	0.0	23.3	0.0	66.7	70.6	90.0	92.9	53.6	96.4	64.3	58.9	90.0	83.3	56.7	100

Organisation	ex	imated pected number							Number su	Ibmitted	
	r	iumber -					All cases		Rectal	tumours	
	Total	MR	Total	ST	MR	ОМ	LOS	Total	ST	MR	
South West London Cancer Network											
Mayday Healthcare NHS Trust	104	83	88	73	67	64	65	22	21	17	
Kingston Hospital NHS Trust	139	111									
St George's Healthcare NHS Trust	84	67	19	16	15	14	0	8	8	7	
The Royal Marsden NHS Foundation Trust	13	10	11	10	4	9	9	4	3	1	
Epsom And St Helier University Hospitals NHS Trust	176	141	140	120	102	112	0	35	29	23	
Peninsula Cancer Network											
South Devon Health Care NHS Foundation Trust	163	130	112	82	70	78	77	39	27	21	
Northern Devon Healthcare NHS Trust	114	91	99	80	63	73	74	25	19	14	
Royal Cornwall Hospitals NHS Trust	211	169	298	235	190	225	227	84	69	48	
Royal Devon and Exeter NHS Foundation Trust	255	204	311	251	207	241	243	88	76	53	
Plymouth Hospitals NHS Trust	213	170	318	259	166	230	223	88	68	32	
Dorset Cancer Network											
Dorset County Hospital NHS Foundation Trust	103	82	111	80	71	79	58	35	21	17	
Poole Hospital NHS Foundation Trust	136	109	165	117	102	106	102	52	26	20	
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust	161	129	208	102	92	96	31	51	25	21	
Avon, Somerset & Wiltshire Cancer Network											
Weston Area Health NHS Trust	95	76	78	64	49	55	39	28	20	13	
Yeovil District Hospital NHS Foundation Trust	86	69	63	48	39	34	34	35	20	15	
University Hospitals Bristol NHS Foundation Trust	96	77	113	90	58	86	33	27	20	9	
Taunton and Somerset NHS Foundation Trust	164	131	190	95	46	89	54	58	25	5	
Royal United Hospital Bath NHS Trust	194	155	89	74	61	69	36	26	21	17	
North Bristol NHS Trust	226	181	239	209	174	202	135	73	59	45	
Three Counties Cancer Network											
Hereford Hospitals NHS Trust	105	84	118	95	85	77	88	46	37	31	
Gloucestershire Hospitals NHS Foundation Trust	343	274	87	77	68	71	39	31	22	17	
Thames Valley Cancer Network											
Heatherwood and Wexham Park Hospitals NHS Foundation Trust	128	102	154	68	68	50	2	43	8	8	
Milton Keynes General Hospital NHS Foundation Trust	74	59	42	10	4	6	5	28	4	0	
Great Western Hospitals NHS Foundation Trust	123	98	106	71	56	68	68	28	26	17	
Oxford Radcliffe Hospitals NHS Trust	278	222	199	199	141	199	199	74	74	41	
Buckinghamshire Hospitals NHS Trust	180	144	60	53	47	46	50	16	14	11	
Royal Berkshire NHS Foundation Trust	165	132	00	55	-17	-10	50	10			
Central South Coast Cancer Network											
Isle of Wight Healthcare NHS Trust	84	67	79	60	54	57	56	22	19	16	
Southampton University Hospitals NHS Trust	226	181	227	170	145	169	42	70	43	37	
Portsmouth Hospitals NHS Trust	245	196	328	274	249	259	259	101	85	80	
Winchester and Eastleigh Healthcare NHS Trust	98	78	104	71	67	70	53	31	20	17	
Basingstoke & North Hampshire NHS Foundation Trust	96	78	104	93	87	93	88	36	20	27	
Salisbury NHS Foundation Trust	103	82	137	105	93	100	101	35	29	27	
Royal West Sussex NHS Trust	134	107	173	103	106	133	134	59	48	22	
· · · · · · · · · · · · · · · · · · ·											
Surrey, West Sussex & Hampshire Cancer Network											
Royal Surrey County Hospital NHS Trust	93	74	64	43	19	38	32	24	11	1	
Frimley Park Hospital NHS Foundation Trust	128	102	86	74	69	74	67	31	20	20	
Ashford and St Peter's Hospitals NHS Trust	124	99	20	0	0	0	0	19	0	0	
Surrey and Sussex Healthcare NHS Trust	113	90	151	142	0	122	0	49	44	0	

comes	Out													teness %	ata comple	D			
Med L (da	CRM	Median no. of nodes	EMVI	Stoma	APER	Urgent or Emergency	Preop RT	MRI ST	MRI All	CT ST	CT All	Nurse	MDT	Derived Dukes	Supplied Dukes	ASA	Urgent	Excision	Age
	64.7	11	32.8	5.9	0.0	5.5	0.0	90.5	90.9	82.2	76.1	59.1	90.9	77.3	55.7	60.3	97.3	94.5	100
	0.0	0	0.0	14.3	14.3	6.3	0.0	25.0	25.0	6.3	10.5	5.3	36.8	52.6	47.4	25.0	25.0	93.8	100
	0.0	24	25.0	0.0	0.0	0.0	0.0	0.0	25.0	10.0	18.2	90.9	81.8	90.9	36.4	20.0	100.0	50.0	100
	0.0	0	0.0	30.4	26.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	65.7	65.7	0.0	0.0	85.0	100
	05.7	15	F 7	10.0	4.0	12.4	AA A	(2.0	64.1	02.7	02.0	70 5	00.1	74.1	17.0	100.0	100.0	02.0	100
	85.7	15 13	5.7	19.0	4.8 0.0	13.4	44.4 26.3	63.0 78.9	64.1 76.0	92.7	92.0	70.5	99.1	74.1	17.0 76.8	100.0 91.2		93.9	100
	0.0 77.1	13	0.0 1.1	0.0 4.2	0.0	95.0 14.0	1.4	17.4	20.2	73.8 0.0	73.7 0.0	79.8 78.2	100.0 99.3	99.0 73.8	76.8	81.3 67.2	96.3 98.7	83.8 81.7	100 100
	94.3	17	30.0	4.2 54.7	30.2	22.7	17.1	78.9	77.3	88.0	88.4	77.5	99.5 96.8	96.1	92.9	61.0	98.8	88.8	100
	94.5 59.4	14	0.0	6.3	0.0	18.5	7.4	76.5	75.0	55.2	51.9	8.8	95.0	80.2	75.5	81.5	76.8	65.3	100
	47.1	15	22.5	23.5	17.6	11.3	9.5	19.0	14.3	60.0	55.0	44.1	85.6	75.7	66.7	66.3	60.0	90.0	100
	50.0	15	34.3	40.0	15.0	16.2	23.1	38.5	44.2	88.0	87.3	77.6	99.4	83.6	37.0	56.4	98.3	92.3	100
	71.4	14	0.0	28.6	19.0	8.8	20.0	76.0	70.6	85.3	83.7	2.4	88.9	87.0	64.4	90.2	100.0	93.1	100
	23.1	14	0.0	0.0	0.0	15.6	20.0	75.0	60.7	81.3	75.6	20.5	93.6	89.7	73.1	42.2	85.9	81.3	100
	6.7	14	5.1	6.7	6.7	75.0	13.6	81.8	80.0	93.8	88.9	1.6	100.0	96.8	82.5	42.2 89.6	95.8	85.4	100
	22.2	17	0.0	11.1	0.0	56.7	5.0	25.0	25.9	67.8	69.0	8.8	97.3	85.0	64.6	41.1	100.0	66.7	100
	40.0	15	0.0	0.0	0.0	5.3	16.0	76.0	77.6	6.3	7.4	28.4	98.9	70.0	62.1	33.7	61.1	49.5	100
	11.8	15	0.0	0.0	0.0	39.2	23.8	71.4	61.5	37.8	40.4	0.0	100.0	95.5	86.5	14.9	100.0	82.4	100
	31.1	16	0.0	2.2	2.2	23.0	1.7	59.3	58.9	53.6	52.3	0.4	99.6	81.2	75.7	94.3	89.5	84.7	100
	93.5	10	10.6	45.2	25.8	20.0	51.4	78.4	78.3	85.3	85.6	81.4	96.6	89.8	83.1	95.8	96.8	93.7	100
	88.2	20	51.5	35.3	17.6	19.5	18.2	81.8	71.0	89.6	86.2	79.3	74.7	93.1	49.4	98.7	96.1	92.2	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	98.1	0.0	0.0	0.0	0.0	100.0	100
	0.0	0	0.0	0.0	0.0	80.0	0.0	75.0	28.6	0.0	0.0	0.0	83.3	26.2	26.2	70.0	80.0	40.0	100
	82.4	15	0.0	47.1	0.0	29.6	23.1	46.2	46.4	84.5	84.9	47.2	96.2	94.3	84.9	80.3	97.2	78.9	100
	80.5	17	33.3	31.7	22.0	11.6	0.0	66.2	66.2	72.4	72.4	60.8	77.9	93.0	25.6	100.0	100.0	78.9	100
	100.0	12	23.4	27.3	0.0	24.5	35.7	100.0	87.5	94.3	91.7	88.3	100.0	98.3	98.3	100.0	100.0	88.7	100
	6.3	14	11.1	50.0	31.3	6.7	52.6	73.7	72.7	53.3	57.0	68.4	91.1	82.3	43.0	68.3	65.0	90.0 95 0	100
	32.4	13	14.5	29.7	24.3	18.2	25.6	60.5	52.9	77.1	74.9	0.0	78.4	91.6 86.9	90.3		100.0 95.6	85.9 94 9	100
	13.8 94.1	13 16	19.7 28.4	28.8 29.4	23.8 5.9	16.4 9.9	23.5 5.0	63.5 50.0	63.4 38.7	89.1 91.5	89.3 91.3	0.0 43.3	0.3 68.3	86.9 79.8	20.1 16.3	85.8 74.6	95.6 100.0	94.9 97.2	100 100
	94.1	14	19.5	14.8	7.4	9.9 8.6	0.0	100.0	100.0	71.0	72.6	45.5	85.8	91.5	10.5	25.8	100.0	97.2	100
	95.5	14	28.0	27.3	13.6	21.0	7.7	92.3	85.7	93.3	93.4	76.6	100.0	88.3	56.2	23.8 98.1	98.1	90.5	100
	69.0	12	0.0	44.8	3.4	10.6	37.5	66.7	67.8	77.5	74.6	38.7	93.1	96.5	89.0	83.4	82.8	71.5	100
					0.0			10.2	20.0	CO -	56.0	10.1	02.0	70.4	22.0	50.4	04.4	46.2	100
	0.0	20	5.3	0.0	0.0	7.0	9.1	18.2	20.8	60.5 75.7	56.3	48.4	82.8	73.4	32.8	58.1 07.2	81.4	44.2	100
	80.0	13	15.9	70.0	5.0	6.8	0.0	100.0	74.2	75.7	69.8	39.5	87.2 5.0	87.2	40.7	97.3	100.0	93.2	100
	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	100

Organisation	ex	mated pected						N	umber sul	omitted	
	n	umber -				1	All cases		Rectal t	umours	
	Total	MR	Total	ST	MR	OM	LOS	Total	ST	MR	
Sussex Cancer Network											
Worthing and Southlands Hospitals NHS Trust	143	114	153	117	97	47	1	47	25	20	
East Sussex Hospitals NHS Trust	214	171	263	210	151	181	187	70	49	33	
Brighton and Sussex University Hospitals NHS Trust	159	127	89	69	44	66	7	35	22	16	
Kent & Medway Cancer Network											
Dartford and Gravesham NHS Trust	70	56	75	71	70	71	70	11	10	9	
Medway NHS Trust	124	99	19	1	1	0	0	7	1	1	
East Kent Hospitals NHS Trust	270	216	196	0	0	0	0	46	0	0	
Maidstone and Tunbridge Wells NHS Trust	174	139	84	70	65	70	69	17	13	9	
Greater Midlands Cancer Network											
Mid Staffordshire General Hospitals NHS Trust	138	110	80	0	0	0	0	24	0	0	
University Hospital of North Staffordshire NHS Trust	226	181									
The Royal Wolverhampton Hospitals NHS Trust	153	122	185	66	60	46	59	65	27	23	
Dudley Group of Hospitals NHS Trust	190	152	129	100	86	90	84	33	27	21	
Shrewsbury and Telford Hospital NHS Trust	228	182	236	187	183	184	3	71	57	54	
North of England Cancer Network											
South Tyneside NHS Foundation Trust	98	78	97	77	67	71	70	34	24	19	
City Hospitals Sunderland NHS Foundation Trust	158	126	124	86	78	80	82	40	24	21	
North Cumbria Acute Hospitals NHS Trust	183	146	124	139	120	131	111	50	35	27	
Gateshead Health NHS Foundation Trust	105	84	87	72	58	58	61	26	21	17	
The Newcastle Upon Tyne Hospitals NHS Foundation Trust	214	171	185	135	113	129	128	58	41	30	
Northumbria Health Care NHS Foundation Trust	214	206	253	193	174	129	120	81	61	52	
South Tees Hospitals NHS Trust	213	170	230	195	174	181	171	56	46	43	
North Tees and Hartlepool NHS Trust	173	138	212	149	129	146	119	70	50	40	
County Durham and Darlington NHS Foundation Trust	268	214	399	247	212	231	218	139	94	79	
Anglia Cancer Network											
Bedford Hospital NHS Trust	95	76	103	76	61	57	25	33	26	17	
	114	91	51	32	25	29	23	33	20	16	
The Queen Elizabeth Hospital King's Lynn NHS Trust Peterborough and Stamford Hospitals NHS Foundation Trust	160	128	103	0	25	29	25	28	20	0	
James Paget Healthcare NHS Foundation Trust	135	108 97	179 122	138 0	120 0	137 0	133 0	52 39	33	23	
West Suffolk Hospitals NHS Trust Cambridge University Hospitals NHS Foundation Trust	121	152	207	188	176	185	185	56	49	40	
Norfolk and Norwich University Hospital NHS Trust	339	271	396	301	238	289	257	101	75	40 59	
Ipswich Hospital NHS Trust	191	153	590	201	230	203	257	101	15	59	
Hinchingbrooke Health Care NHS Trust	75	60	49	46	33	42	38	17	16	9	
Essex Cancer Network											
Southend University Hospital NHS Foundation Trust	175	140									
Basildon and Thurrock University Hospitals NHS Foundation Trust	175		103	92	77	74	77	32	28	21	
Essex Rivers Healthcare NHS Trust	120	96 145	103	92	//	/4	//	52	28	21	
Mid Essex Hospital Services NHS Trust	181	88	7	5	5	5	1	6	5	5	
									· · ·		
North Wales Cancer Network											
North West Wales NHS Trust	118		125	102	89	102	93	44	32	28	
Conwy and Denbighshire NHS Trust	97		96	69	65	55	63	20	13	11	
North East Wales NHS Trust	91		90	71	64	55	67	32	26	23	
South West Wales Cancer Network											
Carmarthenshire NHS Trust	89		86	64	49	60	63	25	17	12	
Swansea NHS Trust	143		138	122	95	118	111	37	29	20	
Bro Morgannwg	116		113	82	70	81	76	38	24	20	

omes %	Out													eteness %	Data comple	[
Mediar LOS (days)	CRM	Median no. of nodes	EMVI	Stoma	APER	Urgent or Emergency	Preop RT	MRI ST	MRI All	CT ST	CT All	Nurse	MDT	Derived Dukes	Supplied Dukes	ASA	Urgent	Excision	Age
32	0.0	12	0.0	5.0	0.0	14.5	0.0	80.0	78.7	0.0	0.0	9.8	97.4	84.3	60.8	0.0	89.7	85.5	100
10	57.6	12	0.0	3.0	0.0	29.0	6.1	57.1	50.0	45.2	44.1	58.2	90.9	85.2	71.5	39.5	97.6	74.8	100
5	6.3	13	0.0	0.0	0.0	82.6	4.5	40.9	34.3	8.7	9.0	46.1	100.0	84.3	59.6	17.4	91.3	63.8	100
7	11.1	17	12.9	0.0	0.0	15.5	10.0	90.0	90.9	87.3	88.0	4.0	90.7	97.3	93.3	94.4	100.0	100.0	100
(100.0	21	0.0	0.0	0.0	0.0	0.0	100.0	57.1	100.0	94.7	5.3	94.7	73.7	68.4	100.0		100.0	100
(0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	73.5	0.0	0.0	0.0	0.0	0.0	100
6	100.0	19	38.5	33.3	0.0	8.6	0.0	84.6	76.5	85.7	88.1	90.5	98.8	92.9	25.0	92.9	97.1	92.9	100
	0.0		0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	05.0		0.0	0.0	0.0	0.0	100
(0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	95.0	0.0	0.0	0.0	0.0	0.0	100
12	0.0	15	0.0	4.3	0.0	12.1	11.1	22.2	10.8	12.1	12.4	0.0	28.6	87.0	74.1	12.1	66.7	92.4	100
9	71.4	13	18.6	19.0	19.0	20.0	14.8	70.4	63.6	81.0	77.5	80.6	93.0	88.4	59.7	94.0	93.0	89.0	100
11	16.7	15	24.0	37.0	22.2	11.2	3.5	66.7	54.9	92.5	75.8	55.1	21.6	93.6	22.5	98.4	98.4	97.9	100
11	42.1	10	10.4	31.6	0.0	10.4	0.0	58.3	52.9	72.7	69.1	35.1	93.8	74.2	73.2	75.3	72.7	87.0	100
9	42.1 85.7	10	23.1	33.3	4.8	10.4	0.0	37.0	32.9	76.7	79.8	55.6	95.6 88.7	83.1	83.1	75.5 86.0	91.9	91.9	100
-	22.2	12	5.0	33.3	0.0	8.6	37.1	68.6	60.0	83.5	79.9	47.3	79.3	81.5	81.0	67.6	77.0	87.1	100
6	76.5	14	32.8	41.2	5.9	15.3	33.3	52.4	57.7	69.4	65.5	72.4	94.3	82.8	79.3	83.3	90.3	84.7	100
	76.7	20	22.1	26.7	3.3	6.7	0.0	73.2	70.7	84.4	83.2	64.9	95.7	88.1	87.6	85.9	57.8	84.4	100
9	65.4	10	17.8	44.2	7.7	8.3	0.0	45.9	42.0	80.3	77.5	25.7	70.4	68.4	68.4	62.7	93.8	93.3	100
8	51.2	14	20.5	37.2	0.0	11.8	32.6	58.7	51.8	68.4	68.7	71.7	92.6	88.3	87.8	78.6	68.4	92.5	100
7	55.0	10	27.1	27.5	7.5	10.1	16.0	50.0	47.1	67.1	62.7	54.2	90.6	76.9	69.3	62.4	67.1	89.9	100
8	46.8	11	8.0	29.1	2.5	9.7	28.7	51.1	46.0	51.4	52.6	52.4	77.2	75.2	72.7	56.3	66.8	91.5	100
1.	0.0	10	0.0	5.0	F 0	10 5	2.0	C1 F	CO 7	447	447	24.0	02.2	60.0	50.2	12	20.0	02.0	100
14	0.0	16	0.0	5.9	5.9	10.5	3.8 0.0	61.5 10.0	69.7 5.1	44.7	44.7	34.0	93.2 88.2	69.9	58.3	1.3 21.9	28.9	82.9 87.5	100
3	0.0	0	0.0 0.0	18.8 0.0	18.8 0.0	6.3 0.0	0.0	0.0	5.1 10.7	28.1 0.0	19.6 23.3	13.7 0.0	88.2 98.1	7.8 24.3	7.8 24.3	21.9	93.8 0.0	0.0	100 100
10	73.9	12	33.3	47.8	13.0	25.4	42.4	48.5	38.5	82.6	79.3	75.4	93.3	78.2	53.1	90.6	97.8		100
(0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	23.1	0.0	22.1	0.0	96.7	88.5	88.5	0.0	0.0		100
6	97.5	14	46.6	37.5	17.5	17.0	53.1	73.5	66.1	82.4	83.1	78.3	51.2	94.2	15.5	81.4	98.9		100
ç	3.4	11	0.4	25.4	1.7	15.9	30.7	6.7	5.9	35.5	38.9	56.1	96.5	69.7	64.9	67.1	98.3		100
9	22.2	11	0.0	33.3	0.0	8.7	62.5	87.5	82.4	73.9	73.5	91.8	98.0	93.9	89.8	91.3	89.1	71.7	100
7	85.7	10	11.7	19.0	19.0	6.5	28.6	32.1	31.3	81.5	83.5	84.5	15.5	90.3	28.2	10.9	100.0	84.8	100
6	40.0	17	0.0	40.0	40.0	0.0	20.0	40.0	33.3	100.0	100.0	57.1	57.1	28.6	0.0	80.0	100.0	100.0	100
10	67.9	13	12.4	28.6	14.3	10.8	53.1	53.1	47.7	89.2	86.4	84.0	100.0	89.6	88.8	67.6	100.0	93.1	100
10	72.7	11	12.3	54.5	36.4	26.1	46.2	61.5	45.0	75.4	78.1	89.6	93.8	99.0	99.0		100.0		100
ç	43.5	26	25.0	56.5	17.4	18.3	73.1	69.2	68.8	78.9	80.0	95.6	95.6	84.4	84.4	95.8	97.2	93.0	100
										1									
12	83.3	8	40.8	83.3	33.3	18.8	5.9	82.4	64.0	82.8	81.4	61.6	96.5	77.9	77.9	100.0	100.0	78.1	100
10	65.0	14	25.3	25.0	25.0	30.3	17.2	24.1	21.6	88.5	87.7	69.6	92.8	84.8	82.6	98.4	98.4		100
	65.0	17	22.9	65.0	40.0	12.2	66.7	70.8	65.8	86.6	82.3	40.7	96.5	78.8	77.9	86.6			100

Organisation		timated opected							Number s	ubmitted	
		number						Rectal	tumours		
	Total	MR	Total	ST	MR	ОМ	LOS	Total	ST	MR	
Ceredigion & Mid Wales NHS Trust	29		32	27	23	26	27	6	3	3	
Pembrokeshire & Derwen NHS Trust	53		51	46	43	46	46	12	9	9	
South East Wales Cancer Network											
Pontypridd & Rhondda NHS Trust	61		62	55	50	54	55	21	18	15	
Gwent Healthcare NHS Trust	185		175	143	118	138	37	48	32	24	
Cardiff & Vale NHS Trust	135		136	110	79	100	63	41	35	19	
North Glamorgan NHS Trust	76		79	72	56	63	59	32	30	20	
Republic of Ireland											
St James Hospital, Ireland											
Beaumont Hospital, Dublin			105	96	84	90	91	44	41	32	
Northern Ireland											
Belfast			121	103	98	99	100	43	37	34	
Other											
Princess Grace Hospital											

			[Data comple	eteness %													Out	comes %
Age	Excision	Urgent	ASA	Supplied Dukes	Derived Dukes	MDT	Nurse	CT All	CT ST	MRI All	MRI ST	Preop RT	Urgent or Emergency	APER	Stoma	EMVI	Median no. of nodes	CRM	Median LOS (days)
100	85.2	100.0	96.3	84.4	84.4	93.8	100.0	84.4	85.2	50.0	66.7	0.0	7.4	33.3	66.7	17.4	8	66.7	12
100	93.5	100.0	97.8	88.2	88.2	94.1	88.2	96.1	95.7	91.7	100.0	44.4	30.4	44.4	55.6	14.0	17	100.0	6
100	92.7	98.2	80.0	80.6	83.9	100.0	72.6	82.3	81.8	61.9	61.1	0.0	9.1	46.7	66.7	48.0	11	100.0	9
100	88.8	93.0	16.1	86.9	90.3	33.7	1.7	85.1	87.4	56.3	62.5	28.1	26.6	20.8	25.0	20.3	13	4.2	8
100	75.5	78.2	37.3	65.4	68.4	93.4	83.8	37.5	37.3	34.1	37.1	25.7	16.4	26.3	42.1	30.4	14	89.5	13
100	80.6	81.9	97.2	78.5	83.5	97.5	88.6	53.2	51.4	18.8	16.7	6.7	13.9	30.0	55.0	17.9	14	25.0	8
									, in the second s										
100	90.6	99.0	83.3	28.6	84.8	12.4	87.6	93.3	93.8	84.1	82.9	51.2	12.5	12.5	21.9	17.9	12	96.9	14
100	97.1	100.0	100.0	0.0	48.8	100.0	74.4	3.3	2.9	55.8	62.2	48.6	11.7	41.2	44.1	20.4	16	88.2	10

Appendix 3: Colorectal cancer outcomes audit in Leicester

Colorectal cancer outcomes audit has been well established in Leicester since 2001. The data are quality assured by a data analyst who is also responsible for the upper GI cancer audit data and who, with the collaboration of one of the clinicians, analyses the data for the annual Leicester Colorectal Cancer Audit Meeting.

This meeting takes place in the early part of the year and looks, year on year, at the patients diagnosed with colorectal cancer in the preceding calendar year. All the members of the Leicester Colorectal Specialists Advisory Group, which includes consultant surgeons, radiologists, pathologists and colorectal clinical nurse specialists, and the colorectal trainees, are invited to attend the meeting. Data are presented showing outcomes of the group as a whole and also on an individual surgeon basis. The latter data were initially anonymously presented but after the first meeting results were surgeon-identifiable. The reasoning behind this is that everyone has become comfortable with this, no individual surgeon's outcomes are significantly different from the others and it was relatively easy to break the code on the basis of the numbers and types of operations done. This forum, in conjunction with the annual protocol review meeting and the annual research meeting that the group also run, gives us the opportunity to ensure that we all keep up to date with current developments, thus individual surgeons feel supported by their colleagues and wider teams.

As a unit, we compare our data with the national data, to which Leicester has consistently and comprehensively contributed. In terms of the headline data of 30-day post-operative mortality, re-admissions within 30 days of discharge, unplanned re-operations, anastomotic leak rates and permanent stoma rates our results have remained relatively constant over the 6 years the full audit has been running. We have also found that, as more data are gathered, the apparent year-on-year fluctuations in individual surgeons' results become less obvious.

There are now details of approximately 2600 patients on the database and the overall 30-day mortality rate is 7 per cent, being 4.5 per cent in the elective group and 17 per cent in the emergency group of patients. Individual surgeons' results vary between an elective 30-day mortality rate of 1.6 per cent for one of the surgeons, who happens to do a lower volume of cancer work, and 6.4 per cent. Equivalent emergency mortality rates are 9.4 per cent and 28.9 per cent. The overall clinical anastomotic leak rate is approximately 6 per cent in patients not having stomas, with no major differences between the individual surgeons. The overall unplanned re-admission rate is 5 per cent and the unplanned re-operation rate is also 5 per cent. The data have also shown a steady rise in the number of new diagnoses each year, from 432 in 2001 to 462 in 2007, the increase being mainly in the colonic cancer group. The number of patients presenting as emergencies has remained frustratingly constant at about 24 per cent of all new diagnoses, as has the number of patients presenting with metastatic disease, 19 per cent. Overall, 80 per cent of patients have had some form of surgery for their disease, with 87 per cent of these having a resection.

To date comparisons within the group have not revealed any outliers but there are procedures in place to examine further any such instance. All participants find the process reassuring, educational and ultimately of benefit to their patients.

MJ Kelly & J Jameson

For the Leicester Colorectal Specialists Advisory Group

Appendix 4: Examples of collection of high quality complete data

Bowel cancer audit - 'how I collect data in Portsmouth'

I have managed the audit of colorectal cancer at Portsmouth for the last ten years. Data capture has evolved over that time towards a more streamlined and efficient process. The introduction of MDT meetings and greater electronic access to information has helped the task of the data manager, as has the overall greater awareness and acceptance by the clinical community of the relevance of audit for both local and national knowledge.

There is a trend towards less individualisation of Hospital Trusts as national requirements need to be addressed, but each unit will still have its own best way of organising the process of audit, with a need to adapt to resources available. Not every hospital has the luxury of a data manager responsible for complete and accurate audit.

The starting point of the audit process begins with being able to ensure that all patients with bowel cancer are identified. At Portsmouth, the weekly MDT meeting (where the treatment of all patients with bowel cancer is discussed) is the primary source of audit data. Secondary sources of identification (plus a 'fail safe' mechanism to ensure all cancers have been identified at the MDT) include a report from the histopathology department listing all colorectal cancers. As data manager I collect data for all parts of the audit process. Much of this information is accessible on electronic 'in-house' databases (staging, pathology, chemotherapy, radiotherapy, post operative length of stay and survival). Details of surgery are taken from the operation note; a proforma, which includes required audit data items, is used in Portsmouth.

With a streamlined systematic process of audit in place, collection of data should be routine and effortless. In practice this isn't always the case, information is not always readily available or accessible to the auditor for various reasons. Successful audit is reliant on finding ways to overcome any hurdles in the flow of information. This may be made easier with the increasing climate of acceptance that audit is here to stay, and that audit may have its uses as opposed to threats for the clinician. On a local level, results of audit data in Portsmouth provide information that may influence decisions on future clinical practice within the unit; eg the median length of stay in hospital is much shorter in patients having laparoscopic surgery as opposed to open surgery. This is not a logical assumption, but a verifiable reality in Portsmouth.

Karen Flashman

Bowel cancer audit - 'how I collect data in Swansea'

I have been collecting, inputting and analysing cancer data for the past 6 years. It all started in 2002 with our own inhouse cancer data collection system, CANTORIS, monitoring all Cancer Standards and subsequently moving our data input to the All Wales Cancer Information System Cymru (CANISC). We started entering limited data only in 2003 and retrospective colorectal cancer data from April 2003. As the number of data fields have gradually increased and been developed within the Colorectal Dataset we have been moving slowly but surely towards prospective data collection. This allows us to include all information needed for National Bowel Cancer Audit Project (NBOCAP), and also Welsh Office directives and targets eg Service and Financial Framework (SaFF).

Identification of cancers

The process of data capture, for information and audit, begins with being able to ensure that all patients with bowel cancer are identified in a timely manner. I rely on 4 main sources for this:

1. Weekly pathology reports

Within the Cancer Information Department we have a weekly download of copy pathology reports for all the suspicious, in-situ and histologically-diagnosed cancers within the Trust. All new cancers are recorded into CANISC from these reports and then distributed to each site specific cancer co-ordinator.

2. Weekly multidisciplinary meeting (MDT)

All suspected and diagnosed cancer patients are discussed at a weekly MDT meeting with regard to their ongoing investigations and treatment pathway. This process helps to identify emergency admissions and any cancers diagnosed on imaging. It is part of my role to organise and attend these meetings, which facilitates the information and fact-finding process.

3. Monthly theatre reports

These reports can pick up any overlooked or incomplete data eg ASA grade, and also be another way to help to identify missed cancer patients. If the patient has only had a colostomy or ileostomy, and has then been referred onto the Cancer Centre, it is often because they have some form of malignancy. Further investigation, using other Trust systems and the consultant's secretaries will shine a light on the situation.

4. Urgent Suspected Cancers referrals

All our USC patients have their pathway tracked from point of referral to confirmed diagnosis. By working closely with our tracking clerk it is possible to start the information collection process in the early days and be ahead of the game and ensure no breach of the Welsh Assembly Government (WAG) Cancer SaFF Target.

Data collection

Every colorectal cancer identified from pathology or through clinical information is recorded on to a single A4 proforma data sheet. This has been designed for convenience of data collection and data entry, and includes a condensed version of the ACP dataset. Relevant information before each MDT is retrieved from the medical notes, if available, and helps to focus on incomplete data, which can then be requested at the meeting. However, this is time consuming and not always that comprehensive. Much of the information required is accessible on several different in-house systems and so, in theory, much can be achieved without actually moving from my department. The data items include mode of referral. clinic dates, waiting lists and inpatient admissions (iPM), pre-operative staging or investigative radiological investigations and reports (RADIS/PACS), histology reports (Wintegrate), and radiotherapy or chemotherapy activity from our Cancer Centre and oncology database. The details of surgery are initially collected by myself from the patient's case-notes and subsequently verified by the surgeon at the MDT and then on completion of a CANISC surgical procedure pro-forma specifically designed for this purpose.

Even though follow up information is not routinely collected, if and when any recurrence or progression of disease has been identified either radiologically of histopathologically at the multidisciplinary meeting, the information is recorded within CaNISC.

Collection of data as described should, in theory, be fairly routine and almost effortless, but as we all know this is not really the case. Without electronic feed of information between systems, and input from clinicians, secretaries, nurse specialists and MDT meetings to name but a few, it remains a continuous challenge.

Julie Cowling

Appendix 5: Local Action Plan (LAP) based on the recommendations of 2009 Annual Report

Recommendation	Achieved Y/N/P/ NK	Planned Action	Suggested Actions	Suggested Responsibility	Date Planned Actioned	Date issue resolves
Data Completeness and Quality						
The Trust participates in the National Bowel Cancer Audit			Contact local Cancer Network for audit advice. Visit www.ic.NHS.uk/canceraudits for information	Cancer Manager / Governance / MDT Clinical lead		
Data on all patients with bowel cancer submitted to the audit			Use MDT meetings to capture all cases discussed. Try to record cases in real time or near real time. Liaise with pathology departments to ensure all relevant data captured	MDT Chair		
All relevant data fields are completed for each patient and hould include the 5 variables used for risk adjustment			Use proforma for data collection at MDT. Identify key person to quality assure data prior to submission. Data inputters understand clinical implications of data	Data Co-ordinator / Cancer Manager / Network Manager		
Actual completeness of at least 30 per cent should be achieved for key data fields			Refer to the essential dataset and ensure that these fields are collected for all relevant cases. Use 2009 audit report to identify data items not being completely collected.	MDT Chair / Data Co-ordinator / Cancer Manager / Network Manager / MDT Chair		
Process of Care						
All patients submitted to the audit are discussed at MDT			Liaise with cancer waiting times team to identify bowel cancer referrals. Liaise with radiology department to identify all imaging suspicious of bowel cancer. Liaise with pathology department to identify cases	MDT Chair / Bowel cancer clinical lead		
All patients with bowel cancer are seen by a cancer nurse specialist			Review the specialist nurse service and ensure that a clear referral process exists	MDT Chair / bowel cancer clinical lead / Clinical nurse specialist lead		
All patients with colon or rectal cancer should have pre- operative staging by a CT scan			Ensure all relevant pre-operative cases are submitted to the audit. Review protocols for availability of CT scanning	MDT Chair / Radiology lead		
Clinical Outcomes						
The number of lymph nodes removed and examined from each surgical specimen should be above the median of 12			Review of nodal harvest process for resection specimens	MDT / Colorectal pathology lead		
Post-operative mortality should be less than 20 per cent for emergency surgery and less than 7 per cent for elective surgery for colorectal cancer			Case note review of each post operative death for lessons learned	MDT Chair and Colorectal surgeons		
Permanent stoma rate should be kept to a minimum			Note permanent stoma rate and compare both with Network and national rates	Colorectal surgeons, Trust Management and Network Managers		
APER rates should be kept to a minimum			Review APER rate and compare with Network and national rates	Colorectal surgeons, Trust Management and Network Managers		
aparoscopic surgery should be performed by adequately trained colorectal surgeons			Ensure adequate training	Colorectal surgical department and Trust management		
Reduce length of stay (median 8 days)			Explore all current initiatives eg pre-assessment, enhanced recovery pathways, laparoscopic approaches to surgery	Colorectal surgeons and clinical management teams		
Completion of the Royal College of Pathology minimum dataset			Look at the completion of the data items within the National Bowel Cancer Audit	MDT lead / Chair and the colorectal pathologists		

The NHS Information Centre for health and social care is working to make information more relevant and accessible to the public, regulators, health and social care professionals and policy makers, leading to improvements in knowledge and efficiency. The NHS IC is a NHS special health authority that collects, analyses and distributes data to reduce the burden on frontline staff, releasing more time for direct care.

National Bowel Cancer Audit report.

Printed copies of the Executive Summary for the 2009 Annual Report can be ordered by quoting reference number 20100209, or call The NHS Information Centre's Contact Centre on 0845 300 6016 or email bowelcancer@ic.nhs.uk

For further information about this report, email bowelcancer@ic.nhs.uk or contact:

National Clinical Audit Support Programme The NHS Information Centre for health and social care 1 Trevelyan Square Boar Lane Leeds LS1 6AE

Telephone: 0845 300 6016 Website: www.ic.nhs.uk For previous reports please refer to: www.ic.nhs.uk